

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 5
MAY 2016**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2016

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

Cumulative Supplement 5

May 2016

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	vii
1.5 Availability of the Edition	viii
1.6 Report of Counts for the Prescription Drug Product List.....	ix
1.7 Cumulative Supplement Legend	x
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

**CUMULATIVE SUPPLEMENT 05
May 2016**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 36th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the

next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

BD RX INC
(BD RX)

FRESENIUS KABI USA LLC
(FRESENIUS KABI USA)

CITRON PHARMA LLC
(CITRON PHARMA LLC)

CASPER PHARMA LLC
(CASPER PHARMA LLC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate

for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Alara NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent

number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination

product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2015</u>	<u>MAR 2016</u>	<u>JUN 2016</u>	<u>SEP 2016</u>	<u>DEC 2016</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	17151 2664 (15.5%)	17251 2693 (15.6%)			
MULTISOURCE	14487 (84.5%)	14558 (84.4%)			
THERAPEUTICALLY EQUIVALENT	14366 (83.8%)	14434 (83.7%)			
NOT THERAPEUTICALLY EQUIVALENT	121 (0.7%)	124 (0.7%)			
EXCEPTIONS ¹	73 (0.4%)	73 (0.4%)			
NEW MOLECULAR ENTITIES APPROVED	28	9			
NUMBER OF APPLICANTS	1011	1007			

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code

for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE; ORAL
ACAMPROSATE CALCIUM

>D>	AB	GLENMARK GENERICS	333MG	A202229	001	Jul 16, 2013	May CRLD
>A>	AB	+	333MG	A202229	001	Jul 16, 2013	May CRLD

ACETAMINOPHEN

SOLUTION; IV (INFUSION)
ACETAMINOPHEN

>A>	AP	PADDOCK LLC	1GM/100ML (10MG/ML)	A202605	001	Jun 13, 2016	May NEWA
	AP	SANDOZ INC	1GM/100ML (10MG/ML)	A204052	001	Mar 22, 2016	Mar NEWA
		OFIRMEV					
	AP	+	MALLINCKRODT IP	1GM/100ML (10MG/ML)	N022450	001	Nov 02, 2010
							Mar CFTG

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
@ INGENUS PHARMS NJ 325MG; 50MG; 40MG
@ SUN PHARM INDS 325MG; 50MG; 40MG
FIORICET

>D>		@ ACTAVIS LABS UT INC	325MG; 50MG; 40MG	A088616	001	Nov 09, 1984	May CMFD
>A>	AA		325MG; 50MG; 40MG	A088616	001	Nov 09, 1984	May CMFD

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL
FIORICET W/ CODEINE

AB	+	ALLERGAN SALES LLC	325MG; 50MG; 40MG; 30MG	N020232	001	Jul 30, 1992	Apr CAHN
----	---	--------------------	-------------------------	---------	-----	--------------	----------

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE
@ SUN PHARM INDS 300MG; 60MG

A089673	001	Feb 10, 1988	Mar CAHN
---------	-----	--------------	----------

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL
ZYFREL

AA		CYPRESS PHARM INC	325MG/15ML; 7.5MG/15ML	A090468	001	Apr 14, 2016	Apr NEWA
----	--	-------------------	------------------------	---------	-----	--------------	----------

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>A>	AA	ACTAVIS LABS FL INC	300MG; 5MG	A206470	001	Jun 02, 2016	May NEWA
>A>	AA		300MG; 7.5MG	A206470	002	Jun 02, 2016	May NEWA
>A>	AA		300MG; 10MG	A206470	003	Jun 02, 2016	May NEWA
	AA	AMNEAL PHARMS NY	325MG; 7.5MG	A040746	002	May 10, 2016	Apr NEWA
	AA	RHODES PHARMS	325MG; 5MG	A202991	001	Apr 12, 2016	Mar NEWA
	AA		325MG; 7.5MG	A202991	002	Apr 12, 2016	Mar NEWA
	AA		325MG; 10MG	A202991	003	Apr 12, 2016	Mar NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL
OXYCODONE AND ACETAMINOPHEN

>D>		@ MALLINCKRODT INC	325MG/5ML; 5MG/5ML	A040680	001	Sep 29, 2006	May CMFD
>A>	AA		325MG/5ML; 5MG/5ML	A040680	001	Sep 29, 2006	May CMFD

TABLET; ORAL
OXYCODONE AND ACETAMINOPHEN

AA		ALVOGEN MALTA	325MG; 5MG	A202677	003	Mar 08, 2016	Feb NEWA
AA			325MG; 7.5MG	A202677	001	Jul 26, 2012	Jan CAHN
AA			325MG; 10MG	A202677	002	Jul 26, 2012	Jan CAHN
AA		AMNEAL PHARMS NY	325MG; 7.5MG	A040778	002	Jun 27, 2014	Apr NEWA
AA		MAYNE PHARMA INC	325MG; 2.5MG	A090177	001	Oct 20, 2008	Feb CAHN
AA			325MG; 5MG	A090177	002	Oct 20, 2008	Feb CAHN
AA			325MG; 7.5MG	A090177	003	Oct 20, 2008	Feb CAHN
AA			325MG; 10MG	A090177	004	Oct 20, 2008	Feb CAHN
		@	500MG; 7.5MG	A090177	005	Oct 20, 2008	Feb CAHN
		@	650MG; 10MG	A090177	006	Oct 20, 2008	Feb CAHN

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

>D>	AB	ALLIED PHARMA INC	325MG; 37.5MG	A202076	001	Mar 30, 2012	May CAHN
>A>	AB	ATLAS PHARMS LLC	325MG; 37.5MG	A202076	001	Mar 30, 2012	May CAHN

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACETAZOLAMIDE

AB		NOSTRUM LABS INC	500MG	A204691	001	Mar 29, 2016	Mar NEWA
----	--	------------------	-------	---------	-----	--------------	----------

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS

ACETYLCYSTEINE

AP		AUROBINDO PHARMA LTD	6GM/30ML (200MG/ML)	A207358	001	Feb 29, 2016	Feb NEWA
----	--	----------------------	---------------------	---------	-----	--------------	----------

TABLET, EFFERVESCENT; ORAL

CETYLEV

		ARBOR PHARMS LLC	500MG	N207916	001	Jan 29, 2016	Jan NEWA
	+		2.5GM	N207916	002	Jan 29, 2016	Jan NEWA

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

SEMPREX-D

	+	AUXILIUM PHARMS INC	8MG; 60MG	N019806	001	Mar 25, 1994	Mar CAHN
--	---	---------------------	-----------	---------	-----	--------------	----------

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

		@ RANBAXY	200MG	A074975	001	Sep 30, 1998	Feb DISC
AB		ZYDUS PHARMS USA INC	200MG	A204313	001	Mar 25, 2016	Mar NEWA

OINTMENT; TOPICAL

ACYCLOVIR

AB		FOUGERA PHARMS INC	5%	A206633	001	May 11, 2016	Apr NEWA
----	--	--------------------	----	---------	-----	--------------	----------

TABLET; BUCCAL

SITAVIG

	+	CIPHER PHARMS US	50MG	N203791	001	Apr 12, 2013	Jan CAHN
--	---	------------------	------	---------	-----	--------------	----------

TABLET; ORAL

ACYCLOVIR

		@ SUN PHARM INDS LTD	400MG	A074980	001	Sep 30, 1998	Feb DISC
		@	800MG	A074980	002	Sep 30, 1998	Feb DISC

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE

		@ HIKMA MAPLE	EQ 500MG BASE/VIAL	A074885	001	Dec 19, 1997	Feb DISC
		@	EQ 1GM BASE/VIAL	A074885	002	Dec 19, 1997	Feb DISC
		ACYCLOVIR SODIUM					
		@ BEDFORD	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997	Feb DISC
		@	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Feb DISC
AP	+		EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Feb CTEC
		@ EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997	Apr CAHN
		@	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Apr CAHN
AP		HIKMA PHARMS LLC	EQ 500MG BASE/VIAL	A205771	001	Feb 29, 2016	Feb NEWA
	+		EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016	Feb CRLD
AP			EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016	Feb NEWA

ADENOSINE

INJECTABLE; INJECTION

ADENOSINE

AP		EUROHLTH INTL SARL	3MG/ML	A076404	001	Jun 16, 2004	Apr CAHN
----	--	--------------------	--------	---------	-----	--------------	----------

SOLUTION; IV (INFUSION)

ADENOSCAN

		@ ASTELLAS	60MG/20ML (3MG/ML)	N020059	001	May 18, 1995	Apr DISC
		@	90MG/30ML (3MG/ML)	N020059	002	May 18, 1995	Apr DISC

ADENOSINE

AP	+	TEVA PHARMS USA	60MG/20ML (3MG/ML)	A077425	001	Aug 29, 2013	Apr CRLD
AP	+		90MG/30ML (3MG/ML)	A077425	002	Aug 29, 2013	Apr CRLD

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

AN	+	@ HI TECH PHARMA	EQ 0.083% BASE	A075063	001	Feb 09, 1999	Mar DISC
		@ LANDELA PHARM	EQ 0.083% BASE	A077569	001	Apr 04, 2006	Mar DISC
		@ MYLAN SPECLT	EQ 0.083% BASE	A072652	001	Feb 21, 1992	Mar DISC
		@ NEPHRON	EQ 0.083% BASE	A074880	001	Sep 17, 1997	Mar CRLD
		@ TEVA PHARMS	EQ 0.083% BASE	A075343	001	Nov 09, 1999	Mar DISC
		@ WATSON LABS INC	EQ 0.083% BASE	A076370	001	Nov 24, 2003	Mar DISC

TABLET; ORAL

ALBUTEROL SULFATE

AB		SUN PHARM INDS	EQ 2MG BASE	A072637	002	Dec 05, 1989	Mar CAHN
AB			EQ 4MG BASE	A072637	001	Dec 05, 1989	Mar CAHN

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

AB		UNICHEM LABS LTD	10MG	A203192	001	Jan 28, 2016	Jan NEWA
----	--	------------------	------	---------	-----	--------------	----------

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB		SUN PHARM INDS	300MG	A071450	001	Jan 09, 1987	Mar CAHN
AB		ZYLOPRIM					
AB		SEBELA IRELAND LTD	100MG	N016084	001		Jan CAHN
AB	+		300MG	N016084	002		Jan CAHN

ALMOTRIPTAN MALATE

TABLET; ORAL

ALMOTRIPTAN MALATE

AB		AJANTA PHARMA LTD	EQ 6.25MG BASE	A205523	001	Mar 03, 2016	Feb NEWA
AB			EQ 12.5MG BASE	A205523	002	Mar 03, 2016	Feb NEWA

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

LOTRONEX

AB		SEBELA IRELAND LTD	EQ 0.5MG BASE	N021107	002	Dec 23, 2003	Feb CAHN
AB	+		EQ 1MG BASE	N021107	001	Feb 09, 2000	Feb CAHN

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

@	ACTAVIS LABS FL INC	0.5MG
@		1MG
@		2MG
@		3MG
@	COREPHARMA	0.5MG
@		1MG
@		2MG
@		3MG
@	IMPAX LABS	0.5MG
@		1MG
@		2MG
@		3MG

A077198	001	May 13, 2010	Jan DISC
A077198	002	May 13, 2010	Jan DISC
A077198	003	May 13, 2010	Jan DISC
A077198	004	May 13, 2010	Jan DISC
A077996	001	Jan 31, 2007	Mar DISC
A077996	002	Jan 31, 2007	Mar DISC
A077996	003	Jan 31, 2007	Mar DISC
A077996	004	Jan 31, 2007	Mar DISC
A077968	004	May 24, 2007	Jan DISC
A077968	003	May 24, 2007	Jan DISC
A077968	002	May 24, 2007	Jan DISC
A077968	001	May 24, 2007	Jan DISC

ALPROSTADIL

INJECTABLE; INJECTION

EDEX

AP	+	@ AUXILIUM PHARMS INC	0.005MG/VIAL	N020649	001	Jun 12, 1997	Mar CAHN
			0.01MG/VIAL	N020649	002	Jun 12, 1997	Mar CAHN
			0.01MG/VIAL	N020649	005	Jul 30, 1998	Mar CAHN
AP			0.02MG/VIAL	N020649	003	Jun 12, 1997	Mar CAHN
	+		0.02MG/VIAL	N020649	006	Jul 30, 1998	Mar CAHN
AP	+		0.04MG/VIAL	N020649	004	Jun 12, 1997	Mar CAHN
	+		0.04MG/VIAL	N020649	007	Jul 30, 1998	Mar CAHN

SUPPOSITORY; URETHRAL

MUSE

+	MEDA PHARMS	0.125MG	N020700	001	Nov 19, 1996	Jan CRLD
+		0.25MG	N020700	002	Nov 19, 1996	Jan CRLD
+		0.5MG	N020700	003	Nov 19, 1996	Jan CRLD

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

AB	BIONPHARMA INC	100MG	A078720	001	May 29, 2008	Jan CAHN
>A> AB	ZYDUS PHARMS USA INC	100MG	A208278	001	May 31, 2016	May NEWA

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

>D> AP	EMCURE PHARMS LTD	EQ 250MG BASE/ML	A204040	001	Dec 12, 2013	May CRLD
>A> AP	+	EQ 250MG BASE/ML	A204040	001	Dec 12, 2013	May CRLD
>D> AP	+	EUROHLTH INTL SARL	A063315	001	Apr 11, 1994	May CRLD
>A> AP		EQ 250MG BASE/ML	A063315	001	Apr 11, 1994	May CRLD
AP	SAGENT PHARMS	EQ 250MG BASE/ML	A203323	001	May 12, 2016	Apr NEWA

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	2.75%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678	002	Mar 26, 1997	Mar CMS1
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	2.75%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678	005	Mar 26, 1997	Mar CMS1
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	2.75%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678	001	Mar 26, 1997	Mar CMS1
CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	4.25%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	009	Mar 26, 1997	Mar CMS1
CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	4.25%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	011	Mar 26, 1997	Mar CMS1
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	4.25%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	012	Mar 26, 1997	Mar CMS1
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	4.25%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	008	Mar 26, 1997	Mar CMS1
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	5%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	016	Mar 26, 1997	Mar CMS1
CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	5%;33MG/100ML;15GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	017	Mar 26, 1997	Mar CMS1
CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	5%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	018	Mar 26, 1997	Mar CMS1
CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	5%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	019	Mar 26, 1997	Mar CMS1
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	5%;33MG/100ML;35GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	021	Mar 26, 1997	Mar CMS1

AMINOLEVULINIC ACID HYDROCHLORIDE

>A>	GEL; TOPICAL					
>A>	AMELUZ					
>A>	+	BIOFRONTERA	10%	N208081	001	May 10, 2016 May NEWA

AMINOPHYLLINE

TABLET; ORAL

AMINOPHYLLINE

>A>	@	IDT AUSTRALIA LTD	100MG	A085261	003		May	CAHN
>A>	@		100MG	A085262	002		May	CAHN
>A>	@		200MG	A085261	002		May	CAHN
>D>	@	SANDOZ	100MG	A085261	003		May	CAHN
>D>	@		100MG	A085262	002		May	CAHN
>D>	@		200MG	A085261	002		May	CAHN

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

>A>	AB	AUROBINDO PHARMA LTD	200MG	A204742	001	Jun 03, 2016	May	NEWA
-----	----	----------------------	-------	---------	-----	--------------	-----	------

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

		@	SUN PHARM INDS INC	10MG	A040816	002	Jun 27, 2008	Mar	DISC
		@		10MG	A089399	002	Jul 14, 1987	Mar	DISC
AB		@		10MG	A089399	002	Jul 14, 1987	Mar	CAHN
		@		25MG	A040816	001	Jun 27, 2008	Mar	DISC
		@		25MG	A089399	001	Jul 14, 1987	Mar	DISC
AB		@		25MG	A089399	001	Jul 14, 1987	Mar	CAHN
		@		50MG	A040816	003	Jun 27, 2008	Mar	DISC
		@		50MG	A089399	003	Jul 14, 1987	Mar	DISC
AB		@		50MG	A089399	003	Jul 14, 1987	Mar	CAHN
		@		75MG	A040816	004	Jun 27, 2008	Mar	DISC
		@		75MG	A089399	004	Jul 14, 1987	Mar	DISC
AB		@		75MG	A089399	004	Jul 14, 1987	Mar	CAHN
		@		100MG	A040816	005	Jun 27, 2008	Mar	DISC
		@		100MG	A089399	005	Jul 14, 1987	Mar	DISC
AB		@		100MG	A089399	005	Jul 14, 1987	Mar	CAHN
		@		150MG	A040816	006	Jun 27, 2008	Mar	DISC
		@		150MG	A089399	006	Jul 14, 1987	Mar	DISC
AB		@		150MG	A089399	006	Jul 14, 1987	Mar	CAHN

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

	@	SUN PHARM INDS	EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986	Mar	CAHN
	@		EQ 25MG BASE;10MG	A070766	001	Dec 10, 1986	Mar	CAHN

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

	@	SUN PHARM INDS	10MG;2MG	A071077	001	Nov 12, 1986	Mar	CAHN
	@		10MG;4MG	A071078	001	Nov 12, 1986	Mar	CAHN
	@		25MG;2MG	A070297	001	Nov 12, 1986	Mar	CAHN
	@		25MG;4MG	A071079	001	Nov 12, 1986	Mar	CAHN

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

>A>	AB	CHINA RESOURCES	EQ 2.5MG BASE	A090752	003	May 16, 2016	May	NEWA	
	AB	INVAGEN PHARMS	EQ 2.5MG BASE	A206367	001	Dec 10, 2015	Feb	CAHN	
	AB		EQ 5MG BASE	A206367	002	Dec 10, 2015	Feb	CAHN	
	AB		EQ 10MG BASE	A206367	003	Dec 10, 2015	Feb	CAHN	
		@	SUN PHARM INDS	EQ 2.5MG BASE	A078081	001	Jan 31, 2008	Mar	CAHN
		@		EQ 5MG BASE	A078081	002	Jan 31, 2008	Mar	CAHN
		@		EQ 10MG BASE	A078081	003	Jan 31, 2008	Mar	CAHN

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB		AUROBINDO PHARMA LTD	EQ 5MG BASE;160MG	A206512	001	Apr 22, 2016	Apr	NEWA
AB			EQ 5MG BASE;320MG	A206512	002	Apr 22, 2016	Apr	NEWA
AB			EQ 10MG BASE;160MG	A206512	003	Apr 22, 2016	Apr	NEWA
AB			EQ 10MG BASE;320MG	A206512	004	Apr 22, 2016	Apr	NEWA

AMMONIA N-13

INJECTABLE; INTRAVENOUS
AMMONIA N 13

AP	MA GENERAL HOSP	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A207025	001	Feb 03, 2016	Jan NEWA
AP	MIDWEST MEDCL	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204457	001	Nov 18, 2015	Jan NEWA

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

AB	+ PERRIGO NEW YORK	EQ 12% BASE	A075774	001	May 01, 2002	Apr CRLD
	LAC-HYDRIN					
	@ RANBAXY	EQ 12% BASE	N020508	001	Aug 29, 1996	Apr DISC

LOTION; TOPICAL

AMMONIUM LACTATE

AB	+ PERRIGO NEW YORK	EQ 12% BASE	A075570	001	Jun 23, 2004	Apr CRLD
	LAC-HYDRIN					
	@ RANBAXY	EQ 12% BASE	N019155	001	Apr 24, 1985	Apr DISC

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

@ SUN PHARM INDS LTD 250MG
@ 500MG

A065016	001	Apr 08, 1999	Feb DISC
A065016	002	Apr 08, 1999	Feb DISC

TABLET; ORAL

AMOXICILLIN

@ SUN PHARM INDS LTD 500MG
@ 875MG

A065059	001	Nov 24, 2000	Feb DISC
A065059	002	Nov 24, 2000	Feb DISC

TABLET, CHEWABLE; ORAL

AMOXICILLIN

@ SUN PHARM INDS LTD 125MG
@ 250MG

A065021	001	Dec 23, 1999	Feb DISC
A065021	002	Dec 23, 1999	Feb DISC

TABLET, EXTENDED RELEASE; ORAL

MOXATAG

+ VERNALIS R AND D LTD 775MG

N050813	001	Jan 23, 2008	Jan CAHN
---------	-----	--------------	----------

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	AUROBINDO PHARMA LTD	200MG/5ML; EQ 28.5MG BASE/5ML	A201090	001	Dec 20, 2011	Feb CDFR
AB		400MG/5ML; EQ 57MG BASE/5ML	A201090	002	Dec 20, 2011	Feb CDFR
AB		600MG/5ML; EQ 42.9MG BASE/5ML	A201091	001	Dec 20, 2011	Feb CDFR
	@ SUN PHARM INDS LTD	200MG/5ML; EQ 28.5MG BASE/5ML	A065132	001	Mar 19, 2003	Feb DISC
	@	400MG/5ML; EQ 57MG BASE/5ML	A065132	002	Mar 19, 2003	Feb DISC
	@	600MG/5ML; EQ 42.9MG BASE/5ML	A065207	002	Jan 30, 2007	Feb DISC

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

@ SUN PHARM INDS LTD 875MG; EQ 125MG BASE

A065102	001	Sep 17, 2002	Feb DISC
---------	-----	--------------	----------

TABLET, CHEWABLE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

@ SUN PHARM INDS LTD 200MG; EQ 28.5MG BASE
@ 400MG; EQ 57MG BASE

A065161	001	Dec 03, 2003	Feb DISC
A065161	002	Dec 03, 2003	Feb DISC

AUGMENTIN '125'

DR REDDYS LABS INC 125MG; EQ 31.25MG BASE

N050597	001	Jul 22, 1985	Mar CTEC
---------	-----	--------------	----------

AUGMENTIN '250'

+ DR REDDYS LABS INC 250MG; EQ 62.5MG BASE

N050597	002	Jul 22, 1985	Mar CRLD
---------	-----	--------------	----------

AMPHETAMINE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE; ORAL

ADZENYS XR-ODT

NEOS THERAPS

EQ 3.1MG BASE

N204326	001	Jan 27, 2016	Jan NEWA
---------	-----	--------------	----------

EQ 6.3MG BASE

N204326	002	Jan 27, 2016	Jan NEWA
---------	-----	--------------	----------

EQ 9.4MG BASE

N204326	003	Jan 27, 2016	Jan NEWA
---------	-----	--------------	----------

EQ 12.5MG BASE

N204326	004	Jan 27, 2016	Jan NEWA
---------	-----	--------------	----------

EQ 15.7MG BASE

N204326	005	Jan 27, 2016	Jan NEWA
---------	-----	--------------	----------

EQ 18.8MG BASE

N204326	006	Jan 27, 2016	May CRLD
---------	-----	--------------	----------

>D>

>A>

+

EQ 18.8MG BASE

N204326	006	Jan 27, 2016	May CRLD
---------	-----	--------------	----------

EQ 18.8MG BASE

N204326	006	Jan 27, 2016	Jan NEWA
---------	-----	--------------	----------

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	IMPAX LABS	1.25MG;1.25MG;1.25MG;1.25MG	A076852	001	Feb 16, 2016	Feb NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A076852	002	Feb 16, 2016	Feb NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A076852	003	Feb 16, 2016	Feb NEWA
AB		5MG;5MG;5MG;5MG	A076852	004	Feb 16, 2016	Feb NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A076852	005	Feb 16, 2016	Feb NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A076852	006	Feb 16, 2016	Feb NEWA
AB	TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A077488	001	Apr 29, 2013	Feb CTNA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A077488	002	Apr 29, 2013	Feb CTNA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A077488	003	Apr 29, 2013	Feb CTNA
AB		5MG;5MG;5MG;5MG	A077488	004	Apr 29, 2013	Feb CTNA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A077488	005	Apr 29, 2013	Feb CTNA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A077488	006	Apr 29, 2013	Feb CTNA

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A206340	001	Feb 05, 2016	Jan NEWA
AB		1.875MG;1.875MG;1.875MG;1.875MG	A206340	002	Feb 05, 2016	Jan NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A206340	003	Feb 05, 2016	Jan NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A206340	004	Feb 05, 2016	Jan NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A206340	005	Feb 05, 2016	Jan NEWA
AB		5MG;5MG;5MG;5MG	A206340	006	Feb 05, 2016	Jan NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A206340	007	Feb 05, 2016	Jan NEWA

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX;INJECTION

AMPHOTEC

@ ALKOPHARMA USA

50MG/VIAL

N050729 001 Nov 22, 1996 Apr DISC

@

100MG/VIAL

N050729 002 Nov 22, 1996 Apr DISC

ARIPIPIRAZOLE

SOLUTION;ORAL

ARIPIPIRAZOLE

AA	+	AMNEAL PHARMS	1MG/ML	A203906	001	Aug 14, 2015	Feb CRLD
----	---	---------------	--------	---------	-----	--------------	----------

TABLET, ORALLY DISINTEGRATING;ORAL

>D>		ABILIFY					
>D>	AB	+	OTSUKA	10MG	N021729	002	Jun 07, 2006 May DISC
>A>		@		10MG	N021729	002	Jun 07, 2006 May DISC
>D>	AB			15MG	N021729	003	Jun 07, 2006 May DISC
>A>		@		15MG	N021729	003	Jun 07, 2006 May DISC
			ARIPIPIRAZOLE				
>D>	AB		ALEMBIC PHARMS LTD	10MG	A202102	001	Apr 28, 2015 May CRLD
>A>		+		10MG	A202102	001	Apr 28, 2015 May CRLD
>D>	AB			15MG	A202102	002	Apr 28, 2015 May CTEC
>A>				15MG	A202102	002	Apr 28, 2015 May CTEC

ARMODAFINIL

TABLET;ORAL

ARMODAFINIL

AB		MYLAN PHARMS INC	50MG	A200043	001	Jun 01, 2012	Apr CMFD
AB			150MG	A200043	002	Jun 01, 2012	Apr CMFD
AB			250MG	A200043	003	Jun 01, 2012	Apr CMFD

NUVIGIL

AB		CEPHALON	50MG	N021875	001	Jun 15, 2007	Apr CTEC
AB			150MG	N021875	003	Jun 15, 2007	Apr CTEC
AB	+		250MG	N021875	004	Jun 15, 2007	Apr CTEC

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION

M.V.I.-12 LYOPHILIZED

@ TELIGENT PHARMA INC

100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL

N018933 002 Aug 08, 1985 Jan CAHN

ASENAPINE MALEATETABLET;SUBLINGUAL
SAPHRIS

FOREST LABS LLC EQ 2.5 BASE

N022117 003 Mar 12, 2015 Mar NEWA

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

@ NOSTRUM LABS INC 325MG;50MG;40MG

A078149 001 Jun 13, 2007 Jan CAHN

FIORINAL

AA + ALLERGAN SALES LLC 325MG;50MG;40MG

N017534 005 Apr 16, 1986 Apr CAHN

TABLET;ORAL

FIORINAL

@ ALLERGAN SALES LLC 325MG;50MG;40MG

N017534 003 Apr 16, 1986 Apr CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

FIORINAL W/CODEINE

AB + ALLERGAN SALES LLC 325MG;50MG;40MG;30MG

N019429 003 Oct 26, 1990 Apr CAHN

ASPIRIN; CARISOPRODOL

TABLET;ORAL

CARISOPRODOL AND ASPIRIN

AB INGENUS PHARMS NJ 325MG;200MG

A040832 001 Jan 07, 2010 Jan CAHN

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET;ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB INGENUS PHARMS NJ 325MG;200MG;16MG

A040860 001 Jan 07, 2010 Mar CMFD

@ 325MG;200MG;16MG

A040860 001 Jan 07, 2010 Jan CAHN

AB + SANDOZ 325MG;200MG;16MG

A040118 001 Apr 16, 1996 Mar CTEC

+ 325MG;200MG;16MG

A040118 001 Apr 16, 1996 Jan CRLD

SOMA COMPOUND W/ CODEINE

@ MEDA PHARMS 325MG;200MG;16MG

N012366 002 Jul 11, 1983 Jan DISC

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL

ASPIRIN AND DIPYRIDAMOLE

AB @ AMNEAL PHARMS 25MG;200MG

A206392 001 Mar 08, 2016 Apr DISC

AB 25MG;200MG

A206392 001 Mar 08, 2016 Feb NEWA

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET;ORAL

OXYCODONE AND ASPIRIN

@ SUN PHARM INDS 325MG;4.5MG;0.38MG

A040260 001 Jul 17, 1998 Mar CAHN

@ 325MG;4.5MG;0.38MG

A087794 001 May 26, 1982 Mar CAHN

ATENOLOL

TABLET;ORAL

ATENOLOL

AB ALVOGEN MALTA 25MG

A073646 001 Jul 31, 1992 Jan CAHN

AB 50MG

A072303 001 Jul 15, 1988 Jan CAHN

AB 100MG

A072304 001 Jul 15, 1988 Jan CAHN

TENORMIN

AB ALVOGEN MALTA 25MG

N018240 004 Apr 09, 1990 Jan CAHN

AB 50MG

N018240 001 Jan CAHN

AB + 100MG

N018240 002 Jan CAHN

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

AB ALVOGEN MALTA 50MG;25MG

A072301 001 May 31, 1990 Jan CAHN

AB 100MG;25MG

A072302 001 May 31, 1990 Jan CAHN

AB SUN PHARM INDS 100MG;25MG

A073582 001 Apr 29, 1993 Mar CAHN

TENORETIC 100

AB + ALVOGEN MALTA 100MG;25MG

N018760 001 Jun 08, 1984 Jan CAHN

TENORETIC 50

AB ALVOGEN MALTA 50MG;25MG

N018760 002 Jun 08, 1984 Jan CAHN

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

>A>	AB	SCIEGEN PHARMS INC	EQ 10MG BASE	A205519	001	May 19, 2016	May NEWA
>A>	AB		EQ 20MG BASE	A205519	002	May 19, 2016	May NEWA
>A>	AB		EQ 40MG BASE	A205519	003	May 19, 2016	May NEWA
>A>	AB		EQ 80MG BASE	A205519	004	May 19, 2016	May NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

@ SUN PHARM INDS

0.025MG;2.5MG

A085506 001

Mar CAHN

AURANOFIN

CAPSULE;ORAL

RIDAURA

+ SEBELA IRELAND LTD 3MG

N018689 001 May 24, 1985 Jan CAHN

AXITINIB

TABLET;ORAL

INLYTA

+ PF PRISM CV 1MG

N202324 001 Jan 27, 2012 Apr CAHN

+ 5MG

N202324 002 Jan 27, 2012 Apr CAHN

AZACITIDINE

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

AP MYLAN INSTITUTIONAL 100MG/VIAL

A204949 001 Apr 28, 2016 Apr NEWA

POWDER;IV (INFUSION), SUBCUTANEOUS

AZACITIDINE

ACTAVIS LLC 100MG/VIAL

N208216 001 Apr 29, 2016 Apr NEWA

AZATHIOPRINE

TABLET;ORAL

IMURAN

AB @ SEBELA IRELAND LTD 25MG

N016324 002

Jan CAHN

+ 50MG

N016324 001

Jan CAHN

AZATHIOPRINE SODIUM

INJECTABLE;INJECTION

IMURAN

@ SEBELA IRELAND LTD EQ 100MG BASE/VIAL

N017391 001

Jan CAHN

AZILSARTAN KAMEDOXOMIL

TABLET;ORAL

EDARBI

ARBOR PHARMS LLC EQ 40MG MEDOXOMIL

N200796 001 Feb 25, 2011 Jan CAHN

+ EQ 80MG MEDOXOMIL

N200796 002 Feb 25, 2011 Jan CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL

EDARBYCLOR

ARBOR PHARMS LLC EQ 40MG MEDOXOMIL;12.5MG

N202331 001 Dec 20, 2011 Jan CAHN

+ EQ 40MG MEDOXOMIL;25MG

N202331 002 Dec 20, 2011 Jan CAHN

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

BX LUPIN LTD EQ 100MG BASE/5ML

A065488 001 May 15, 2015 Apr CTEC

BX EQ 200MG BASE/5ML

A065488 002 May 15, 2015 Apr CTEC

AZTREONAM

INJECTABLE;INJECTION

AZTREONAM

@ EUROHLTH INTL SARL 1GM/VIAL

A065286 001 Mar 23, 2011 Mar DISC

@ 2GM/VIAL

A065286 002 Mar 23, 2011 Mar DISC

BACLOFENINJECTABLE; INTRATHECAL
BACLOFEN

AP	SINTETICA SA	0.05MG/ML	A091193	001	May 03, 2016	Apr	NEWA
AP		0.5MG/ML	A091193	002	May 03, 2016	Apr	NEWA
AP		2MG/ML	A091193	003	May 03, 2016	Apr	NEWA

LIORESAL

>D>	AP	+	MEDTRONIC NEURO	0.05MG/ML	N020075	003	Nov 07, 1996	May	CAHN
>D>	AP	+		0.5MG/ML	N020075	001	Jun 17, 1992	May	CAHN
>D>	AP	+		2MG/ML	N020075	002	Jun 17, 1992	May	CAHN
>A>	AP	+	SAOL THERAPS RES LTD	0.05MG/ML	N020075	003	Nov 07, 1996	May	CAHN
>A>	AP	+		0.5MG/ML	N020075	001	Jun 17, 1992	May	CAHN
>A>	AP	+		2MG/ML	N020075	002	Jun 17, 1992	May	CAHN

TABLET; ORAL

BACLOFEN

AB	NORTHSTAR HLTHCARE	10MG	A078401	002	Sep 18, 2009	Jan	NEWA
----	--------------------	------	---------	-----	--------------	-----	------

BARIUM SULFATEFOR SUSPENSION; ORAL
E-Z-HD

+	BRACCO	334GM/BOTTLE	N208036	001	Jan 11, 2016	Jan	NEWA
---	--------	--------------	---------	-----	--------------	-----	------

SUSPENSION; ORAL
READI-CAT 2

+	BRACCO	2% (9GM/450ML)	N208143	001	Jan 15, 2016	Jan	NEWA
---	--------	----------------	---------	-----	--------------	-----	------

READI-CAT 2 SMOOTHIES
BRACCO

		2% (9GM/450ML)	N208143	002	Jan 15, 2016	Jan	NEWA
--	--	----------------	---------	-----	--------------	-----	------

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

@	ACTAVIS LABS FL INC	5MG	A076267	001	Feb 11, 2004	Jan	DISC
@		10MG	A076267	002	Feb 11, 2004	Jan	DISC
@		20MG	A076267	003	Feb 11, 2004	Jan	DISC
@		40MG	A076267	004	Feb 11, 2004	Jan	DISC

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@	ACTAVIS LABS FL INC	5MG; 6.25MG	A076342	001	Feb 11, 2004	Jan	DISC
@		10MG; 12.5MG	A076342	002	Feb 11, 2004	Jan	DISC
@		20MG; 12.5MG	A076342	003	Feb 11, 2004	Jan	DISC
@		20MG; 25MG	A076342	004	Feb 11, 2004	Jan	DISC
@	IVAX SUB TEVA PHARMS	5MG; 6.25MG	A076348	001	Feb 11, 2004	Mar	DISC
@		10MG; 12.5MG	A076348	002	Feb 11, 2004	Mar	DISC
@		20MG; 12.5MG	A076348	003	Feb 11, 2004	Mar	DISC
@		20MG; 25MG	A076348	004	Feb 11, 2004	Mar	DISC
@	SUN PHARM INDS LTD	5MG; 6.25MG	A077483	001	Sep 08, 2005	Mar	DISC
@		10MG; 12.5MG	A077483	002	Sep 08, 2005	Mar	DISC
@		20MG; 12.5MG	A077483	003	Sep 08, 2005	Mar	DISC
@		20MG; 25MG	A077483	004	Sep 08, 2005	Mar	DISC

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

>A>	AP	ACCORD HLTHCARE	25MG/VIAL	A205574	001	May 19, 2016	May	NEWA
>A>	AP		100MG/VIAL	A205574	002	May 19, 2016	May	NEWA
	AP	GLENMARK PHARMS LTD	25MG/VIAL	A204771	001	Mar 24, 2016	Mar	NEWA
	AP		100MG/VIAL	A204771	002	Mar 24, 2016	Mar	NEWA
>A>	AP	HOSPIRA INC	25MG/VIAL	A204086	001	May 20, 2016	May	NEWA
>A>	AP		100MG/VIAL	A204086	002	May 20, 2016	May	NEWA
	AP	INNOPHARMA LICENSING	25MG/VIAL	A205476	001	Mar 24, 2016	Mar	NEWA
	AP		100MG/VIAL	A205476	002	Mar 24, 2016	Mar	NEWA

TREANDA

AP	+	CEPHALON	25MG/VIAL	N022249	002	May 01, 2009	Mar	CFTG
AP	+		100MG/VIAL	N022249	001	Mar 20, 2008	Mar	CFTG

BENZONATATE

CAPSULE; ORAL							
BENZONATATE							
AA	BIONPHARMA INC	100MG	A081297	001	Jan 29, 1993	Jan	CAHN
AA		200MG	A081297	002	Oct 30, 2007	Jan	CAHN

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL							
BENZAMYCIN PAK							
+	CUTANEA	5%; 3%	N050769	001	Nov 27, 2000	Feb	CAHN

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL							
BENZPHETAMINE HYDROCHLORIDE							
@	IMPAX LABS	50MG	A040845	001	Nov 18, 2008	Mar	DISC

BETAMETHASONE DIPROPIONATE

SPRAY; TOPICAL							
SERNIVO							
+	PROMIUS PHARMA LLC	EQ 0.05% BASE/SPRAY	N208079	001	Feb 05, 2016	Feb	NEWA

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL							
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE							
AB	GLENMARK PHARMS	EQ 0.05% BASE; 1%	A202894	001	Oct 30, 2015	Mar	CAHN

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC							
BETAXOLOL HYDROCHLORIDE							
AT	TELIGENT PHARMA INC	EQ 0.5% BASE	A075630	001	Apr 12, 2001	Jan	CAHN

BETHANECHOL CHLORIDE

TABLET; ORAL							
BETHANECHOL CHLORIDE							
@	IMPAX LABS	5MG	A040739	001	Nov 01, 2006	Mar	DISC
@		10MG	A040741	001	Nov 01, 2006	Mar	DISC
@		25MG	A040740	001	Nov 01, 2006	Mar	DISC
@		50MG	A040721	004	Nov 01, 2006	Mar	DISC

BIMATOPROST

SOLUTION/DROPS; TOPICAL							
BIMATOPROST							
AT	SANDOZ INC	0.03%	A202719	001	Apr 19, 2016	Apr	NEWA

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE; ORAL							
HELIDAC							
@	SEBELA IRELAND LTD	262.4MG, N/A, N/A; N/A, 250MG, N/A; N/A, N/A, 500MG	N050719	001	Aug 15, 1996	Jan	CAHN

BISOPROLOL FUMARATE

TABLET; ORAL							
BISOPROLOL FUMARATE							
@	SUN PHARM INDS	5MG	A075474	001	Oct 25, 2002	Mar	CAHN
@		10MG	A075474	002	Oct 25, 2002	Mar	CAHN

BRIVARACETAM

SOLUTION; INTRAVENOUS							
BRIVIACT							
>D>	+	UBC INC	50MG/5ML (10MG/ML)	N205837	001	Feb 18, 2016	May CMS1
	+		50MG/5ML (10MG/ML)	N205837	001	Feb 18, 2016	Feb NEWA
>A>	+	UCB INC	50MG/5ML (10MG/ML)	N205837	001	May 12, 2016	May CMS1
SOLUTION; ORAL							
BRIVIACT							
>D>	+	UBC INC	10MG/ML	N205838	001	Feb 18, 2016	May CMS1
>A>	+		10MG/ML	N205838	001	May 12, 2016	May CMS1
	+		10MG/ML	N205838	001	Feb 18, 2016	Feb NEWA
TABLET; ORAL							
BRIVIACT							
>D>		UCB INC	10MG	N205836	001	Feb 18, 2016	May CMS1
>A>			10MG	N205836	001	May 12, 2016	May CMS1

TABLET;ORAL
BRIVIACT

		10MG	N205836	001	Feb 18, 2016	Feb	NEWA
>D>		25MG	N205836	002	Feb 18, 2016	May	CMS1
>A>		25MG	N205836	002	May 12, 2016	May	CMS1
		25MG	N205836	002	Feb 18, 2016	Feb	NEWA
>D>		50MG	N205836	003	Feb 18, 2016	May	CMS1
>A>		50MG	N205836	003	May 12, 2016	May	CMS1
		50MG	N205836	003	Feb 18, 2016	Feb	NEWA
>D>		75MG	N205836	004	Feb 18, 2016	May	CMS1
>A>		75MG	N205836	004	May 12, 2016	May	CMS1
		75MG	N205836	004	Feb 18, 2016	Feb	NEWA
>D>	+	100MG	N205836	005	Feb 18, 2016	May	CMS1
>A>	+	100MG	N205836	005	May 12, 2016	May	CMS1
	+	100MG	N205836	005	Feb 18, 2016	Feb	NEWA

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC
BROMSITE

+	INSITE VISION INC	EQ 0.075% ACID	N206911	001	Apr 08, 2016	Apr	NEWA
---	-------------------	----------------	---------	-----	--------------	-----	------

BROMOCRIPTINE MESYLATE

CAPSULE;ORAL
BROMOCRIPTINE MESYLATE

AB	+	MYLAN	EQ 5MG BASE	A077226	001	Apr 04, 2005	Jan	CRLD
		PARLODEL						
		@ US PHARMS HOLDINGS I	EQ 5MG BASE	N017962	002	Mar 01, 1982	Jan	DISC
		TABLET;ORAL						
		BROMOCRIPTINE MESYLATE						
AB	+	PADDOCK LLC	EQ 2.5MG BASE	A077646	001	Oct 01, 2008	Jan	CRLD
AB		SANDOZ INC	EQ 2.5MG BASE	A074631	001	Jan 13, 1998	Feb	CAHN
		PARLODEL						
AB		US PHARMS HOLDINGS I	EQ 2.5MG BASE	N017962	001		Apr	CMFD
		@	EQ 2.5MG BASE	N017962	001		Jan	DISC

BUDESONIDE

CAPSULE;ORAL
BUDESONIDE

	AB		ACTAVIS ELIZABETH	3MG		A206623	001	Apr 08, 2016	Mar	NEWA
			ENTOCORT EC							
>D>	AB	+	ELAN PHARMA INTL LTD	3MG		N021324	001	Oct 02, 2001	May	CAHN
	AB	+		3MG		N021324	001	Oct 02, 2001	Jan	CAHN
>A>	AB	+	PERRIGO PHARMA INTL	3MG		N021324	001	Oct 02, 2001	May	CAHN
			SUSPENSION;INHALATION							
			BUDESONIDE							
	AN		TEVA PHARMS USA	1MG/2ML		A204548	001	Mar 08, 2016	Feb	NEWA

BUMETANIDE

INJECTABLE;INJECTION
BUMETANIDE

AP	+	EUROHLTH INTL SARL	0.25MG/ML	A074441	001	Jan 27, 1995	Apr	CAHN
----	---	--------------------	-----------	---------	-----	--------------	-----	------

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION
BUPIVACAINE HYDROCHLORIDE

>A>	AP	AUROBINDO PHARMA LTD	0.25%	A207183	001	May 13, 2016	May	NEWA
>A>	AP		0.5%	A207183	002	May 13, 2016	May	NEWA

BUPRENORPHINE HYDROCHLORIDE

>A>		IMPLANT;IMPLANTATION						
>A>		PROBUPHINE						
>A>	+	TITAN PHARMS	EQ 80MG BASE/IMPLANT	N204442	001	May 26, 2016	May	NEWA
		TABLET;SUBLINGUAL						
		BUPRENORPHINE HYDROCHLORIDE						
AB		SUN PHARM INDS LTD	EQ 2MG BASE	A201760	001	Jan 29, 2016	Jan	NEWA
AB			EQ 8MG BASE	A201760	002	Jan 29, 2016	Jan	NEWA

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
BUPROPION HYDROCHLORIDE

AB1	INVAGEN PHARMS	100MG	A206674	001	Feb 09, 2016	Jan NEWA
AB1		150MG	A206674	002	Feb 09, 2016	Jan NEWA
AB1		200MG	A206674	003	Feb 09, 2016	Jan NEWA
AB1	SCIEGEN PHARMS INC	100MG	A205794	001	Mar 01, 2016	Feb NEWA
AB1		150MG	A205794	002	Mar 01, 2016	Feb NEWA
AB1		200MG	A205794	003	Mar 01, 2016	Feb NEWA

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
CONTRAVE

+	OREXIGEN	90MG;8MG	N200063	001	Sep 10, 2014	Apr CAHN
---	----------	----------	---------	-----	--------------	----------

BUSULFAN

INJECTABLE;INJECTION
BUSULFAN

AP	LUITPOLD PHARMS INC	6MG/ML	A202259	001	Dec 22, 2015	Mar CAHN
----	---------------------	--------	---------	-----	--------------	----------

BUTORPHANOL TARTRATE

INJECTABLE;INJECTION
BUTORPHANOL TARTRATE

	@ CLARIS	2MG/ML	A075697	001	Oct 23, 2001	Jan CAHN
AP	EUROHLTH INTL SARL	2MG/ML	A075046	001	Aug 12, 1998	Apr CAHN
	BUTORPHANOL TARTRATE PRESERVATIVE FREE					
	@ CLARIS	1MG/ML	A075695	001	Oct 23, 2001	Mar CAHN
	@	2MG/ML	A075695	002	Oct 23, 2001	Mar CAHN
AP	EUROHLTH INTL SARL	1MG/ML	A075045	001	Aug 12, 1998	Apr CAHN
AP		2MG/ML	A075045	002	Aug 12, 1998	Apr CAHN

CABERGOLINE

TABLET;ORAL
CABERGOLINE

@	IMPAX LABS INC	0.5MG	A077843	001	Jul 03, 2007	Mar DISC
---	----------------	-------	---------	-----	--------------	----------

CABOZANTINIB S-MALATE

TABLET;ORAL
CABOMETYX

	EXELIXIS INC	EQ 20MG BASE	N208692	001	Apr 25, 2016	Apr NEWA
		EQ 40MG BASE	N208692	002	Apr 25, 2016	Apr NEWA
+		EQ 60MG BASE	N208692	003	Apr 25, 2016	Apr NEWA

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY;RECTAL
MIGERGOT

+	HORIZON PHARMA	100MG;2MG	A086557	001	Oct 04, 1983	Jan CAHN
---	----------------	-----------	---------	-----	--------------	----------

CALCIPOTRIENE

CREAM;TOPICAL
CALCIPOTRIENE

AB	GLENMARK PHARMS	0.005%	A205772	001	Jun 09, 2015	Mar CAHN
----	-----------------	--------	---------	-----	--------------	----------

CALCITRIOL

CAPSULE;ORAL
CALCITRIOL

AB	BIONPHARMA INC	0.25MCG	A091174	001	May 24, 2013	Jan CAHN
AB		0.5MCG	A091174	002	May 24, 2013	Jan CAHN

INJECTABLE;INJECTION
CALCITRIOL

	AKORN	0.001MG/ML	A078066	001	Jan 29, 2008	Feb CTEC
@	ROCKWELL MEDCL	0.001MG/ML	A076206	001	Sep 17, 2003	Feb DISC

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@	FRESENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379	002		Feb DISC
---	-----------------	---	---------	-----	--	----------

DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

@	FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379	003		Feb DISC
---	-----------------	---	---------	-----	--	----------

SOLUTION;INTRAPERITONEAL

DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

@ FRESSENIUS MEDCL	25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379	007	Jun 24, 1988	Feb DISC
--------------------	---	---------	-----	--------------	----------

DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@ FRESSENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379	001		Feb DISC
--------------------	--	---------	-----	--	----------

DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@ FRESSENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	004	Jul 07, 1982	Feb DISC
--------------------	---	---------	-----	--------------	----------

DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

@ FRESSENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	005	Jul 07, 1982	Feb DISC
--------------------	---	---------	-----	--------------	----------

DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

@ FRESSENIUS MEDCL	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	008	Jun 24, 1988	Feb DISC
--------------------	---	---------	-----	--------------	----------

DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@ FRESSENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	006	Jul 07, 1982	Feb DISC
--------------------	--	---------	-----	--------------	----------

DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	010	Nov 18, 1985	Feb CTEC
-----------------	---	---------	-----	--------------	----------

DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	011	Nov 18, 1985	Feb CTEC
-----------------	---	---------	-----	--------------	----------

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

@ APOTEX	12.5MG	A074737	001	Oct 28, 1998	Mar DISC
@	25MG	A074737	002	Oct 28, 1998	Mar DISC
@	50MG	A074737	003	Oct 28, 1998	Mar DISC
@	100MG	A074737	004	Oct 28, 1998	Mar DISC
@ SANDOZ	12.5MG	A074363	001	Nov 09, 1995	Jan DISC
@	25MG	A074363	002	Nov 09, 1995	Jan DISC
@	50MG	A074363	003	Nov 09, 1995	Jan DISC
@	100MG	A074363	004	Nov 09, 1995	Jan DISC
@ STASON	12.5MG	A074677	004	May 30, 1997	Mar DISC
@	25MG	A074677	002	May 30, 1997	Mar DISC
@	50MG	A074677	001	May 30, 1997	Mar DISC
@	100MG	A074677	003	May 30, 1997	Mar DISC

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB	MYLAN IRELAND LTD	100MG	A076697	001	May 20, 2011	Jan CAHN
AB		200MG	A076697	002	May 20, 2011	Jan CAHN
AB		300MG	A076697	003	May 20, 2011	Jan CAHN

CARBIDOPA

TABLET;ORAL

CARBIDOPA

AB	EDENBRIDGE PHARMS	25MG	A205304	001	Feb 17, 2016	Feb NEWA
----	-------------------	------	---------	-----	--------------	----------

CARBIDOPA; LEVODOPA

TABLET;ORAL

CARBIDOPA AND LEVODOPA

>A>	@ IDT AUSTRALIA LTD	10MG;100MG	A073586	001	Jun 29, 1995	May CAHN
>A>	@	25MG;100MG	A073587	001	Jun 29, 1995	May CAHN
>A>	@	25MG;250MG	A073620	001	Jun 29, 1995	May CAHN
>D>	@ SANDOZ	10MG;100MG	A073586	001	Jun 29, 1995	May CAHN
>D>	@	25MG;100MG	A073587	001	Jun 29, 1995	May CAHN
>D>	@	25MG;250MG	A073620	001	Jun 29, 1995	May CAHN

CARBINOXAMINE MALEATE

TABLET;ORAL

CARBINOXAMINE MALEATE

>A>	MIKART INC	6MG	A207484	001	May 31, 2016	May NEWA
-----	------------	-----	---------	-----	--------------	----------

CARBOPLATIN

INJECTABLE;IV (INFUSION)
CARBOPLATIN

	@	ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732	001	Feb 06, 2012	Apr	DISC
	@		150MG/15ML (10MG/ML)	A078732	002	Feb 06, 2012	Apr	DISC
	@		450MG/45ML (10MG/ML)	A078732	003	Feb 06, 2012	Apr	DISC
	@		600MG/60ML (10MG/ML)	A078732	004	Feb 06, 2012	Apr	DISC
AP		SANDOZ INC	50MG/5ML (10MG/ML)	A078280	001	May 08, 2008	Feb	CAHN
AP			150MG/15ML (10MG/ML)	A078280	002	May 08, 2008	Feb	CAHN
AP			450MG/45ML (10MG/ML)	A078280	003	May 08, 2008	Feb	CAHN
AP		SANJA PHARMS CO	50MG/5ML (10MG/ML)	A205487	001	Mar 28, 2016	Mar	NEWA
AP			150MG/15ML (10MG/ML)	A205487	002	Mar 28, 2016	Mar	NEWA
AP			450MG/45ML (10MG/ML)	A205487	003	Mar 28, 2016	Mar	NEWA

CARFILZOMIB

POWDER;INTRAVENOUS
KYPROLIS

+	ONYX THERAP	60MG/VIAL	N202714	001	Jul 20, 2012	Feb	CAHN
---	-------------	-----------	---------	-----	--------------	-----	------

CARISOPRODOL

TABLET;ORAL
CARISOPRODOL

AA		INGENUS PHARMS NJ	350MG	A040823	001	Oct 22, 2008	Jan	CAHN
>D>	AB	SHASUN PHARMS LTD	250MG	A205513	001	Nov 12, 2015	May	CAHN
>D>	AA		350MG	A205513	002	Nov 12, 2015	May	CAHN
>A>	AB	STRIDES PHARMA	250MG	A205513	001	Nov 12, 2015	May	CAHN
>A>	AA		350MG	A205513	002	Nov 12, 2015	May	CAHN

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION;ORAL
CEFADROXIL

@	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003	Feb	DISC
@		EQ 250MG BASE/5ML	A065115	002	Mar 26, 2003	Feb	DISC
@		EQ 500MG BASE/5ML	A065115	003	Mar 26, 2003	Feb	DISC

CEFAZOLIN SODIUM

INJECTABLE;INJECTION
CEFAZOLIN SODIUM

AP		HOSPIRA INC	EQ 1GM BASE/VIAL	A201654	001	Feb 03, 2016	Jan	NEWA
----	--	-------------	------------------	---------	-----	--------------	-----	------

CEFDITOREN PIVOXIL

TABLET;ORAL
SPECTRACEF

@	VANSEN PHARMA	200MG	N021222	001	Aug 29, 2001	Apr	DISC
@		400MG	N021222	002	Jul 21, 2008	Apr	DISC

CEFEPIME HYDROCHLORIDE

INJECTABLE;INJECTION
CEFEPIME HYDROCHLORIDE

AP		QILU PHARM CO LTD	EQ 500MG BASE/VIAL	A203704	001	Feb 01, 2016	Jan	NEWA
AP			EQ 1GM BASE/VIAL	A203704	002	Feb 01, 2016	Jan	NEWA
AP			EQ 2GM BASE/VIAL	A203704	003	Feb 01, 2016	Jan	NEWA

CEFOTAXIME SODIUM

INJECTABLE;INJECTION
CEFOTAXIME SODIUM

AP		HOSPIRA INC	EQ 1GM BASE/VIAL	A203132	001	Feb 19, 2016	Feb	NEWA
AP			EQ 2GM BASE/VIAL	A203132	002	Feb 19, 2016	Feb	NEWA
		CLAFORAN						
AP	+	US PHARM HOLDINGS	EQ 500MG BASE/VIAL	N050547	001		Jan	CAHN
AP	+		EQ 1GM BASE/VIAL	N050547	002		Jan	CAHN
AP	+		EQ 2GM BASE/VIAL	N050547	003		Jan	CAHN
AP	+		EQ 10GM BASE/VIAL	N050547	004	Dec 29, 1983	Jan	CAHN
		CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER						
	+	US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	002	May 20, 1985	Jan	CAHN
	+		EQ 40MG BASE/ML	N050596	004	May 20, 1985	Jan	CAHN
		CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
	@	US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	001	May 20, 1985	Jan	CAHN
	@		EQ 40MG BASE/ML	N050596	003	May 20, 1985	Jan	CAHN

CEFOTETAN DISODIUMINJECTABLE; INJECTION
CEFOTAN

	@ TELIGENT PHARMA INC	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993	Jan CAHN
AP		EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Feb CMFD
	@	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Jan CAHN
	@	EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993	Jan CAHN
AP		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Feb CMFD
	@	EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Jan CAHN
	@	EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Jan CAHN

CEFOXITIN SODIUMINJECTABLE; INJECTION
CEFOXITIN

>A>	AP	ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A065467	001	Aug 31, 2011	May CAHN
>A>	AP		EQ 2GM BASE/VIAL	A065467	002	Aug 31, 2011	May CAHN
>A>	AP		EQ 10GM BASE/VIAL	A065464	001	Aug 31, 2011	May CAHN
>D>	AP	ANTIBIOTICOS BRASIL	EQ 1GM BASE/VIAL	A065467	001	Aug 31, 2011	May CAHN
>D>	AP		EQ 2GM BASE/VIAL	A065467	002	Aug 31, 2011	May CAHN
>D>	AP		EQ 10GM BASE/VIAL	A065464	001	Aug 31, 2011	May CAHN

CEFPODOXIME PROXETILFOR SUSPENSION; ORAL
CEFPODOXIME PROXETIL

@	SUN PHARM INDS LTD	EQ 50MG BASE/5ML	A065082	001	May 31, 2002	Feb DISC
@		EQ 100MG BASE/5ML	A065082	002	May 31, 2002	Feb DISC

TABLET; ORAL
CEFPODOXIME PROXETIL

@	SUN PHARM INDS LTD	EQ 100MG BASE	A065083	001	Aug 20, 2003	Feb DISC
@		EQ 200MG BASE	A065083	002	Aug 20, 2003	Feb DISC

CEFTRIAXONE SODIUMINJECTABLE; INJECTION
CEFTRIAXONE

@	HOSPIRA INC	EQ 1GM BASE/VIAL	A065231	001	Aug 02, 2005	Apr DISC
@		EQ 1GM BASE/VIAL	A202563	001	Aug 20, 2012	Apr DISC
@		EQ 2GM BASE/VIAL	A065231	002	Aug 02, 2005	Apr DISC
@		EQ 2GM BASE/VIAL	A202563	002	Aug 20, 2012	Apr DISC
	ROCEPHIN					
@	HOFFMANN LA ROCHE	EQ 500MG BASE/VIAL	A063239	002	Aug 13, 1993	Apr DISC
@		EQ 1GM BASE/VIAL	A063239	003	Aug 13, 1993	Apr DISC

CEFUROXIME AXETILFOR SUSPENSION; ORAL
CEFTIN

	GLAXOSMITHKLINE	EQ 125MG BASE/5ML	N050672	001	Jun 30, 1994	Feb CTEC
+		EQ 250MG BASE/5ML	N050672	002	Apr 29, 1997	Feb CTEC

	CEFUROXIME AXETIL					
@	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065323	001	Feb 05, 2008	Feb DISC
@		EQ 250MG BASE/5ML	A065323	002	Feb 05, 2008	Feb DISC

TABLET; ORAL
CEFUROXIME AXETIL

@	SUN PHARM INDS LTD	EQ 125MG BASE	A065118	001	Apr 25, 2003	Feb DISC
@		EQ 250MG BASE	A065118	002	Apr 25, 2003	Feb DISC
@		EQ 500MG BASE	A065118	003	Apr 25, 2003	Feb DISC

CEFUROXIME SODIUMINJECTABLE; INJECTION
ZINACEF

AP	+	IGI LABS INC	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Jan CAHN
AP	+		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Jan CAHN

ZINACEF IN PLASTIC CONTAINER

@	IGI LABS INC	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	Jan CAHN
+		EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	Jan CAHN

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS
ZINACEF

AB	+	IGI LABS INC	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Jan CAHN
----	---	--------------	--------------------	---------	-----	--------------	----------

CELECOXIBCAPSULE;ORAL
CELECOXIB

AB	AUROBINDO PHARMA LTD	50MG	A206827	001	Feb 01, 2016	Jan NEWA
AB		100MG	A206827	002	Feb 01, 2016	Jan NEWA
AB		200MG	A206827	003	Feb 01, 2016	Jan NEWA
AB		400MG	A206827	004	Feb 01, 2016	Jan NEWA
AB	MACLEODS PHARMS LTD	50MG	A204590	001	Mar 16, 2016	Feb NEWA
AB		100MG	A204590	002	Mar 16, 2016	Feb NEWA
AB		200MG	A204590	003	Mar 16, 2016	Feb NEWA
AB		400MG	A204590	004	Mar 16, 2016	Feb NEWA

CEPHALEXINCAPSULE;ORAL
CEPHALEXIN@ SUN PHARM INDS LTD EQ 250MG BASE
@ EQ 500MG BASEA065007 001 Sep 16, 1999 Feb DISC
A065007 002 Sep 16, 1999 Feb DISCFOR SUSPENSION;ORAL
KEFLEX@ PRAGMA PHARMS LLC EQ 100MG BASE/ML
@ EQ 125MG BASE/5ML
@ EQ 250MG BASE/5MLN050406 003 Mar CAHN
N050406 001 Mar CAHN
N050406 002 Mar CAHNCETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CETIRIZINE HYDROCHLORIDE

AA NOSTRUM LABS INC 5MG/5ML
@ WOCKHARDT 5MG/5MLA090191 001 Nov 12, 2009 Mar CAHN
A078757 001 Aug 28, 2009 Apr DISCCHLORHEXIDINE GLUCONATESOLUTION;DENTAL
PERIOGARD

AT COLGATE-PALMOLIVE CO 0.12%

A203212 001 Jan 28, 2016 Jan NEWA

CHLOROQUINE PHOSPHATE

TABLET;ORAL

CHLOROQUINE PHOSPHATE

@ IMPAX LABS EQ 150MG BASE
@ EQ 300MG BASEA080880 001 Mar DISC
A040516 001 Aug 29, 2003 Mar DISCCHLORPHENIRAMINE MALEATE

TABLET;ORAL

CHLORPHENIRAMINE MALEATE

@ AUROLIFE PHARMA LLC 4MG

A080961 001 Mar CAHN

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE,CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA MAYNE PHARMA INC 4MG/5ML;5MG/5ML;60MG/5ML

A205657 001 Aug 03, 2015 Feb CAHN

CHLORPROPAMIDE

TABLET;ORAL

CHLORPROPAMIDE

@ AUROLIFE PHARMA LLC 100MG
@ 250MGA088725 001 Aug 31, 1984 Mar CAHN
A088726 001 Aug 31, 1984 Mar CAHNCHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

AB MYLAN 25MG
AB SUN PHARM INDS 25MGA086831 002 Jan CTEC
A089286 002 Jul 21, 1986 Jan NEWACHLORZOXAZONE

TABLET;ORAL

CHLORZOXAZONE

@ AUROLIFE PHARMA LLC 250MG
@ 500MG
+ MIKART 750MG
@ SUN PHARM INDS 500MGA089852 001 May 04, 1988 Feb CAHN
A089853 001 May 04, 1988 Feb CAHN
A040861 002 Jun 01, 2010 Apr CRLD
A089970 001 Sep 27, 1990 Mar CAHN

CICLESONIDE

AEROSOL, METERED; INHALATION
ALVESCO

+ TAKEDA GMBH 0.08MG/INH N021658 002 Jan 10, 2008 Jan CRLD

CILASTATIN SODIUM; IMIPENEM

>D> POWDER; INTRAMUSCULAR
>D> PRIMAXIN

>D> MERCK EQ 500MG BASE/VIAL; 500MG/VIAL N050630 001 Dec 14, 1990 May DISC
>A> @ EQ 500MG BASE/VIAL; 500MG/VIAL N050630 001 Dec 14, 1990 May DISC

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

>A> @ IDT AUSTRALIA LTD EQ 100MG BASE A075939 001 Mar 03, 2005 May CAHN
>A> @ EQ 250MG BASE A075939 002 Jun 09, 2004 May CAHN
>A> @ EQ 500MG BASE A075939 003 Jun 09, 2004 May CAHN
>A> @ EQ 750MG BASE A075939 004 Jun 09, 2004 May CAHN
>D> @ SANDOZ EQ 100MG BASE A075939 001 Mar 03, 2005 May CAHN
>D> @ EQ 250MG BASE A075939 002 Jun 09, 2004 May CAHN
>D> @ EQ 500MG BASE A075939 003 Jun 09, 2004 May CAHN
>D> @ EQ 750MG BASE A075939 004 Jun 09, 2004 May CAHN

CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE

SOLUTION/DROPS; OTIC
OTOVEL

+ LABORATORIOS SALVAT EQ 0.3% BASE; 0.025% N208251 001 Apr 29, 2016 Apr NEWA

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

@ ACTAVIS LABS FL INC 212.6MG; EQ 287.5MG BASE A077417 001 Nov 30, 2010 Jan DISC
@ 425.2MG; EQ 574.9MG BASE A077809 001 Nov 30, 2010 Jan DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

@ SUN PHARM INDS EQ 10MG BASE A077052 001 Jul 03, 2006 Mar CAHN
@ EQ 20MG BASE A077052 002 Jul 03, 2006 Mar CAHN
@ EQ 40MG BASE A077052 003 Jul 03, 2006 Mar CAHN

CLARITHROMYCIN

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

AB ALLIED PHARMA INC 500MG A203243 001 Feb 29, 2016 Feb NEWA
>A> @ IDT AUSTRALIA LTD 500MG A065250 001 Aug 25, 2005 May CAHN
>D> @ SANDOZ 500MG A065250 001 Aug 25, 2005 May CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

>A> AA MYLAN PHARMS INC EQ 75MG BASE/5ML A203063 001 May 25, 2016 May NEWA

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

AP EUROHLTH INTL SARL EQ 150MG BASE/ML A065206 001 Sep 24, 2004 Apr CAHN

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

VELTIN

BX + AQUA PHARMS LLC 1.2%; 0.025% N050803 001 Jul 16, 2010 Jan CAHN

CLOBETASOL PROPIONATE

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

AB + FOUGERA PHARMS 0.05% A074407 001 Feb 23, 1996 Mar CRLD
@ FOUGERA PHARMS 0.05% N019323 001 Dec 27, 1985 Mar DISC

CLOMIPRAMINE HYDROCHLORIDECAPSULE;ORAL
ANAFRANIL

AB	+	MALLINCKRODT LLC	25MG	N019906	001	Dec 29, 1989	Jan CRLD
AB			50MG	N019906	002	Dec 29, 1989	Jan CRLD

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

@ AUROLIFE PHARMA LLC	0.1MG
@	0.2MG
@	0.3MG

A070887	001	Aug 31, 1988	Feb CAHN
A070886	001	Aug 31, 1988	Feb CAHN
A071294	001	Aug 31, 1988	Feb CAHN

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

AB		SUN PHARM INDS	EQ 75MG BASE	A078133	001	Jun 10, 2013	Mar CAHN
----	--	----------------	--------------	---------	-----	--------------	----------

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

CLORAZEPATE DIPOTASSIUM

@ AUROLIFE PHARMA LLC	3.75MG
@	7.5MG
@	15MG

A072219	001	Aug 26, 1988	Apr CAHN
A072220	001	Aug 26, 1988	Feb CAHN
A072112	001	Aug 26, 1988	Feb CAHN

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

@ AUROLIFE PHARMA LLC	3.75MG
@	7.5MG
@	15MG

A072512	001	May 11, 1990	Mar CAHN
A072513	001	May 11, 1990	Mar CAHN
A072514	001	May 11, 1990	Feb CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA		NOSTRUM LABS INC	10MG/5ML; 6.25MG/5ML	A090180	001	Mar 17, 2010	Feb CAHN
----	--	------------------	----------------------	---------	-----	--------------	----------

COLCHICINE

CAPSULE;ORAL

MITIGARE

+	HIKMA INTL PHARMS	0.6MG
---	-------------------	-------

N204820	001	Sep 26, 2014	Mar CRLD
---------	-----	--------------	----------

COLCHICINE; PROBENECID

TABLET;ORAL

PROBENECID AND COLCHICINE

AB		INGENUS PHARMS NJ	0.5MG;500MG	A040618	001	May 13, 2008	Jan CAHN
----	--	-------------------	-------------	---------	-----	--------------	----------

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS;OTIC

COLY-MYCIN S

+	ENDO PHARMS INC	EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG BASE/ML;0.5MG/ML
---	-----------------	---

N050356	001		Feb CAHN
---------	-----	--	----------

CORTICOTROPIN

INJECTABLE;INJECTION

PURIFIED CORTROPHIN GEL

@ ANI PHARMS	40 UNITS/ML
@	80 UNITS/ML

N008975	001		Feb CAHN
N008975	002		Feb CAHN

CORTICOTROPIN-ZINC HYDROXIDE

INJECTABLE;INJECTION

CORTROPHIN-ZINC

@ ANI PHARMS	40 UNITS/ML
--------------	-------------

N009854	001		Feb CAHN
---------	-----	--	----------

CYANOCOBALAMIN

INJECTABLE;INJECTION

CYANOCOBALAMIN

AP		SOMERSET THERAPS LLC	1MG/ML	A206503	001	Dec 11, 2015	Mar CAHN
----	--	----------------------	--------	---------	-----	--------------	----------

SPRAY, METERED;NASAL
NASCOBAL

+	ENDO PHARMS INC	0.5MG/SPRAY
---	-----------------	-------------

N021642	001	Jan 31, 2005	Feb CAHN
---------	-----	--------------	----------

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION
CYTOXAN (LYOPHILIZED)

@ BAXTER HLTHCARE 500MG/VIAL
@ 1GM/VIAL
@ 2GM/VIAL

N012142 003 Mar DISC
N012142 004 Aug 30, 1982 Mar DISC
N012142 005 Aug 30, 1982 Mar DISC

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA INGENUS PHARMS NJ

4MG

A205087 001 Sep 23, 2015 Jan CAHN

CYTARABINE

INJECTABLE; INJECTION
CYTARABINE

AP MYLAN PHARMS INC 20MG/ML
AP 20MG/ML

A200915 001 Dec 13, 2011 Mar CAHN
A200916 001 Dec 13, 2011 Mar CAHN

DACLATASVIR DIHYDROCHLORIDE

TABLET; ORAL

DAKLINZA

BRISTOL-MYERS SQUIBB EQ 90MG BASE

N206843 003 Apr 13, 2016 Apr NEWA

DACTINOMYCIN

INJECTABLE; INJECTION
DACTINOMYCIN

@ EUROHLTH INTL SARL 0.5MG/VIAL

A090304 001 Mar 16, 2010 Feb DISC

DALBAVANCIN HYDROCHLORIDE

POWDER; IV (INFUSION)
DALVANCE

+ DURATA THERAPS INTL EQ 500MG BASE/VIAL

N021883 001 May 23, 2014 Jan CDFR

DANTROLENE SODIUM

INJECTABLE; INJECTION
DANTROLENE SODIUM

AP MYLAN INSTITUTIONAL 20MG/VIAL

A205239 001 Feb 18, 2016 Feb NEWA

DAPSONE

GEL; TOPICAL
ACZONE

+ ALLERGAN INC 7.5%

N207154 001 Feb 24, 2016 Feb NEWA

TABLET; ORAL

DAPSONE

AB ALVOGEN 25MG
AB 100MG
AB NORTH CREEK PHARMS 25MG
AB 100MG
AB NOSTRUM LABS INC 25MG
AB 100MG

A205429 001 Jan 07, 2016 Mar CAHN
A205429 002 Jan 07, 2016 Mar CAHN
A204074 001 May 10, 2016 Apr NEWA
A204074 002 May 10, 2016 Apr NEWA
A203887 001 May 06, 2016 Apr NEWA
A203887 002 May 06, 2016 Apr NEWA

DAPTOMYCIN

POWDER; INTRAVENOUS
CUBICIN

AP + CUBIST 500MG/VIAL
DAPTOMYCIN

N021572 002 Sep 12, 2003 Jan CDFR

AP HOSPIRA INC 500MG/VIAL
AP TEVA PARENTERAL 500MG/VIAL

A202857 001 Sep 12, 2014 Jan CDFR
A091039 001 Mar 25, 2016 Mar NEWA

POWDER; IV (INFUSION)
CUBICIN

@ CUBIST 250MG/VIAL

N021572 001 Sep 12, 2003 Jan CDFR

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL
ENABLEX

AB APIL EQ 7.5MG BASE
AB + EQ 15MG BASE

N021513 001 Dec 22, 2004 Jan CAHN
N021513 002 Dec 22, 2004 Jan CAHN

DASATINIB

TABLET; ORAL

>A>	DASATINIB						
>A>	AB	APOTEX INC	20MG	A202103	001	Jun 10, 2016	May NEWA
>A>	AB		50MG	A202103	002	Jun 10, 2016	May NEWA
>A>	AB		70MG	A202103	003	Jun 10, 2016	May NEWA
>A>	AB		100MG	A202103	004	Jun 10, 2016	May NEWA
		SPRYCEL					
>D>		BRISTOL MYERS SQUIBB	20MG	N021986	001	Jun 28, 2006	May CFTG
>A>	AB		20MG	N021986	001	Jun 28, 2006	May CFTG
>D>			50MG	N021986	002	Jun 28, 2006	May CFTG
>A>	AB		50MG	N021986	002	Jun 28, 2006	May CFTG
>D>			70MG	N021986	003	Jun 28, 2006	May CFTG
>A>	AB		70MG	N021986	003	Jun 28, 2006	May CFTG
>D>	+		100MG	N021986	004	May 30, 2008	May CFTG
>A>	AB	+	100MG	N021986	004	May 30, 2008	May CFTG

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL; INJECTION

DAUNOXOME

>D>	+	GALEN (UK)	EQ 2MG BASE/ML	N050704	002	Apr 08, 1996	May DISC
>A>	@		EQ 2MG BASE/ML	N050704	002	Apr 08, 1996	May DISC

DEFERASIROX

TABLET, FOR SUSPENSION; ORAL

DEFERASIROX

AB	ACTAVIS ELIZABETH	125MG	A203560	001	Jan 26, 2016	Jan NEWA
AB		250MG	A203560	002	Jan 26, 2016	Jan NEWA
AB		500MG	A203560	003	Jan 26, 2016	Jan NEWA
	EXJADE					
AB	NOVARTIS	125MG	N021882	001	Nov 02, 2005	Jan CFTG
AB		250MG	N021882	002	Nov 02, 2005	Jan CFTG
AB	+	500MG	N021882	003	Nov 02, 2005	Jan CFTG

DEFIBROTIDE SODIUM

SOLUTION; IV (INFUSION)

DEFITELIO

+	GENTIUM SPA	200MG/2.5ML (80MG/ML)	N208114	001	Mar 30, 2016	Mar NEWA
---	-------------	-----------------------	---------	-----	--------------	----------

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DEMECLOCYCLINE HYDROCHLORIDE

@	IMPAX LABS	150MG	A065094	001	Mar 22, 2004	Mar DISC
@		300MG	A065094	002	Mar 22, 2004	Mar DISC

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

AB	AMNEAL PHARMS CO	10MG	A208105	001	Mar 17, 2016	Mar NEWA
AB		25MG	A208105	002	Mar 17, 2016	Mar NEWA
AB		50MG	A208105	003	Mar 17, 2016	Mar NEWA
AB		75MG	A208105	004	Mar 17, 2016	Mar NEWA
AB		100MG	A208105	005	Mar 17, 2016	Mar NEWA
AB		150MG	A208105	006	Mar 17, 2016	Mar NEWA
AB	INDICUS PHARMA	10MG	A207433	001	May 05, 2016	Apr NEWA
AB		25MG	A207433	002	May 05, 2016	Apr NEWA
AB		50MG	A207433	003	May 05, 2016	Apr NEWA
AB		75MG	A207433	004	May 05, 2016	Apr NEWA
AB		100MG	A207433	005	May 05, 2016	Apr NEWA
AB		150MG	A207433	006	May 05, 2016	Apr NEWA
	NORPRAMIN					
AB	US PHARM HOLDINGS	10MG	N014399	007	Feb 11, 1982	Jan CAHN
AB		25MG	N014399	001		Jan CAHN
AB		50MG	N014399	003		Jan CAHN
AB		75MG	N014399	004		Jan CAHN
AB	+	100MG	N014399	005		Jan CAHN
AB		150MG	N014399	006		Jan CAHN

DESLORATADINESOLUTION; ORAL
DESLORATADINE

>A>	AA	TARO	0.5MG/ML	A202936	001	May 26, 2016	May NEWA
-----	----	------	----------	---------	-----	--------------	----------

DESONIDECREAM; TOPICAL
DESONIDE

AB		G AND W LABS INC	0.05%	A074027	001	Sep 28, 1992	Jan CAHN
----	--	------------------	-------	---------	-----	--------------	----------

DESOXIMETASONEOINTMENT; TOPICAL
DESOXIMETASONE

AB		NOVEL LABS INC	0.25%	A206792	001	May 10, 2016	Apr NEWA
>A>	AB	PERRIGO ISRAEL	0.25%	A077770	001	Apr 20, 2015	May CAHN
>D>	AB	PERRIGO NEW YORK	0.25%	A077770	001	Apr 20, 2015	May CAHN
AB		TELIGENT PHARMA INC	0.25%	A208101	001	Feb 25, 2016	Feb NEWA

DESVENLAFAXINE SUCCINATETABLET, EXTENDED RELEASE; ORAL
DESVENLAFAXINE SUCCINATE

AB		ROXANE	EQ 50MG BASE	A204082	001	Feb 16, 2016	Feb NEWA
AB			EQ 100MG BASE	A204083	001	Feb 16, 2016	Feb NEWA

DEXAMETHASONETABLET; ORAL
DEXAMETHASONE

>A>		@ IDT AUSTRALIA LTD	0.75MG	A080399	001		May CAHN
>D>		@ SANDOZ	0.75MG	A080399	001		May CAHN
		@ SUN PHARM INDS	0.25MG	A084013	001		Mar CAHN
		@	0.25MG	A084764	001		Mar CAHN
		@	0.5MG	A084084	001		Mar CAHN
		@	0.5MG	A084766	001		Mar CAHN
		@	0.75MG	A084081	001		Mar CAHN
		@	0.75MG	A084765	001		Mar CAHN
		@	1.5MG	A084086	001		Mar CAHN
		@	1.5MG	A084763	001		Mar CAHN

DEXAMETHASONE SODIUM PHOSPHATEINJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE

AP	+	FRESENIUS KABI USA	EQ 10MG PHOSPHATE/ML	A040491	001	Apr 11, 2003	Mar CTNA
----	---	--------------------	----------------------	---------	-----	--------------	----------

DEXILANSOPRAZOLETABLET, ORALLY DISINTEGRATING, DELAYED RELEASE; ORAL
DEXILANT SOLUTAB

+		TAKEDA PHARMS USA	30MG	N208056	001	Jan 26, 2016	Jan NEWA
---	--	-------------------	------	---------	-----	--------------	----------

DEXMEDETOMIDINE HYDROCHLORIDEINJECTABLE; INJECTION
DEXMEDETOMIDINE HYDROCHLORIDE

AP		ACCORD HLTHCARE INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204023	001	Feb 09, 2016	Jan NEWA
AP		AUROBINDO PHARMA LTD	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A205867	001	Mar 17, 2016	Mar NEWA
>A>	AP	SANDOZ INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A091465	001	Jun 14, 2016	May NEWA
		PRECEDEX					
	+	HOSPIRA	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	N021038	004	Nov 14, 2014	Feb CRLD

DEXMETHYLPHENIDATE HYDROCHLORIDETABLET; ORAL
DEXMETHYLPHENIDATE HYDROCHLORIDE

AB		SUN PHARM INDS	2.5MG	A201231	001	Sep 24, 2015	Feb CAHN
AB			5MG	A201231	002	Sep 24, 2015	Feb CAHN
AB			10MG	A201231	003	Sep 24, 2015	Feb CAHN

DEXRAZOXANE HYDROCHLORIDEINJECTABLE;INJECTION
TOTECT

+ CLINIGEN HLTHCARE EQ 500MG BASE/VIAL N022025 001 Sep 06, 2007 Mar CAHN

DEXTROAMPHETAMINE SULFATECAPSULE, EXTENDED RELEASE;ORAL
DEXTROAMPHETAMINE SULFATE

AB	MYLAN PHARMS INC	5MG	A206735	001	Jan 27, 2016	Jan NEWA
AB		10MG	A206735	002	Jan 27, 2016	Jan NEWA
AB		15MG	A206735	003	Jan 27, 2016	Jan NEWA

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

AA	NESHER PHARMS	5MG	A206588	001	Mar 28, 2016	Mar NEWA
AA		10MG	A206588	002	Mar 28, 2016	Mar NEWA
AA	NOVEL LABS INC	5MG	A204330	001	Mar 16, 2016	Feb NEWA
AA		10MG	A204330	002	Mar 16, 2016	Feb NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

@ ANI PHARMS 15MG/5ML;6.25MG/5ML N011265 002 Apr 02, 1984 Feb CMS1

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER

BAXTER HLTHCARE 5GM/100ML;31MG/100ML;141MG/100ML;2 N017484 001 Feb CMS1
0MG/100ML;12MG/100ML;260MG/100MLDEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 75 IN PLASTIC CONTAINER

@ BAXTER HLTHCARE 5GM/100ML;205MG/100ML;100MG/100ML; N018840 001 Jun 29, 1983 Feb CMS1
120MG/100ML;220MG/100MLDIAZEPAM

INJECTABLE;INJECTION

DIAZEPAM

@ EUROHLTH INTL SARL 5MG/ML A070313 001 Dec 16, 1985 Jan CAHN

TABLET;ORAL

DIAZEPAM

DAVA PHARMS INC 2MG A070228 002 Sep 26, 1985 Jan NEWA
5MG A070228 003 Sep 26, 1985 Jan NEWADICLOFENAC POTASSIUM

CAPSULE;ORAL

DICLOFENAC POTASSIUM

AB	BIONPHARMA INC	25MG	A204648	001	Feb 23, 2016	Feb NEWA
----	----------------	------	---------	-----	--------------	----------

ZIPSOR

AB	+ DEPOMED INC	25MG	N022202	001	Jun 16, 2009	Feb CFTG
----	---------------	------	---------	-----	--------------	----------

FOR SOLUTION;ORAL

CAMBIA

AB	+ DEPOMED INC	50MG	N022165	001	Jun 17, 2009	Apr CFTG
----	---------------	------	---------	-----	--------------	----------

DICLOFENAC POTASSIUM

AB	PAR FORM	50MG	A202964	001	May 02, 2016	Apr NEWA
----	----------	------	---------	-----	--------------	----------

TABLET;ORAL

CATAFLAM

@ NOVARTIS 50MG N020142 002 Nov 24, 1993 Mar DISC

DICLOFENAC POTASSIUM

AB	+ MYLAN	50MG	A075463	001	Jul 26, 1999	Mar CRLD
----	---------	------	---------	-----	--------------	----------

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

AB	AMNEAL PHARMS	1%	A208077	001	Mar 18, 2016	Mar NEWA
----	---------------	----	---------	-----	--------------	----------

AB	TARO	3%	A206298	001	Apr 28, 2016	Apr NEWA
----	------	----	---------	-----	--------------	----------

VOLTAREN

AB	+ GLAXOSMITHKLINE CONS	1%	N022122	001	Oct 17, 2007	Mar CFTG
----	------------------------	----	---------	-----	--------------	----------

		SOLUTION; TOPICAL					
		DICLOFENAC SODIUM					
>D>	AT	IGI LABS INC	1.5%	A202769	001	Jul 08, 2015	May CAHN
>A>	AT	TELLIGENT PHARMA INC	1.5%	A202769	001	Jul 08, 2015	May CAHN
		SOLUTION/DROPS; OPHTHALMIC					
		DICLOFENAC SODIUM					
	AT	RISING PHARMS INC	0.1%	A078553	001	Dec 28, 2007	Jan CAHN
		TABLET, EXTENDED RELEASE; ORAL					
		DICLOFENAC SODIUM					
AB	+	ACTAVIS ELIZABETH	100MG	A075910	001	Jan 07, 2002	Feb CRLD
		VOLTAREN-XR					
		@ NOVARTIS	100MG	N020254	001	Mar 08, 1996	Feb DISC
<u>DICLOFENAC SODIUM; MISOPROSTOL</u>							
		TABLET, DELAYED RELEASE; ORAL					
		DICLOFENAC SODIUM AND MISOPROSTOL					
AB		EXELA PHARMA SCS LLC	50MG; 0.2MG	A200540	001	Mar 14, 2014	Mar CAHN
AB			75MG; 0.2MG	A200540	002	Mar 14, 2014	Mar CAHN
<u>DICYCLOMINE HYDROCHLORIDE</u>							
		CAPSULE; ORAL					
		DICYCLOMINE HYDROCHLORIDE					
		@ SUN PHARM INDS	10MG	A084505	001	Oct 21, 1986	Mar CAHN
		INJECTABLE; INJECTION					
		DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE)					
AP		EUROHLTH INTL SARL	10MG/ML	A040465	001	Jun 30, 2003	Mar CMS1
		SYRUP; ORAL					
		BENTYL					
		@ APTALIS PHARMA US	10MG/5ML	N007961	002	Oct 15, 1984	Jan DISC
		DICYCLOMINE HYDROCHLORIDE					
	+	MIKART	10MG/5ML	A040169	001	Mar 24, 2005	Jan CRLD
		TABLET; ORAL					
		DICYCLOMINE HYDROCHLORIDE					
		@ SUN PHARM INDS	20MG	A084600	001	Jul 29, 1985	Mar CAHN
<u>DIENOEST; ESTRADIOL VALERATE</u>							
		TABLET; ORAL					
		ESTRADIOL VALERATE AND DIENOEST					
AB		WATSON LABS INC	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M	A202349	001	May 06, 2016	Apr NEWA
			G, N/A				
		NATAZIA					
AB	+	BAYER HLTHCARE	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M	N022252	001	May 06, 2010	Apr CFTG
			G, N/A				
<u>DIETHYLPROPION HYDROCHLORIDE</u>							
		TABLET; ORAL					
		DIETHYLPROPION HYDROCHLORIDE					
		@ COREPHARMA	25MG	A040828	001	Nov 05, 2008	Mar DISC
		TENUATE					
AA	+	ACTAVIS LABS UT INC	25MG	N011722	002		Apr CAHN
AA	+	ALLERGAN SALES LLC	25MG	N011722	002		Mar CAHN
		TABLET, EXTENDED RELEASE; ORAL					
		TENUATE DOSPAN					
AB	+	ACTAVIS LABS UT INC	75MG	N012546	001		Apr CAHN
AB	+	ALLERGAN SALES LLC	75MG	N012546	001		Mar CAHN
<u>DIFLUNISAL</u>							
		TABLET; ORAL					
		DIFLUNISAL					
>A>		@ IDT AUSTRALIA LTD	500MG	A074604	001	Jun 10, 1996	May CAHN
>D>		@ SANDOZ	500MG	A074604	001	Jun 10, 1996	May CAHN
<u>DIHYDROERGOTAMINE MESYLATE</u>							
		INJECTABLE; INJECTION					
		DIHYDROERGOTAMINE MESYLATE					
AP		EUROHLTH INTL SARL	1MG/ML	A040453	001	Jun 09, 2003	Apr CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL							
DILTIAZEM HYDROCHLORIDE							
	@	ACTAVIS LABS FL INC	120MG	A074852	001	Oct 10, 1997	Jan DISC
	@		180MG	A074852	002	Oct 10, 1997	Jan DISC
	@		240MG	A074852	003	Oct 10, 1997	Jan DISC
AB3		VALEANT PHARMS NORTH	120MG	A075116	001	Dec 23, 1999	Jan CAHN
AB3			180MG	A075116	002	Dec 23, 1999	Jan CAHN
AB3			240MG	A075116	003	Dec 23, 1999	Jan CAHN
AB3			300MG	A075116	004	Dec 23, 1999	Jan CAHN
INJECTABLE;INJECTION							
DILTIAZEM HYDROCHLORIDE							
AP	+	EUROHLTH INTL SARL	5MG/ML	A074617	001	Feb 28, 1996	Apr CAHN

DINOPROSTONE

INSERT, EXTENDED RELEASE;VAGINAL
CERVIDIL

+ FERRING PHARMS INC 10MG N020411 001 Mar 30, 1995 Jan CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE;ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

@ HIKMA PHARMS 50MG A083567 001 Feb CAHN

@ SUN PHARM INDS 25MG A089488 001 Jan 02, 1987 Mar CAHN

DIPYRIDAMOLE

INJECTABLE;INJECTION

DIPYRIDAMOLE

AP + EUROHLTH INTL SARL 5MG/ML A074939 001 Apr 13, 1998 Apr CAHN

TABLET;ORAL

DIPYRIDAMOLE

>A> @ IDT AUSTRALIA LTD 25MG A086944 002 Apr 16, 1991 May CAHN

>A> @ 50MG A087562 001 Feb 25, 1992 May CAHN

>A> @ 75MG A087561 001 Feb 25, 1992 May CAHN

>D> @ SANDOZ 25MG A086944 002 Apr 16, 1991 May CAHN

>D> @ 50MG A087562 001 Feb 25, 1992 May CAHN

>D> @ 75MG A087561 001 Feb 25, 1992 May CAHN

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL

DISOPYRAMIDE PHOSPHATE

@ AUROLIFE PHARMA LLC EQ 100MG BASE A070470 001 Dec 10, 1985 Feb CAHN

@ EQ 150MG BASE A070471 001 Dec 10, 1985 Feb CAHN

@ SUN PHARM INDS EQ 100MG BASE A070351 001 Dec 17, 1985 Mar CAHN

@ EQ 150MG BASE A070352 001 Dec 17, 1985 Mar CAHN

DISULFIRAM

TABLET;ORAL

DISULFIRAM

AB ALVOGEN MALTA 250MG A091681 001 Aug 08, 2013 Jan CAHN

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE;ORAL

DIVALPROEX SODIUM

@ IMPAX LABS EQ 250MG VALPROIC ACID A078791 001 May 06, 2009 Feb DISC

@ EQ 500MG VALPROIC ACID A078791 002 Aug 04, 2009 Feb DISC

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOBUTAMINE HYDROCHLORIDE

@ TELIGENT PHARMA INC EQ 12.5MG BASE/ML A074098 001 Feb 21, 1995 Jan CAHN

DOCETAXEL

SOLUTION;IV (INFUSION)

DOCETAXEL

EAGLE PHARMS 20MG/ML (20MG/ML) N205934 001 Dec 22, 2015 Jan CAHN

80MG/4ML (20MG/ML) N205934 002 Dec 22, 2015 Jan CAHN

160MG/8ML (20MG/ML) N205934 003 Dec 22, 2015 Jan CAHN

DOFETILIDE

CAPSULE;ORAL

>A> DOFETILIDE

>A> AB	TIGER PHARMS LLC	0.125MG	A207058	001	Jun 06, 2016	May NEWA
>A> AB		0.25MG	A207058	002	Jun 06, 2016	May NEWA
>A> AB		0.5MG	A207058	003	Jun 06, 2016	May NEWA

TIKOSYN

>D>	PFIZER	0.125MG	N020931	001	Oct 01, 1999	May CFTG
>A> AB		0.125MG	N020931	001	Oct 01, 1999	May CFTG
>D>		0.25MG	N020931	002	Oct 01, 1999	May CFTG
>A> AB		0.25MG	N020931	002	Oct 01, 1999	May CFTG
>D>	+	0.5MG	N020931	003	Oct 01, 1999	May CFTG
>A> AB	+	0.5MG	N020931	003	Oct 01, 1999	May CFTG

DOLASETRON MESYLATE

INJECTABLE;INJECTION

ANZEMET

+	US PHARM HOLDINGS	12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997	Jan CAHN
+		100MG/5ML (20MG/ML)	N020624	001	Sep 11, 1997	Jan CAHN
+		500MG/25ML (20MG/ML)	N020624	003	Dec 11, 2001	Jan CAHN

TABLET;ORAL

ANZEMET

	US PHARM HOLDINGS	50MG	N020623	001	Sep 11, 1997	Jan CAHN
+		100MG	N020623	002	Sep 11, 1997	Jan CAHN

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL

DONEPEZIL HYDROCHLORIDE

AB	DEXCEL PHARMA	23MG	A203713	001	Feb 19, 2016	Feb NEWA
AB	INDICUS PHARMA	23MG	A203419	001	Apr 12, 2016	Mar NEWA
AB	OSMOTICA PHARM CORP	23MG	A203114	001	Jan 26, 2016	Jan NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

DONEPEZIL HYDROCHLORIDE

@	SUN PHARM INDS	5MG	A077975	002	Dec 11, 2009	Mar CAHN
@		10MG	A077975	001	Dec 11, 2009	Mar CAHN

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION

DOXAPRAM HYDROCHLORIDE

AP	EUROHLTH INTL SARL	20MG/ML	A076266	001	Jan 10, 2003	Apr CAHN
----	--------------------	---------	---------	-----	--------------	----------

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

@	IDT AUSTRALIA LTD	EQ 1MG BASE	A075432	001	Oct 18, 2000	Mar CAHN
@		EQ 2MG BASE	A075432	002	Oct 18, 2000	Mar CAHN
@		EQ 4MG BASE	A075432	003	Oct 18, 2000	Mar CAHN
@		EQ 8MG BASE	A075432	004	Oct 18, 2000	Mar CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

@	SUN PHARM INDS	EQ 25MG BASE	A071502	001	Feb 18, 1988	Mar CAHN
@		EQ 50MG BASE	A071653	001	Feb 18, 1988	Mar CAHN
@		EQ 75MG BASE	A071654	001	Feb 18, 1988	Mar CAHN
@		EQ 100MG BASE	A071521	001	Feb 18, 1988	Mar CAHN

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 3MG BASE	A202337	001	Jan 20, 2016	Jan NEWA
AB		EQ 6MG BASE	A202337	002	Jan 20, 2016	Jan NEWA

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

AP	AKORN INC	2MCG/ML (2MCG/ML)	A203929	002	Mar 28, 2016	Mar NEWA
	HECTOROL					
AP	GENZYME CORP	2MCG/ML (2MCG/ML)	N021027	002	Apr 06, 2000	Mar CFTG

DOXORUBICIN HYDROCHLORIDEINJECTABLE;INJECTION
DOXORUBICIN HYDROCHLORIDE

>D>	AP	+	ACTAVIS INC	2MG/ML	A203622	001	Jun 27, 2014	May	CRLD
>A>	AP			2MG/ML	A203622	001	Jun 27, 2014	May	CRLD
>D>	AP	+		200MG/100ML	A203622	002	Jun 27, 2014	May	CRLD
>A>	AP			200MG/100ML	A203622	002	Jun 27, 2014	May	CRLD
>D>	AP		PHARMACIA AND UPJOHN	2MG/ML	N050629	001	Dec 23, 1987	May	CRLD
>A>	AP	+		2MG/ML	N050629	001	Dec 23, 1987	May	CRLD
>D>	AP			200MG/100ML	N050629	002	May 03, 1988	May	CRLD
>A>	AP	+		200MG/100ML	N050629	002	May 03, 1988	May	CRLD

DOXYCYCLINECAPSULE;ORAL
DOXYCYCLINE

AB			G AND W LABS INC	EQ 50MG BASE	A204446	001	May 28, 2015	Mar	CAHN
AB				EQ 75MG BASE	A204446	002	May 28, 2015	Mar	CAHN
AB				EQ 100MG BASE	A204446	003	May 28, 2015	Mar	CAHN
AB			ZYDUS PHARMS USA INC	EQ 50MG BASE	A205115	001	Feb 18, 2016	Feb	NEWA
AB				EQ 75MG BASE	A205115	002	Feb 18, 2016	Feb	NEWA
AB				EQ 100MG BASE	A205115	003	Feb 18, 2016	Feb	NEWA

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

ACTICLATE CAP

		+	AQUA PHARMS	EQ 75MG BASE	N208253	001	Apr 26, 2016	Apr	NEWA
AB			SUN PHARM INDS	EQ 100MG BASE	A062676	001	Jul 10, 1986	Mar	CAHN

TABLET;ORAL

DOXYCYCLINE HYCLATE

		@	COREPHARMA	EQ 20MG BASE	A065182	001	May 13, 2005	Mar	DISC
AB			SUN PHARM INDS	EQ 20MG BASE	A065134	001	May 13, 2005	Mar	CAHN
AB				EQ 100MG BASE	A062677	001	Jul 10, 1986	Mar	CAHN
		@	VINTAGE PHARMS	EQ 100MG BASE	A062538	001	Apr 07, 1986	Mar	DISC

TABLET, DELAYED RELEASE;ORAL

DORYX

>A>			MAYNE PHARMA	EQ 60MG BASE	N050795	007	May 20, 2016	May	NEWA
	AB			EQ 80MG BASE	N050795	004	Apr 11, 2013	Apr	CFTG
>A>				EQ 120MG BASE	N050795	008	May 20, 2016	May	NEWA
>D>		+		EQ 200MG BASE	N050795	005	Apr 11, 2013	May	CFTG
>A>	AB	+		EQ 200MG BASE	N050795	005	Apr 11, 2013	May	CFTG
			DOXTERIC						
>D>			MAYNE PHARMA	EQ 50MG BASE	N050795	006	Dec 19, 2014	May	CFTG
>A>	AB			EQ 50MG BASE	N050795	006	Dec 19, 2014	May	CFTG
			DOXYCYCLINE HYCLATE						
		@	IMPAX LABS INC	EQ 75MG BASE	A090505	001	Dec 28, 2010	Mar	DISC
		@		EQ 100MG BASE	A090505	002	Dec 28, 2010	Mar	DISC
>A>	AB		MYLAN	EQ 50MG BASE	A090431	003	May 23, 2016	May	NEWA
	AB			EQ 80MG BASE	A090431	004	Apr 29, 2016	Apr	NEWA
>A>	AB			EQ 200MG BASE	A090431	005	May 19, 2016	May	NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

MELAMISA

AB			NOVAST LABS LTD	3MG;0.02MG	A202016	001	Jan 26, 2016	Jan	NEWA
----	--	--	-----------------	------------	---------	-----	--------------	-----	------

TABLET;ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL

AB			GLENMARK PHARMS LTD	3MG;0.03MG	A204848	001	Mar 25, 2016	Mar	NEWA
----	--	--	---------------------	------------	---------	-----	--------------	-----	------

DUTASTERIDE

CAPSULE;ORAL

DUTASTERIDE

AB			AUROLIFE PHARMA LLC	0.5MG	A202660	001	Nov 20, 2015	Apr	CAHN
AB			BIONPHARMA INC	0.5MG	A200899	001	Nov 20, 2015	Jan	CAHN
AB			INTERGEL PHARMS INC	0.5MG	A206373	001	Mar 17, 2016	Feb	NEWA
>A>	AB		MYLAN PHARMS INC	0.5MG	A203241	001	Jun 14, 2016	May	NEWA
AB			STRIDES PHARMA	0.5MG	A204262	001	Nov 20, 2015	Mar	CAHN

ECONAZOLE NITRATECREAM; TOPICAL
ECONAZOLE NITRATE

>D>	AB	IGI LABS INC	1%	A076574	001	Dec 17, 2004	May CAHN
>A>	AB	TELIGENT PHARMA INC	1%	A076574	001	Dec 17, 2004	May CAHN

EDROPHONIUM CHLORIDEINJECTABLE; INJECTION
TENSILON

@	TELIGENT PHARMA INC	10MG/ML	N007959	001		Jan CAHN
	TENSILON PRESERVATIVE FREE					
@	TELIGENT PHARMA INC	10MG/ML	N007959	002		Jan CAHN

EFAVIRENZTABLET; ORAL
EFAVIRENZ

AB	MYLAN LABS LTD	600MG	A091471	001	Feb 17, 2016	Feb NEWA
	SUSTIVA					
AB	+ BRISTOL MYERS SQUIBB	600MG	N021360	002	Feb 01, 2002	Feb CFTG

ELBASVIR; GRAZOPREVRTABLET; ORAL
ZEPATIER

+	MERCK SHARP DOHME	50MG; 100MG	N208261	001	Jan 28, 2016	Jan NEWA
---	-------------------	-------------	---------	-----	--------------	----------

ELUXADOLINETABLET; ORAL
VIBERZI

>A>	ALLERGAN HOLDINGS	75MG	N206940	001	May 27, 2015	May CAHN
>A>	+	100MG	N206940	002	May 27, 2015	May CAHN
>D>	FOREST TOSARA LTD	75MG	N206940	001	May 27, 2015	May CAHN
>D>	+	100MG	N206940	002	May 27, 2015	May CAHN

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATETABLET; ORAL
ODEFSEY

+	GILEAD SCIENCES INC	200MG; EQ 25MG BASE; EQ 25MG BASE	N208351	001	Mar 01, 2016	Apr CAIN
---	---------------------	-----------------------------------	---------	-----	--------------	----------

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATETABLET; ORAL
ODEFSEY

+	GILEAD SCIENCES INC	200MG; EQ 25MG BASE; EQ 25MG BASE	N208351	001	Mar 01, 2016	Mar NEWA
---	---------------------	-----------------------------------	---------	-----	--------------	----------

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATETABLET; ORAL
DESCOVY

+	GILEAD SCIENCES INC	200MG; EQ 25MG BASE	N208215	001	Apr 04, 2016	Apr NEWA
---	---------------------	---------------------	---------	-----	--------------	----------

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATETABLET; ORAL
TRUVADA

GILEAD	100MG; 150MG	N021752	002	Mar 10, 2016	Mar NEWA
	133MG; 200MG	N021752	003	Mar 10, 2016	Mar NEWA
	167MG; 250MG	N021752	004	Mar 10, 2016	Mar NEWA

ENALAPRILATINJECTABLE; INJECTION
ENALAPRILAT

AP	+	EUROHLTH INTL SARL	1.25MG/ML	A075634	001	Aug 22, 2000	Apr CAHN
----	---	--------------------	-----------	---------	-----	--------------	----------

EPHEDRINE SULFATESOLUTION; INTRAVENOUS
AKOVAZ

+	FLAMEL IRELAND LTD	50MG/ML	N208289	001	Apr 29, 2016	Apr NEWA
---	--------------------	---------	---------	-----	--------------	----------

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
EPINASTINE HYDROCHLORIDE
AT SOMERSET THERAPS LLC 0.05% A090951 001 Oct 31, 2011 Mar CAHN

EPINEPHRINE

INJECTABLE;INJECTION
SUS-PHRINE SULFITE FREE
@ FOREST LABS 1.5MG/AMP N007942 003 Feb 05, 1999 Mar CMS1
@ 5MG/ML N007942 001 Mar CMS1
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
AUVI-Q
BX + KALEO INC EQ 0.15MG/DELIVERY N201739 002 Aug 10, 2012 Mar CAHN
BX EQ 0.3MG/DELIVERY N201739 001 Aug 10, 2012 Mar CAHN
>D> TWINJECT 0.15
>D> BX + AMEDRA PHARMS EQ 0.15MG/DELIVERY N020800 002 May 28, 2004 May DISC
>A> @ EQ 0.15MG/DELIVERY N020800 002 May 28, 2004 May DISC
>D> TWINJECT 0.3
>D> BX + AMEDRA PHARMS EQ 0.3MG/DELIVERY N020800 001 May 30, 2003 May DISC
>A> @ EQ 0.3MG/DELIVERY N020800 001 May 30, 2003 May DISC

EPINEPHRINE HYDROCHLORIDE

SOLUTION;IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS
EPINEPHRINE

BELCHER PHARMS LLC EQ 1MG BASE/ML (EQ 1MG BASE/ML) N205029 001 Jul 29, 2014 Feb CDFR

ERGOCALCIFEROL

CAPSULE;ORAL
DRISDOL
AA + US PHARM HOLDINGS 50,000 IU N003444 001 Jan CAHN
VITAMIN D
AA BIONPHARMA INC 50,000 IU A080704 001 Jan CAHN

ERGOLOID MESYLATES

TABLET;ORAL
ERGOLOID MESYLATES
AB SUN PHARM INDS 1MG A081113 001 Oct 31, 1991 Mar CAHN

ERYTHROMYCIN

SOLUTION;TOPICAL
C-SOLVE-2
@ FOUGERA PHARMS 2% A062468 001 Jul 03, 1985 Feb DISC
ERYTHRO-STATIN
@ HI TECH PHARMA 2% A064101 001 Oct 22, 1996 Feb DISC
ERYTHROMYCIN
AT + FOUGERA PHARMS 2% A064187 001 Sep 30, 1997 Jan CRLD
AT PERRIGO NEW YORK 2% A063038 001 Jan 11, 1991 Jan CRLD

ESCITALOPRAM OXALATE

SOLUTION;ORAL
ESCITALOPRAM OXALATE
AA MACLEODS PHARMS LTD EQ 5MG BASE/5ML A202754 001 Mar 31, 2016 Mar NEWA

ESMOLOL HYDROCHLORIDE

SOLUTION;INTRAVENOUS
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER
+ HQ SPCLT PHARMA 2GM/100ML (20MG/ML) N205703 002 Apr 07, 2016 Apr NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL
ESOMEPRAZOLE MAGNESIUM
AB AUROBINDO PHARMA LTD EQ 20MG BASE A205606 001 Apr 21, 2016 Apr NEWA
AB EQ 40MG BASE A205606 002 Apr 21, 2016 Apr NEWA
BX HETERO LABS LTD III EQ 20MG BASE A202784 001 Sep 21, 2015 Apr CTEC
BX EQ 40MG BASE A202784 002 Sep 21, 2015 Apr CTEC

ESTRADIOL

		CREAM;VAGINAL					
		ESTRACE					
	+	ALLERGAN SALES LLC	0.01%	A086069	001	Jan 31, 1984	Apr CAHN
		FILM, EXTENDED RELEASE;TRANSDERMAL					
		ALORA					
BX		ALLERGAN SALES LLC	0.025MG/24HR	N020655	004	Apr 05, 2002	Mar CAHN
BX			0.05MG/24HR	N020655	001	Dec 20, 1996	Mar CAHN
BX			0.075MG/24HR	N020655	002	Dec 20, 1996	Mar CAHN
BX			0.1MG/24HR	N020655	003	Dec 20, 1996	Mar CAHN

ESTRADIOL ACETATE

		INSERT, EXTENDED RELEASE;VAGINAL					
		FEMRING					
		APIL	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003	Jan CAHN
	+		EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003	Jan CAHN
		TABLET;ORAL					
		FEMTRACE					
		APIL	0.45MG	N021633	001	Aug 20, 2004	Jan CAHN
			0.9MG	N021633	002	Aug 20, 2004	Jan CAHN
	+		1.8MG	N021633	003	Aug 20, 2004	Jan CAHN

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

		TABLET;ORAL-28					
		ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL					
AB		JAI PHARMA LTD	0.05MG;1MG	A204704	001	Feb 09, 2016	Jan NEWA
		ZOVIA 1/50E-28					
AB	+	WATSON LABS	0.05MG;1MG	A072723	001	Dec 30, 1991	Jan CTEC

ETHINYL ESTRADIOL; LEVONORGESTREL

		TABLET;ORAL					
		FAYOSIM					
AB		LUPIN LTD	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	A205943	001	Mar 29, 2016	Mar NEWA
		QUARTETTE					
AB	+	TEVA BRANDED PHARM	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	N204061	001	Mar 28, 2013	Mar CFTG
		TABLET;ORAL-28					
		LEVONORGESTREL AND ETHINYL ESTRADIOL					
>A>	AB1	AMNEAL PHARMS	0.02MG;0.1MG	A201108	001	Feb 05, 2014	May CAHN
>D>	AB1	HAUPT PHARMA	0.02MG;0.1MG	A201108	001	Feb 05, 2014	May CAHN

ETHINYL ESTRADIOL; NORETHINDRONE

		TABLET;ORAL-21					
		BREVICON 21-DAY					
		@ ALLERGAN SALES LLC	0.035MG;0.5MG	N017566	001		Apr CAHN
		NORINYL 1+35 21-DAY					
AB		ALLERGAN SALES LLC	0.035MG;1MG	N017565	001		Mar CAHN
		TABLET;ORAL-28					
		BREVICON 28-DAY					
AB		ALLERGAN SALES LLC	0.035MG;0.5MG	N017743	001		Mar CAHN
		NORINYL 1+35 28-DAY					
AB		ALLERGAN SALES LLC	0.035MG;1MG	N017565	002		Mar CAHN
		TABLET, CHEWABLE;ORAL					
		FEMCON FE					
AB	+	APIL	0.035MG;0.4MG	N021490	001	Nov 14, 2003	Jan CAHN
		NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
AB	+	APIL	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Jan CAHN
AB		LUPIN LTD	0.035MG;0.4MG	A091332	001	Mar 23, 2016	Mar NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

		CAPSULE;ORAL					
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
		@ APIL	0.02MG;1MG	N204426	001	Apr 19, 2013	Apr CAHN
		TABLET;ORAL					
		FEMHRT					
AB		APIL	0.0025MG;0.5MG	N021065	001	Jan 14, 2005	Jan CAHN
		@	0.005MG;1MG	N021065	002	Oct 15, 1999	Jan CAHN
>A>		LERIBANE					
>A>	AB	NOVAST LABS LTD	0.0025MG;0.5MG	A203435	002	Jun 03, 2016	May NEWA

		TABLET;ORAL						
>A>		LERIBANE						
>A>	AB		0.005MG;1MG	A203435	001	Jun 03, 2016	May NEWA	
		LO LOESTRIN FE						
>D>	+	APIL	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010	May CFTG	
>A>	AB	+	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010	May CFTG	
		+	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010	Jan CAHN	
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
>A>	AB	JAI PHARMA LTD	0.01MG,0.01MG;1MG,N/A	A205049	001	May 31, 2016	May NEWA	
		TABLET;ORAL-21						
		ESTROSTEP 21						
		@ APIL	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130	001	Oct 09, 1996	Jan CAHN	
		LOESTRIN 21 1.5/30						
	AB	APIL	0.03MG;1.5MG	N017875	001		Apr CAHN	
		LOESTRIN 21 1/20						
	AB	APIL	0.02MG;1MG	N017876	001		Apr CAHN	
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL						
	AB	GLENMARK PHARMS LTD	0.02MG;1MG	A206969	001	Jan 20, 2016	Jan NEWA	
		TABLET;ORAL-28						
		ESTROSTEP FE						
	AB	+	APIL	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130	002	Oct 09, 1996	Jan CAHN
		LOESTRIN FE 1.5/30						
	AB	+	APIL	0.03MG;1.5MG	N017355	001		Apr CAHN
		LOESTRIN FE 1/20						
	AB	APIL	0.02MG;1MG	N017354	001		Apr CAHN	
		TABLET, CHEWABLE;ORAL						
>A>		MIBELAS 24 FE						
>A>	AB	LUPIN ATLANTIS	0.02MG;1MG	A206287	001	May 24, 2016	May NEWA	
		MINASTRIN 24 FE						
>D>	+	APIL	0.02MG;1MG	N203667	001	May 08, 2013	May CFTG	
>A>	AB	+	0.02MG;1MG	N203667	001	May 08, 2013	May CFTG	
		+	0.02MG;1MG	N203667	001	May 08, 2013	Jan CAHN	
		TABLET, CHEWABLE, TABLET;ORAL						
		LO MINASTRIN FE						
	+	APIL	0.01MG,0.01MG,N/A;1MG,N/A,N/A	N204654	001	Jul 24, 2013	Jan CAHN	
<u>ETHINYL ESTRADIOL; NORGESTIMATE</u>								
		TABLET;ORAL-28						
		NORGESTIMATE AND ETHINYL ESTRADIOL						
>A>	AB	AMNEAL PHARMS	0.035MG;0.25MG	A203865	001	Oct 27, 2015	May CAHN	
	AB	GLENMARK PHARMS LTD	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A204057	001	Feb 23, 2016	Feb NEWA	
>D>	AB	HAUPT PHARMA	0.035MG;0.25MG	A203865	001	Oct 27, 2015	May CAHN	
>A>	AB		0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A203873	001	May 12, 2016	May NEWA	
	AB	JAI PHARMA LTD	0.035MG, 0.035MG, 0.035MG;0.18MG, 0.215MG, 0.25MG	A201897	001	Jan 27, 2016	Jan NEWA	
	AB		0.035MG;0.25MG	A201896	001	Jan 27, 2016	Jan NEWA	
	AB	LUPIN LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A205588	001	Apr 26, 2016	Apr NEWA	
<u>ETHOSUXIMIDE</u>								
		CAPSULE;ORAL						
		ETHOSUXIMIDE						
	AB	BIONPHARMA INC	250MG	A040430	001	Oct 28, 2002	Jan CAHN	
<u>ETIDRONATE DISODIUM</u>								
		TABLET;ORAL						
		DIDRONEL						
	AB	APIL	200MG	N017831	001		Apr CAHN	
	AB	+	400MG	N017831	002		Apr CAHN	
<u>ETODOLAC</u>								
		CAPSULE;ORAL						
		ETODOLAC						
>A>		@ IDT AUSTRALIA LTD	200MG	A074840	001	Aug 29, 1997	May CAHN	
>A>		@	300MG	A074840	002	Aug 29, 1997	May CAHN	
		@ LEHIGH VALLEY	300MG	A074929	001	Jan 30, 1998	Feb CAHN	
>D>		@ SANDOZ	200MG	A074840	001	Aug 29, 1997	May CAHN	
>D>		@	300MG	A074840	002	Aug 29, 1997	May CAHN	

ETOMIDATE

INJECTABLE;INJECTION
ETOMIDATE

AP	EUROHLTH INTL SARL	2MG/ML	A074593	001	Nov 04, 1996	Apr CAHN
AP	HIKMA FARMACEUTICA	2MG/ML	A202354	001	Feb 25, 2016	Feb NEWA

EXEMESTANE

TABLET;ORAL
EXEMESTANE

AB	ALVOGEN MALTA	25MG	A200898	001	Jul 28, 2014	Jan CAHN
----	---------------	------	---------	-----	--------------	----------

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
BYDUREON PEN

+	ASTRAZENECA AB	2MG	N022200	002	Feb 28, 2014	Feb NEWA
---	----------------	-----	---------	-----	--------------	----------

FAMOTIDINE

INJECTABLE;INJECTION
FAMOTIDINE

AP	EUROHLTH INTL SARL	10MG/ML	A075651	001	Apr 16, 2001	Apr CAHN
AP		10MG/ML	A075684	001	Apr 16, 2001	Apr CAHN
	FAMOTIDINE PRESERVATIVE	FREE				
AP	EUROHLTH INTL SARL	10MG/ML	A075622	001	Apr 16, 2001	Apr CAHN
AP		10MG/ML	A075825	001	Apr 17, 2001	Apr CAHN

TABLET;ORAL

FAMOTIDINE

@	SUN PHARM INDS	20MG	A075639	002	Dec 12, 2001	Mar CAHN
---	----------------	------	---------	-----	--------------	----------

@		40MG	A075639	001	Dec 12, 2001	Mar CAHN
---	--	------	---------	-----	--------------	----------

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL
FELODIPINE

AB	SUN PHARM INDS	2.5MG	A075896	001	Nov 02, 2004	Mar CAHN
AB		5MG	A075896	002	Nov 02, 2004	Mar CAHN
AB		10MG	A075896	003	Nov 02, 2004	Mar CAHN

FENOFIBRATE

TABLET;ORAL
FENOFIBRATE

AB	AUROBINDO PHARMA LTD	48MG	A205118	001	May 05, 2016	Apr NEWA
AB		145MG	A205118	002	May 05, 2016	Apr NEWA

FENOFIBRIC ACID

TABLET;ORAL
FIBRICOR

	ARALENZ PHARMS	35MG	N022418	001	Aug 14, 2009	Apr CAHN
+		105MG	N022418	002	Aug 14, 2009	Apr CAHN

FENOPROFEN CALCIUM

CAPSULE;ORAL
FENOPROFEN CALCIUM

@	AUROLIFE PHARMA LLC	EQ 200MG BASE	A072394	001	Oct 17, 1988	Mar CAHN
@		EQ 300MG BASE	A072395	001	Oct 17, 1988	Feb CAHN

TABLET;ORAL

FENOPROFEN CALCIUM

@	AUROLIFE PHARMA LLC	EQ 600MG BASE	A072396	001	Oct 17, 1988	Feb CAHN
@	SUN PHARM INDS	EQ 600MG BASE	A072902	001	Dec 21, 1990	Mar CAHN

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL
FENTANYL-12

AB	AVEVA	12.5MCG/HR	A077449	005	Sep 11, 2015	Jan NEWA
----	-------	------------	---------	-----	--------------	----------

FERRIC PYROPHOSPHATE CITRATE

FOR SOLUTION;INTRAVENOUS
TRIFERIC

+	ROCKWELL MEDICAL INC	272MG IRON/PACKET	N208551	001	Apr 25, 2016	Apr NEWA
---	----------------------	-------------------	---------	-----	--------------	----------

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL
FESOTERODINE FUMARATE

@ ALKEM LABS LTD	4MG	A204827	001	Dec 10, 2015	Jan DISC
@	8MG	A204827	002	Dec 10, 2015	Jan DISC

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@ BARR	60MG;120MG	A076236	001	Apr 14, 2005	Mar DISC
@ IMPAX PHARMS	60MG;120MG	A076298	001	Nov 12, 2010	Mar DISC

FLAVOXATE HYDROCHLORIDE

TABLET;ORAL
FLAVOXATE HYDROCHLORIDE

@ IMPAX PHARMS	100MG	A076234	001	Aug 28, 2003	Mar DISC
----------------	-------	---------	-----	--------------	----------

FLECAINIDE ACETATE

TABLET;ORAL
FLECAINIDE ACETATE

>A>	@ IDT AUSTRALIA LTD	50MG	A076030	001	Oct 28, 2002	May CAHN
>A>	@	100MG	A076030	002	Oct 28, 2002	May CAHN
>A>	@	150MG	A076030	003	Oct 28, 2002	May CAHN
>D>	@ SANDOZ	50MG	A076030	001	Oct 28, 2002	May CAHN
>D>	@	100MG	A076030	002	Oct 28, 2002	May CAHN
>D>	@	150MG	A076030	003	Oct 28, 2002	May CAHN

>A> FLUCICLOVINE F-18

>A> SOLUTION;INTRAVENOUS
>A> AXUMIN

>A>	+ BLUE EARTH	9-221mCi/ML	N208054	001	May 27, 2016	May NEWA
-----	--------------	-------------	---------	-----	--------------	----------

FLUCONAZOLE

FOR SUSPENSION;ORAL
FLUCONAZOLE

@ SUN PHARM INDS LTD	50MG/5ML	A076332	001	Jul 29, 2004	Feb DISC
@	200MG/5ML	A076332	002	Jul 29, 2004	Feb DISC

INJECTABLE;INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

	EUROHLTH INTL SARL	100MG/50ML (2MG/ML)	A076087	002	Sep 26, 2008	Apr CAHN
AP		200MG/100ML (2MG/ML)	A076087	001	Jul 29, 2004	Apr CAHN
AP		400MG/200ML (2MG/ML)	A076087	003	Jul 29, 2004	Apr CAHN
	@ TEVA PHARMS USA	200MG/100ML (2MG/ML)	A076653	001	Jul 29, 2004	Jan DISC
	@	400MG/200ML (2MG/ML)	A076653	002	Jul 29, 2004	Jan DISC

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ACS DOBFAR INFO SA	200MG/100ML (2MG/ML)	A079104	001	Jul 30, 2009	Mar CMS1
AP		400MG/200ML (2MG/ML)	A079104	002	Jul 30, 2009	Mar CMS1

TABLET;ORAL

FLUCONAZOLE

>A>	@ IDT AUSTRALIA LTD	50MG	A076086	001	Jul 29, 2004	May CAHN
>A>	@	100MG	A076086	002	Jul 29, 2004	May CAHN
>A>	@	150MG	A076086	003	Jul 29, 2004	May CAHN
>A>	@	200MG	A076086	004	Jul 29, 2004	May CAHN
>D>	@ SANDOZ	50MG	A076086	001	Jul 29, 2004	May CAHN
>D>	@	100MG	A076086	002	Jul 29, 2004	May CAHN
>D>	@	150MG	A076086	003	Jul 29, 2004	May CAHN
>D>	@	200MG	A076086	004	Jul 29, 2004	May CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS
FLUDEOXYGLUCOSE F18

AP	KREITCHMAN PET CTR	10-100mCi/ML	A203942	001	Apr 11, 2016	Mar NEWA
AP	+ QUEEN HAMAMATSU PET	10-100mCi/ML	A203771	001	Aug 31, 2015	Mar CTEC
AP	ZEVACOR PHARMA INC	20-300mCi/ML	A203591	001	Aug 31, 2015	Feb CAHN

FLUMAZENIL

INJECTABLE;INJECTION
FLUMAZENIL

AP	EUROHLTH INTL SARL	0.5MG/5ML (0.1MG/ML)	A076256	002	Oct 12, 2004	Apr CAHN
AP		1MG/10ML (0.1MG/ML)	A076256	001	Oct 12, 2004	Apr CAHN

FLUOCINOLONE ACETONIDE

OIL;TOPICAL

FLUOCINOLONE ACETONIDE

AT	LYNE	0.01%	A090982	001	Apr 25, 2016	Apr NEWA
AT		0.01%	A203377	001	Apr 25, 2016	Apr NEWA
>A> AT	TARO	0.01%	A202368	001	May 19, 2016	May NEWA
>A> AT		0.01%	A209336	001	May 19, 2016	May NEWA

OIL/DROPS;OTIC

FLUOCINOLONE ACETONIDE

AT	LYNE	0.01%	A203378	001	Apr 25, 2016	Apr NEWA
----	------	-------	---------	-----	--------------	----------

FLUOROURACIL

INJECTABLE;INJECTION

FLUOROURACIL

AP	SAGENT PHARMS	2.5GM/50ML (50MG/ML)	A203609	001	Feb 17, 2016	Feb NEWA
AP		5GM/100ML (50MG/ML)	A203609	002	Feb 17, 2016	Feb NEWA
	@ SPECTRUM PHARMS	500MG/10ML (50MG/ML)	N012209	001		Jan CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE

@ SUN PHARM INDS

EQ 10MG BASE

A075787 001 Jan 29, 2002 Mar CAHN

@

EQ 20MG BASE

A075787 002 Jan 29, 2002 Mar CAHN

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

+ EDMONT PHARMS LLC

EQ 60MG BASE

N202133 001 Oct 06, 2011 Mar CRLD

SARAFEM

AB1	APIL	EQ 10MG BASE	N021860	001	May 19, 2006	Jan CAHN
AB1		EQ 15MG BASE	N021860	002	May 19, 2006	Jan CAHN
AB1 +		EQ 20MG BASE	N021860	003	May 19, 2006	Jan CAHN

FLURANDRENOLIDE

CREAM;TOPICAL

CORDRAN SP

AT	+ AQUA PHARMS	0.05%	N012806	002		Mar CFTG
----	---------------	-------	---------	-----	--	----------

FLURANDRENOLIDE

AT	TELIGENT PHARMA INC	0.05%	A205342	001	Apr 13, 2016	Mar NEWA
----	---------------------	-------	---------	-----	--------------	----------

TAPE;TOPICAL

CORDRAN

+ ALLERGAN SALES LLC

0.004MG/SQ CM

N016455 001 Apr CAHN

FLURANDRENOLIDE; NEOMYCIN SULFATE

CREAM;TOPICAL

CORDRAN N

@ LILLY

0.05%;EQ 3.5MG BASE/GM

N050346 001 Mar CMS1

OINTMENT;TOPICAL

CORDRAN N

@ LILLY

0.05%;EQ 3.5MG BASE/GM

N050345 001 Mar CMS1

FLURAZEPAM HYDROCHLORIDE

CAPSULE;ORAL

FLURAZEPAM HYDROCHLORIDE

@ AUROLIFE PHARMA LLC

15MG

A071716 001 Jul 31, 1991 Feb CAHN

@

30MG

A071717 001 Jul 31, 1991 Feb CAHN

>A>	@ HIKMA INTL PHARMS	15MG	A071107	001	Dec 08, 1986	May CAHN
-----	---------------------	------	---------	-----	--------------	----------

>D>	@ HIKMA PHARMS LLC	15MG	A071107	001	Dec 08, 1986	May CAHN
-----	--------------------	------	---------	-----	--------------	----------

@ SUN PHARM INDS

15MG

A070454 001 Aug 04, 1986 Mar CAHN

@

30MG

A070455 001 Aug 04, 1986 Mar CAHN

FLURBIPROFEN

TABLET;ORAL

FLURBIPROFEN

@ AUROLIFE PHARMA LLC

50MG

A074448 001 Jul 28, 1995 Feb CAHN

@

100MG

A074448 002 Jul 28, 1995 Feb CAHN

FLUTICASONE FUROATEPOWDER; INHALATION
ARNUITY ELLIPTA

+	GLAXOSMITHKLINE	0.1MG/INH	N205625	001	Aug 20, 2014	Mar CRLD
---	-----------------	-----------	---------	-----	--------------	----------

FLUTICASONE FUROATE; VILANTEROL TRIFENATATEPOWDER; INHALATION
BREO ELLIPTA

+	GLAXO GRP LTD	0.2MG/INH;EQ 0.025MG BASE/INH	N204275	002	Apr 30, 2015	Mar CRLD
---	---------------	-------------------------------	---------	-----	--------------	----------

FLUVASTATIN SODIUMTABLET, EXTENDED RELEASE; ORAL
FLUVASTATIN SODIUM

>D>	AB	MYLAN PHARMS INC	80MG	A202458	001	Sep 11, 2015	May CPOT
>A>	AB		EQ 80MG BASE	A202458	001	Sep 11, 2015	May CPOT
>D>	AB	TEVA PHARMS USA	80MG	A079011	001	Jan 27, 2016	May CPOT
>A>	AB		EQ 80MG BASE	A079011	001	Jan 27, 2016	May CPOT
	AB		80MG	A079011	001	Jan 27, 2016	Jan NEWA
		LESCOL XL					
>D>	AB	+	NOVARTIS	80MG	N021192	001	Oct 06, 2000
>A>	AB	+		EQ 80MG BASE	N021192	001	Oct 06, 2000

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

@	NOSTRUM LABS INC	25MG	A075900	001	Feb 23, 2006	Feb CAHN
@		50MG	A075900	002	Feb 23, 2006	Feb CAHN
@		100MG	A075900	003	Feb 23, 2006	Feb CAHN
@	SUN PHARM INDS	25MG	A076125	001	Apr 29, 2002	Mar CAHN
@		50MG	A076125	002	Apr 29, 2002	Mar CAHN
@		100MG	A076125	003	Apr 29, 2002	Mar CAHN

FOLIC ACID

INJECTABLE; INJECTION

FOLVITE

>D>		@	HIKMA (MAPLE)	5MG/ML	N005897	008	
>A>		@	WYETH PHARMS INC	5MG/ML	N005897	008	

TABLET; ORAL

FOLIC ACID

@	SUN PHARM INDS	1MG	A040582	001	Jul 18, 2005	Mar CAHN
---	----------------	-----	---------	-----	--------------	----------

FOLVITE

>D>		@	HIKMA (MAPLE)	1MG	N005897	004	
>A>		@	WYETH PHARMS INC	1MG	N005897	004	

FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED; INHALATION

BEVESPI AEROSPHERE

+	PEARL THERAPS INC	0.0048MG/INH;0.0090MG/INH	N208294	001	Apr 25, 2016	Apr NEWA
---	-------------------	---------------------------	---------	-----	--------------	----------

FOSAMPRENAVIR CALCIUM

TABLET; ORAL

FOSAMPRENAVIR CALCIUM

AB		MYLAN PHARMS INC	EQ 700MG BASE	A204060	001	Apr 15, 2016	Apr NEWA
		LEXIVA					

AB	+	VIIV HLTHCARE	EQ 700MG BASE	N021548	001	Oct 20, 2003	Apr CFTG
----	---	---------------	---------------	---------	-----	--------------	----------

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

EMEND

>D>		+	MERCK AND CO INC	EQ 150MG BASE/VIAL	N022023	002	Nov 12, 2010
>A>	AP	+		EQ 150MG BASE/VIAL	N022023	002	Nov 12, 2010
>A>			FOSAPREPITANT DIMEGLUMINE				
>A>	AP		FRESENIUS KABI USA	EQ 150MG BASE/VIAL	A206197	001	Jun 09, 2016

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

@	ACTAVIS LABS FL INC	10MG	A076620	001	Oct 15, 2004	Jan DISC
@		20MG	A076620	002	Oct 15, 2004	Jan DISC
@		40MG	A076620	003	Oct 15, 2004	Jan DISC

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

@	ACTAVIS LABS FL INC	10MG;12.5MG	A076608	001	Dec 03, 2004	Jan	DISC
@		20MG;12.5MG	A076608	002	Dec 03, 2004	Jan	DISC
@	SUN PHARM INDS LTD	10MG;12.5MG	A076739	001	Dec 17, 2004	Feb	DISC
@		20MG;12.5MG	A076739	002	Dec 17, 2004	Feb	DISC

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVATRIPTAN SUCCINATE

AB	GLENMARK PHARMS LTD	EQ 2.5MG BASE	A204730	001	Mar 11, 2016	Feb	NEWA
----	---------------------	---------------	---------	-----	--------------	-----	------

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

>A>	AP	CLARIS	10MG/ML	A202747	001	Jan 27, 2014	May	CAHN
>D>	AP	CLARIS LIFESCIENCES	10MG/ML	A202747	001	Jan 27, 2014	May	CAHN
	@	EUROHLTH INTL SARL	10MG/ML	A071439	001	Sep 14, 1990	Jan	CAHN
	@	LUITPOLD	10MG/ML	N018579	001	Nov 30, 1983	Feb	DISC

TABLET; ORAL

FUROSEMIDE

	@	SUN PHARM INDS	20MG	A070043	001	Sep 26, 1985	Mar	CAHN
	@		80MG	A070100	001	Jan 26, 1988	Mar	CAHN
		LASIX						
AB		US PHARM HOLDINGS	20MG	N016273	002		Jan	CAHN
AB			40MG	N016273	001		Jan	CAHN
AB	+		80MG	N016273	003		Jan	CAHN

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

AB		SCIEGEN PHARMS INC	100MG	A204989	001	Feb 18, 2016	Feb	NEWA
AB			300MG	A204989	002	Feb 18, 2016	Feb	NEWA
AB			400MG	A204989	003	Feb 18, 2016	Feb	NEWA
	@	SUN PHARM INDS	100MG	A076537	001	Jun 30, 2005	Mar	CAHN
	@		300MG	A076537	002	Jun 30, 2005	Mar	CAHN
	@		400MG	A076537	003	Jun 30, 2005	Mar	CAHN

SOLUTION; ORAL

GABAPENTIN

AA		TRIS PHARMA INC	250MG/5ML	A091286	001	Mar 14, 2016	Feb	NEWA
----	--	-----------------	-----------	---------	-----	--------------	-----	------

TABLET; ORAL

GABAPENTIN

AB		SCIEGEN PHARMS INC	600MG	A205101	001	Feb 04, 2016	Jan	NEWA
AB			800MG	A205101	002	Feb 04, 2016	Jan	NEWA

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDE

@	IMPAX LABS	EQ 8MG BASE	A078484	001	May 27, 2009	Feb	DISC
@		EQ 16MG BASE	A078484	002	May 27, 2009	Feb	DISC
@		EQ 24MG BASE	A078484	003	May 27, 2009	Feb	DISC

SOLUTION; ORAL

GALANTAMINE HYDROBROMIDE

>D>	AA	ROXANE	4MG/ML	A078185	001	Jan 30, 2009	May	CRLD	
>A>		+	4MG/ML	A078185	001	Jan 30, 2009	May	CRLD	
>D>		RAZADYNE							
>D>	AA	+	JANSSEN PHARMS	4MG/ML	N021224	001	Jun 22, 2001	May	DISC
>A>		@		4MG/ML	N021224	001	Jun 22, 2001	May	DISC

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

AP		ACTAVIS INC	200MG/5.26ML (38MG/ML)	A204549	001	Apr 11, 2016	Mar	NEWA
AP			1GM/26.3ML (38MG/ML)	A204549	002	Apr 11, 2016	Mar	NEWA
AP			2GM/52.6ML (38MG/ML)	A204549	003	Apr 11, 2016	Mar	NEWA
AP	+	HOSPIRA INC	200MG/5.26ML (38MG/ML)	N200795	001	Aug 04, 2011	Mar	CFTG
AP	+		1GM/26.3ML (38MG/ML)	N200795	002	Aug 04, 2011	Mar	CFTG
AP	+		2GM/52.6ML (38MG/ML)	N200795	003	Aug 04, 2011	Mar	CFTG

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

@ ACTAVIS LABS FL INC	1MG	A076995	001	Apr 27, 2010	Jan DISC
@	2MG	A076995	002	Apr 27, 2010	Jan DISC
@	4MG	A076995	003	Apr 27, 2010	Jan DISC

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

ROSIGLITAZONE MALEATE AND GLIMEPIRIDE

+ TEVA PHARMS USA	1MG; 4MG	A078709	001	Apr 01, 2016	Mar NEWA
	2MG; 4MG	A078709	002	Apr 01, 2016	Mar NEWA
	2MG; 8MG	A078709	004	Apr 01, 2016	Mar NEWA
	4MG; 4MG	A078709	003	Apr 01, 2016	Mar NEWA
	4MG; 8MG	A078709	005	Apr 01, 2016	Mar NEWA

GLYBURIDE

TABLET; ORAL

GLYBURIDE

AB1 PHARMADAX INC	1.25MG	A203581	001	Apr 14, 2016	Apr NEWA
AB1	2.5MG	A203581	002	Apr 14, 2016	Apr NEWA
AB1	5MG	A203581	003	Apr 14, 2016	Apr NEWA
AB1 ZYDUS PHARMS USA INC	1.25mg	A206749	001	May 10, 2016	Apr NEWA
AB1	2.5mg	A206749	002	May 10, 2016	Apr NEWA
AB1	5MG	A206749	003	May 10, 2016	Apr NEWA

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

@ COREPHARMA	1.25MG; 250MG	A076731	001	Nov 19, 2004	Jan DISC
@	2.5MG; 500MG	A076731	002	Nov 19, 2004	Jan DISC
@	5MG; 500MG	A076731	003	Nov 19, 2004	Jan DISC
AB ZYDUS PHARMS USA INC	1.25MG; 250MG	A206748	001	Feb 29, 2016	Feb NEWA
AB	2.5MG; 500MG	A206748	002	Feb 29, 2016	Feb NEWA
AB	5MG; 500MG	A206748	003	Feb 29, 2016	Feb NEWA

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

AP + HIKMA FARMACEUTICA	0.2MG/ML	A090963	001	Sep 21, 2011	Feb CRLD
ROBINUL					
@ EUROHLTH INTL SARL	0.2MG/ML	N017558	001		Feb DISC

TABLET; ORAL

GLYCOPYRROLATE

>A> @ HIKMA INTL PHARMS	1MG	A040836	001	Mar 05, 2009	May CAHN
>A> @	2MG	A040836	002	Mar 05, 2009	May CAHN
>D> @ HIKMA PHARMS LLC	1MG	A040836	001	Mar 05, 2009	May CAHN
>D> @	2MG	A040836	002	Mar 05, 2009	May CAHN
AA RISING PHARMS INC	1MG	A040821	001	Dec 29, 2008	Jan CAHN
AA	2MG	A040821	002	Dec 29, 2008	Jan CAHN
ROBINUL					
AA + CASPER PHARMA LLC	1MG	N012827	001		Jan CAHN
ROBINUL FORTE					
AA + CASPER PHARMA LLC	2MG	N012827	002		Jan CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP BIONPHARMA INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Jan CAHN
AP	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Jan CAHN
AP HIKMA FARMACEUTICA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078629	001	Dec 23, 2009	Jan CMS1
AP	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078629	002	Dec 23, 2009	Jan CMS1

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

AP BIONPHARMA INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Jan CAHN
-------------------	---------------------------------	---------	-----	--------------	----------

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

@ COREPHARMA	EQ 1MG BASE	A078260	001	Dec 31, 2007	Mar DISC
--------------	-------------	---------	-----	--------------	----------

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYCOFENIX

+	MISSION PHARMACAL CO	200MG/5ML; 2.5MG/5ML; 30MG/5ML	N022279	001	May 14, 2015	Apr CAHN
---	----------------------	--------------------------------	---------	-----	--------------	----------

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

@	IMPAX LABS INC	EQ 1MG BASE	A202238	001	Oct 20, 2015	Mar DISC
@		EQ 2MG BASE	A202238	002	Oct 20, 2015	Mar DISC
@		EQ 3MG BASE	A202238	003	Oct 20, 2015	Mar DISC
@		EQ 4MG BASE	A202238	004	Oct 20, 2015	Mar DISC

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

@	CYCLE PHARMS LTD	2MG	A071130	001	Feb 17, 1987	Jan CAHN
@	SUN PHARM INDS	2MG	A071172	001	Jan 02, 1987	Mar CAHN
@		5MG	A071212	001	Jan 07, 1988	Mar CAHN
@		10MG	A071173	001	Jan 07, 1988	Mar CAHN
@		20MG	A071177	001	Jan 07, 1988	Mar CAHN
@	VINTAGE	0.5MG	A071235	002	Nov 03, 1986	Jan CMS1
@		1MG	A071235	003	Nov 03, 1986	Jan CMS1
@		5MG	A071235	004	Nov 03, 1986	Jan CMS1
@		10MG	A071235	005	Jul 20, 1987	Jan CMS1

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

>A>	AP	FRESENIUS KABI USA	5,000 UNITS/ML	A206552	001	Jun 10, 2016	May NEWA
-----	----	--------------------	----------------	---------	-----	--------------	----------

HEXACHLOROPHENE

>D> EMULSION; TOPICAL

>D> PHISOHEX

>D>	+	SANOFI AVENTIS US	3%	N006882	001		May DISC
-----	---	-------------------	----	---------	-----	--	----------

>A>	@		3%	N006882	001		May DISC
-----	---	--	----	---------	-----	--	----------

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

@	ACTAVIS ELIZABETH	1.5MG; 5MG	A040295	001	Dec 01, 2000	Jan CMS1
---	-------------------	------------	---------	-----	--------------	----------

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

AP		MYLAN INSTITUTIONAL	20MG/ML	A204680	001	Apr 28, 2016	Apr NEWA
----	--	---------------------	---------	---------	-----	--------------	----------

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

@	ACTAVIS GRP PTC	10MG	A091679	001	Mar 04, 2013	Apr DISC
@		25MG	A091679	002	Mar 04, 2013	Apr DISC
@		50MG	A091679	003	Mar 04, 2013	Apr DISC
@		100MG	A091679	004	Mar 04, 2013	Apr DISC
@	SUN PHARM INDS	10MG	A089359	001	Jul 25, 1986	Mar CAHN
@		25MG	A089258	001	May 05, 1986	Mar CAHN
@		50MG	A089259	001	May 05, 1986	Mar CAHN

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDRALAZINE AND HYDROCHLOROTHIAZIDE

@	WATSON LABS	25MG; 15MG	A085827	001		Feb CMS1
---	-------------	------------	---------	-----	--	----------

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@	SUN PHARM INDS	25MG; 15MG; 0.1MG	A088570	001	Apr 10, 1984	Mar CAHN
---	----------------	-------------------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDECAPSULE;ORAL
MICROZIDE

AB + ALLERGAN SALES LLC 12.5MG N020504 001 Dec 27, 1996 Apr CAHN

TABLET;ORAL

HYDROCHLOROTHIAZIDE

@ AUROLIFE PHARMA LLC 25MG A083899 001 Feb CAHN

@ 50MG A085219 001 Feb CAHN

@ HIKMA INTL PHARMS 25MG A084878 002 Jul 12, 2006 May CAHN

>A> AB 50MG A084878 001 May CAHN

>D> @ HIKMA PHARMS LLC 25MG A084878 002 Jul 12, 2006 May CAHN

>D> AB 50MG A084878 001 May CAHN

@ SUN PHARM INDS 25MG A083972 001 Mar CAHN

@ 50MG A083972 002 Mar CAHN

@ 100MG A083972 003 Mar CAHN

ORETIC

@ ABBVIE 50MG N011971 002 Jan DISC

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB AUROBINDO PHARMA LTD 25MG;300MG A203630 003 Mar 31, 2016 Mar NEWA

AB INTL SPECLT CHEMS 12.5MG;150MG A203036 001 Jan 15, 2016 Jan NEWA

AB 12.5MG;300MG A203036 002 Jan 15, 2016 Jan NEWA

AB 25MG;300MG A203036 003 Jan 15, 2016 Mar CTEC

25MG;300MG A203036 003 Jan 15, 2016 Jan NEWA

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

ZESTORETIC

AB ALVOGEN MALTA 12.5MG;10MG N019888 003 Nov 18, 1993 Jan CAHN

AB + 12.5MG;20MG N019888 001 Sep 20, 1990 Jan CAHN

AB + 25MG;20MG N019888 002 Jul 20, 1989 Jan CAHN

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

AB SUN PHARM INDS 25MG;25MG A089534 001 Jul 02, 1987 Mar CAHN

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB PRINSTON INC 12.5MG;80MG A206083 001 Feb 08, 2016 Jan NEWA

AB 12.5MG;160MG A206083 002 Feb 08, 2016 Jan NEWA

AB 12.5MG;320MG A206083 003 Feb 08, 2016 Jan NEWA

AB 25MG;160MG A206083 004 Feb 08, 2016 Jan NEWA

AB 25MG;320MG A206083 005 Feb 08, 2016 Jan NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

@ ACTAVIS LABS FL INC 5MG;200MG A077454 001 Jun 23, 2010 Jan DISC

>A> AB AUROLIFE PHARMA LLC 7.5MG;200MG A204575 001 Jun 02, 2016 May NEWA

HYDROCORTISONE

TABLET;ORAL

HYDROCORTISONE

AB PHARMACEUTICS INTL 5MG A207029 001 Apr 26, 2016 Apr NEWA

AB 10MG A207029 002 Apr 26, 2016 Apr NEWA

AB 20MG A207029 003 Apr 26, 2016 Apr NEWA

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS;OTIC

PEDIOTIC

@ MONARCH PHARMS 1%;EQ 3.5MG BASE/ML;10,000
UNITS/ML A062822 001 Sep 29, 1987 Jan DISC

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

>A>	AB	AUROLIFE PHARMA LLC	2MG	A205814	001	May 13, 2016	May NEWA
>A>	AB		4MG	A205814	002	May 13, 2016	May NEWA
>A>	AB		8MG	A205814	003	May 13, 2016	May NEWA

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

CYANOKIT

@ SERB SA

2.5GM/VIAL (5GM/KIT)

N022041 002 Dec 15, 2006 Jan CAHN

+

5GM/VIAL (5GM/KIT)

N022041 001 Apr 08, 2011 Jan CAHN

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

AB		WATSON LABS	200MG	A040133	001	Nov 30, 1995	Feb CMFD
----	--	-------------	-------	---------	-----	--------------	----------

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

HYDROXYPROGESTERONE CAPROATE

+ ASPEN GLOBAL INC 250MG/ML

A200271 001 Aug 24, 2015 Jan CAHN

SOLUTION; INTRAMUSCULAR
MAKENA

+ LUMARA HEALTH INC 250MG/ML (250MG/ML)

N021945 002 Feb 19, 2016 Feb NEWA

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

@ AUROLIFE PHARMA LLC 10MG

A087869 001 Dec 20, 1982 Feb CAHN

@ 25MG

A087870 001 Dec 20, 1982 Feb CAHN

@ 50MG

A087871 001 Dec 20, 1982 Feb CAHN

>A> AB ECI PHARMS LLC 10MG

A040804 001 Jun 30, 2008 May CAHN

>A> AB 25MG

A040804 002 Jun 30, 2008 May CAHN

>A> AB 50MG

A040804 003 Jun 30, 2008 May CAHN

>D> AB HERITAGE PHARMS INC 10MG

A040804 001 Jun 30, 2008 May CAHN

>D> AB 25MG

A040804 002 Jun 30, 2008 May CAHN

>D> AB 50MG

A040804 003 Jun 30, 2008 May CAHN

@ SUN PHARM INDS 10MG

A089381 001 May 19, 1986 Mar CAHN

@ 25MG

A089382 001 May 19, 1986 Mar CAHN

@ 50MG

A089383 001 May 19, 1986 Mar CAHN

@ 100MG

A087862 001 Apr 18, 1983 Mar CAHN

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS

IBANDRONATE SODIUM

AP		ACCORD HLTHCARE	EQ 3MG BASE/3ML	A206058	001	Feb 05, 2016	Jan NEWA
----	--	-----------------	-----------------	---------	-----	--------------	----------

TABLET; ORAL

IBANDRONATE SODIUM

AB		AUROBINDO PHARMA LTD	EQ 150MG BASE	A204502	001	Mar 11, 2016	Feb NEWA
----	--	----------------------	---------------	---------	-----	--------------	----------

AB		SUN PHARM INDS	EQ 150MG BASE	A078996	001	Aug 15, 2012	Mar CAHN
----	--	----------------	---------------	---------	-----	--------------	----------

IBUPROFEN

TABLET; ORAL

IBUPROFEN

@ AUROLIFE PHARMA LLC 300MG

A070734 001 Jun 12, 1986 Feb CAHN

@ 400MG

A070735 001 Jun 12, 1986 Feb CAHN

@ 600MG

A070736 001 Jun 12, 1986 Feb CAHN

@ 800MG

A071938 001 Jan 14, 1988 Mar CAHN

>D> AB SHASUN USA 400MG

A078329 001 Feb 05, 2009 May CAHN

>D> AB 600MG

A078329 002 Feb 05, 2009 May CAHN

>D> AB 800MG

A078329 003 Feb 05, 2009 May CAHN

>A> AB STRIDES PHARMA 400MG

A078329 001 Feb 05, 2009 May CAHN

>A> AB 600MG

A078329 002 Feb 05, 2009 May CAHN

>A> AB 800MG

A078329 003 Feb 05, 2009 May CAHN

@ SUN PHARM INDS 400MG

A070079 001 Jul 24, 1985 Mar CAHN

@ 600MG

A070080 001 Jul 24, 1985 Mar CAHN

@ 800MG

A071448 001 Feb 18, 1987 Mar CAHN

IBUPROFEN LYSINE

INJECTABLE;INTRAVENOUS
IBUPROFEN LYSINE

AP		EXELA PHARMA SCIENCE	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	A202402	001	Mar 30, 2016	Mar NEWA
AP	+	RECORDATI RARE	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903	001	Apr 13, 2006	Mar CFTG

IMIPRAMINE HYDROCHLORIDE

TABLET;ORAL
IMIPRAMINE HYDROCHLORIDE

AB		SUN PHARM INDS	10MG	A081048	001	Jun 05, 1990	Mar CAHN
AB			25MG	A081049	001	Jun 05, 1990	Mar CAHN
AB			50MG	A081050	001	Jun 05, 1990	Mar CAHN

IMIPRAMINE PAMOATE

CAPSULE;ORAL
IMIPRAMINE PAMOATE

AB	+	ROXANE	EQ 75MG HCL	A091099	001	Apr 16, 2010	Feb CRLD
		TOFRANIL-PM					
	@	MALLINCKRODT INC	EQ 75MG HCL	N017090	001		Feb DISC
	@		EQ 100MG HCL	N017090	004		Feb DISC
	@		EQ 125MG HCL	N017090	003		Feb DISC
	@		EQ 150MG HCL	N017090	002		Feb DISC

INDIUM IN-111 CHLORIDE

INJECTABLE;INJECTION
INDIUM IN 111 CHLORIDE

+	MALLINKRODT NUCLEAR	5mCi/0.5ML	N019841	001	Sep 27, 1994	Jan CAHN
---	---------------------	------------	---------	-----	--------------	----------

INDIUM IN-111 OXYQUINOLINE

INJECTABLE;INJECTION
INDIUM IN 111 OXYQUINOLINE

+	GE HEALTHCARE	1mCi/ML	N019044	001	Dec 24, 1985	Mar CMS1
---	---------------	---------	---------	-----	--------------	----------

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE;INJECTION
OCTREOSCAN

+	MALLINKRODT NUCLEAR	3mCi/ML	N020314	001	Jun 02, 1994	Jan CAHN
---	---------------------	---------	---------	-----	--------------	----------

INDOCYANINE GREEN

INJECTABLE;INJECTION
INDOCYANINE GREEN

AP		DIAGNOSTIC GREEN	25MG/VIAL	A040811	001	Nov 21, 2007	Jan CAHN
----	--	------------------	-----------	---------	-----	--------------	----------

INDOMETHACIN SODIUM

INJECTABLE;INJECTION
INDOMETHACIN SODIUM

AP		HOSPIRA INC	EQ 1MG BASE/VIAL	A204118	001	Apr 19, 2016	Apr NEWA
----	--	-------------	------------------	---------	-----	--------------	----------

INSULIN DETEMIR RECOMBINANT

INJECTABLE;SUBCUTANEOUS
LEVEMIR FLEXPEN

@	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	002	Jun 16, 2005	Feb DISC
---	------------------	------------------------------	---------	-----	--------------	----------

INSULIN HUMAN

SOLUTION;SUBCUTANEOUS
HUMULIN R

+	LILLY	10000 UNITS/20ML (500 UNITS/ML)	N018780	004	Mar 31, 1994	Jan CAIN
	HUMULIN R KWIKPEN					
+	LILLY	1500 UNITS/3ML (500 UNITS/ML)	N018780	002	Dec 29, 2015	Jan NEWA

INSULIN RECOMBINANT HUMAN

POWDER;INHALATION
AFREZZA

	MANNKIND	4 UNITS/INH	N022472	001	Jun 27, 2014	Mar CAHN
+		8 UNITS/INH	N022472	002	Jun 27, 2014	Mar CAHN
		12 UNITS/INH	N022472	003	Apr 17, 2015	Mar CAHN

IRBESARTANTABLET; ORAL
IRBESARTAN

>A>	AB	HISUN PHARM HANGZHOU	75MG	A206194	001	Jun 14, 2016	May NEWA
>A>	AB		150MG	A206194	002	Jun 14, 2016	May NEWA
>A>	AB		300MG	A206194	003	Jun 14, 2016	May NEWA

IRINOTECAN HYDROCHLORIDEINJECTABLE; INJECTION
CAMPTOSAR

AP	+	PFIZER INC	300MG/15ML (20MG/ML)	N020571	003	Aug 05, 2010	Apr CTEC
IRINOTECAN HYDROCHLORIDE							
AP		QILU PHARM CO LTD	40MG/2ML (20MG/ML)	A203380	001	May 03, 2016	Apr NEWA
AP			100MG/5ML (20MG/ML)	A203380	002	May 03, 2016	Apr NEWA
AP			300MG/15ML (20MG/ML)	A203380	003	May 03, 2016	Apr NEWA
AP		SANDOZ INC	40MG/2ML (20MG/ML)	A090137	001	Nov 12, 2009	Jan CAHN
AP			100MG/5ML (20MG/ML)	A090137	002	Nov 12, 2009	Jan CAHN

IRON DEXTRANINJECTABLE; INJECTION
INFED

BP	+	ALLERGAN SALES LLC	EQ 50MG IRON/ML	N017441	001		Apr CAHN
----	---	--------------------	-----------------	---------	-----	--	----------

ISONIAZIDTABLET; ORAL
ISONIAZID

@	SUN PHARM INDS	100MG	A080136	001		Mar CAHN
@		300MG	A083633	001		Mar CAHN

ISOSORBIDE DINITRATECAPSULE, EXTENDED RELEASE; ORAL
DILATRATE-SR

+	AUXILIUM PHARMS INC	40MG	N019790	001	Sep 02, 1988	Mar CAHN
---	---------------------	------	---------	-----	--------------	----------

TABLET; ORAL

ISOSORBIDE DINITRATE

@	SUN PHARM INDS	5MG	A086166	002	Sep 19, 1986	Mar CAHN
---	----------------	-----	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE DINITRATE

@	COREPHARMA	40MG	A040723	001	Mar 17, 2008	Mar DISC
+	SUN PHARM INDS INC	40MG	A040009	001	Dec 30, 1998	Mar CTEC

ISOSULFAN BLUEINJECTABLE; INJECTION
ISOSULFAN BLUE

AP		AUROBINDO PHARMA LTD	1%	A206831	001	Feb 02, 2016	Jan NEWA
AP	+	MYLAN INSTITUTIONAL	1%	A090874	001	Jul 20, 2010	Jan CTEC

ITRACONAZOLE

CAPSULE; ORAL

ITRACONAZOLE

>A>	AB	ACCORD HLTHCARE	100MG	A205991	001	May 26, 2016	May NEWA
-----	----	-----------------	-------	---------	-----	--------------	----------

SOLUTION; ORAL

ITRACONAZOLE

@	AMNEAL PHARMS	10MG/ML	A205573	001	Oct 30, 2015	Apr DISC
---	---------------	---------	---------	-----	--------------	----------

SPORANOX

+	JANSSEN PHARMS	10MG/ML	N020657	001	Feb 21, 1997	Apr CTEC
---	----------------	---------	---------	-----	--------------	----------

IVERMECTINLOTION; TOPICAL
SKLICE

>A>	+	ARBOR PHARMS LLC	0.5%	N202736	001	Feb 07, 2012	May CAHN
>D>	+	SANOFI PASTEUR INC	0.5%	N202736	001	Feb 07, 2012	May CAHN

KETOCONAZOLE

TABLET; ORAL

KETOCONAZOLE

@	SUN PHARM INDS	200MG	A075314	001	Jun 15, 1999	Jan CAHN
---	----------------	-------	---------	-----	--------------	----------

KETOPROFEN

CAPSULE;ORAL

KETOPROFEN

@ AUROLIFE PHARMA LLC

50MG

A074024 001 Dec 29, 1995 Feb CAHN

@

75MG

A074024 002 Dec 29, 1995 Feb CAHN

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION

KETOROLAC TROMETHAMINE

>D> @ BEDFORD

30MG/ML

A075228 001 Apr 26, 1999 May CAHN

@ EUROHLTH INTL SARL

15MG/ML

A075222 001 Apr 26, 1999 Apr CAHN

@

30MG/ML

A075222 002 Apr 26, 1999 Apr CAHN

>A>

@

30MG/ML

A075228 001 Apr 26, 1999 May CAHN

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION

LABETALOL HYDROCHLORIDE

AP SAGENT STRIDES

5MG/ML

A079134 001 Feb 03, 2010 Jan CTNA

TRANDATE

@ SEBELA IRELAND LTD

5MG/ML

N019425 001 Dec 31, 1985 Jan CAHN

TABLET;ORAL

LABETALOL HYDROCHLORIDE

AB NOSTRUM LABS INC

100MG

A075215 001 Jul 29, 1999 Jan CAHN

AB

200MG

A075215 002 Jul 29, 1999 Jan CAHN

AB

300MG

A075215 003 Jul 29, 1999 Jan CAHN

LACOSAMIDE

SOLUTION;ORAL

LACOSAMIDE

AA AMNEAL PHARMS

10MG/ML

A204839 001 Apr 28, 2016 Apr NEWA

VIMPAT

AA + UCB INC

10MG/ML

N022255 001 Apr 20, 2010 Apr CFTG

TABLET;ORAL

LACOSAMIDE

AB ACTAVIS LABS FL INC

50MG

A204855 001 Apr 28, 2016 Apr NEWA

AB

100MG

A204855 002 Apr 28, 2016 Apr NEWA

AB

150MG

A204855 003 Apr 28, 2016 Apr NEWA

AB

200MG

A204855 004 Apr 28, 2016 Apr NEWA

AB

ALEMBIC PHARMS LTD

50MG

A204974 001 Apr 28, 2016 Apr NEWA

AB

100MG

A204974 002 Apr 28, 2016 Apr NEWA

AB

150MG

A204974 003 Apr 28, 2016 Apr NEWA

AB

200MG

A204974 004 Apr 28, 2016 Apr NEWA

AB

AUROBINDO PHARMA LTD

50MG

A204994 001 Apr 28, 2016 Apr NEWA

AB

100MG

A204994 002 Apr 28, 2016 Apr NEWA

AB

150MG

A204994 003 Apr 28, 2016 Apr NEWA

AB

200MG

A204994 004 Apr 28, 2016 Apr NEWA

AB

MSN LABS PVT LTD

50MG

A204921 001 Apr 28, 2016 Apr NEWA

AB

100MG

A204921 002 Apr 28, 2016 Apr NEWA

AB

150MG

A204921 003 Apr 28, 2016 Apr NEWA

AB

200MG

A204921 004 Apr 28, 2016 Apr NEWA

AB

MYLAN PHARMS INC

50MG

A205026 001 Apr 28, 2016 Apr NEWA

AB

100MG

A205026 002 Apr 28, 2016 Apr NEWA

AB

150MG

A205026 003 Apr 28, 2016 Apr NEWA

AB

200MG

A205026 004 Apr 28, 2016 Apr NEWA

AB

SUN PHARMA GLOBAL

50MG

A205031 001 Apr 28, 2016 Apr NEWA

AB

100MG

A205031 002 Apr 28, 2016 Apr NEWA

AB

150MG

A205031 003 Apr 28, 2016 Apr NEWA

AB

200MG

A205031 004 Apr 28, 2016 Apr NEWA

VIMPAT

AB UCB INC

50MG

N022253 001 Oct 28, 2008 Apr CFTG

AB

100MG

N022253 002 Oct 28, 2008 Apr CFTG

AB

150MG

N022253 003 Oct 28, 2008 Apr CFTG

AB

+

200MG

N022253 004 Oct 28, 2008 Apr CFTG

LAMIVUDINE

TABLET;ORAL

LAMIVUDINE

AB MYLAN PHARMS INC

150MG

A204528 001 Mar 04, 2016 Feb NEWA

AB

300MG

A204528 002 Mar 04, 2016 Feb NEWA

LAMOTRIGINE

TABLET, EXTENDED RELEASE;ORAL
LAMICTAL XR

AB + GLAXOSMITHKLINE LLC 200MG N022115 004 May 29, 2009 Jan CRLD

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC
LATANOPROST

AT FDC LTD 0.005% A202442 001 Apr 22, 2016 Apr NEWA

LETROZOLE

TABLET;ORAL
LETROZOLE

>A> AB HIKMA PHARMS 2.5MG A203796 001 Jun 03, 2016 May NEWA
AB KREMERS URBAN PHARMS 2.5MG A091098 001 Jun 03, 2011 Jan CAHN

LEUCOVORIN CALCIUM

TABLET;ORAL
LEUCOVORIN CALCIUM

>A> @ IDT AUSTRALIA LTD EQ 15MG BASE A075327 001 Mar 24, 1999 May CAHN
>D> @ SANDOZ EQ 15MG BASE A075327 001 Mar 24, 1999 May CAHN

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION
LEVALBUTEROL HYDROCHLORIDE

AN RITEDOSE CORP EQ 0.0103% BASE A203653 001 Mar 22, 2016 Mar NEWA
AN EQ 0.021% BASE A203653 002 Mar 22, 2016 Mar NEWA
AN EQ 0.042% BASE A203653 003 Mar 22, 2016 Mar NEWA

LEVETIRACETAM

INJECTABLE;IV (INFUSION)
LEVETIRACETAM

AP AUROBINDO PHARMA LTD 500MG/5ML (100MG/ML) A204312 001 Feb 01, 2016 Jan NEWA
>A> AP JUBILANT LIFE 500MG/5ML (100MG/ML) A206838 001 Jun 02, 2016 May NEWA

TABLET, EXTENDED RELEASE;ORAL
LEVETIRACETAM

AB INTELLIPHARMACEUTICS 500MG A204511 001 Feb 23, 2016 Feb NEWA
AB 750MG A204511 002 Feb 23, 2016 Feb NEWA
>A> AB LOTUS PHARM CO LTD 500MG A202095 002 Jun 06, 2016 May NEWA
>A> AB 750MG A202095 001 Jun 06, 2016 May NEWA
AB SUN PHARM INDS 500MG A091285 001 Sep 12, 2011 Mar CAHN
AB 750MG A091285 002 Sep 12, 2011 Mar CAHN

TABLET, FOR SUSPENSION;ORAL
SPRITAM

APRECIA PHARMS CO 250MG N207958 001 Jul 31, 2015 Feb CDFR
500MG N207958 002 Jul 31, 2015 Feb CDFR
750MG N207958 003 Jul 31, 2015 Feb CDFR
+ 1GM N207958 004 Jul 31, 2015 Mar CRLD
1GM N207958 004 Jul 31, 2015 Feb CDFR

LEVOFLOXACIN

INJECTABLE;INJECTION
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP AUROBINDO PHARMA LTD EQ 250MG/50ML (EQ 5MG/ML) A206919 001 Feb 10, 2016 Jan NEWA
AP EQ 500MG/100ML (EQ 5MG/ML) A206919 002 Feb 10, 2016 Jan NEWA
AP EQ 750MG/150ML (EQ 5MG/ML) A206919 003 Feb 10, 2016 Jan NEWA

SOLUTION/DROPS;OPHTHALMIC
LEVOFLOXACIN

AT + RISING PHARMS INC 0.5% A077700 001 Dec 20, 2010 Jan CAHN

LEVONORGESTREL

TABLET;ORAL
LEVONORGESTREL

+ PERRIGO R AND D 0.75MG A090740 001 Dec 30, 2010 Apr CRLD
@ WATSON LABS 0.75MG A078665 001 Aug 28, 2009 Apr DISC
PLAN B
@ TEVA BRANDED PHARM 0.75MG N021045 002 Aug 24, 2006 Apr DISC

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

>D> LEVOTHROID

>D> AB4	LLOYD	0.025MG	N021116	001	Oct 24, 2002	May DISC
>A>	@	0.025MG	N021116	001	Oct 24, 2002	May DISC
>D> AB4		0.05MG	N021116	002	Oct 24, 2002	May DISC
>A>	@	0.05MG	N021116	002	Oct 24, 2002	May DISC
>D> AB4		0.075MG	N021116	003	Oct 24, 2002	May DISC
>A>	@	0.075MG	N021116	003	Oct 24, 2002	May DISC
>D> AB4		0.088MG	N021116	010	Oct 24, 2002	May DISC
>A>	@	0.088MG	N021116	010	Oct 24, 2002	May DISC
>D> AB4		0.1MG	N021116	004	Oct 24, 2002	May DISC
>A>	@	0.1MG	N021116	004	Oct 24, 2002	May DISC
>D> AB4		0.112MG	N021116	011	Oct 24, 2002	May DISC
>A>	@	0.112MG	N021116	011	Oct 24, 2002	May DISC
>D> AB4		0.125MG	N021116	005	Oct 24, 2002	May DISC
>A>	@	0.125MG	N021116	005	Oct 24, 2002	May DISC
>D> AB4		0.137MG	N021116	012	Dec 07, 2004	May DISC
>A>	@	0.137MG	N021116	012	Dec 07, 2004	May DISC
>D> AB4		0.15MG	N021116	006	Oct 24, 2002	May DISC
>A>	@	0.15MG	N021116	006	Oct 24, 2002	May DISC
>D> AB4		0.175MG	N021116	007	Oct 24, 2002	May DISC
>A>	@	0.175MG	N021116	007	Oct 24, 2002	May DISC
>D> AB4		0.2MG	N021116	008	Oct 24, 2002	May DISC
>A>	@	0.2MG	N021116	008	Oct 24, 2002	May DISC
>D> AB4 +		0.3MG	N021116	009	Oct 24, 2002	May DISC
>A>	@	0.3MG	N021116	009	Oct 24, 2002	May DISC

LEVOTHYROXINE SODIUM

>D> AB1, AB2, AB3, AB4	MYLAN	0.3MG	A076187	011	Jun 05, 2002	May CRLD
>A> AB1, AB2, AB3, AB4 +		0.3MG	A076187	011	Jun 05, 2002	May CRLD

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

AT	TELLIGENT PHARMA INC	5%	A205318	001	Feb 01, 2016	Jan NEWA
----	----------------------	----	---------	-----	--------------	----------

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER

@ HOSPIRA	400MG/100ML	N018388	002			Feb DISC
-----------	-------------	---------	-----	--	--	----------

LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER

@ HOSPIRA	800MG/100ML	N018388	003	Nov 05, 1982		Feb DISC
-----------	-------------	---------	-----	--------------	--	----------

JELLY;TOPICAL

ANESTACON

@ BIONPHARMA INC	2%	A080429	001			Jan CAHN
------------------	----	---------	-----	--	--	----------

SOLUTION;TOPICAL

LIDOCAINE HYDROCHLORIDE

>D> AT	IGI LABS INC	4%	A204494	001	Mar 12, 2014	May CAHN
>A> AT	TELLIGENT PHARMA INC	4%	A204494	001	Mar 12, 2014	May CAHN

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

>A> TABLET, EXTENDED RELEASE;ORAL

>A> JENTADUETO XR

>A>	BOEHRINGER INGELHEIM	2.5MG;1GM	N208026	001	May 27, 2016	May NEWA
-----	----------------------	-----------	---------	-----	--------------	----------

>A> +		5MG;1GM	N208026	002	May 27, 2016	May NEWA
-------	--	---------	---------	-----	--------------	----------

LINEZOLID

SOLUTION;IV (INFUSION)

LINEZOLID

AP	FRESENIUS KABI USA	600MG/300ML (2MG/ML)	A204764	001	Mar 15, 2016	Feb NEWA
----	--------------------	----------------------	---------	-----	--------------	----------

TABLET;ORAL

LINEZOLID

AB	GATE PHARMS	600MG	A091210	001	Feb 05, 2016	Jan NEWA
AB	GLENMARK PHARMS	600MG	A078987	001	Dec 21, 2015	Mar CAHN

LIOTHYRONINE SODIUM

TABLET; ORAL

LIOTHYRONINE SODIUM

AB	MAYNE PHARMA INC	EQ 0.005MG BASE	A090097	001	Mar 20, 2009	Mar CAHN
AB		EQ 0.025MG BASE	A090097	002	Mar 20, 2009	Mar CAHN
AB		EQ 0.05MG BASE	A090097	003	Mar 20, 2009	Mar CAHN
AB	SUN PHARM INDS LTD	EQ 0.005MG BASE	A091382	001	Apr 20, 2016	Apr NEWA
AB		EQ 0.025MG BASE	A091382	002	Apr 20, 2016	Apr NEWA
AB		EQ 0.05MG BASE	A091382	003	Apr 20, 2016	Apr NEWA

LISINOPRIL

TABLET; ORAL

ZESTRIL

AB	ALVOGEN MALTA	2.5MG	N019777	005	Apr 29, 1993	Jan CAHN
AB		5MG	N019777	001	May 19, 1988	Jan CAHN
AB		10MG	N019777	002	May 19, 1988	Jan CAHN
AB		20MG	N019777	003	May 19, 1988	Jan CAHN
AB		30MG	N019777	006	Jan 20, 1999	Jan CAHN
AB	+	40MG	N019777	004	May 19, 1988	Jan CAHN

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

AB	DELCOR ASSET CORP	150MG	A076243	002	Feb 24, 2003	Feb CAHN
AB		300MG	A076243	001	Jun 27, 2002	Feb CAHN
AB		600MG	A078763	001	Apr 15, 2008	Feb CAHN
AB	HIKMA PHARMS	600MG	A078763	001	Apr 15, 2008	Jan CMFD

LOMITAPIDE MESYLATE

CAPSULE; ORAL

JUXTAPID

	AEGERION	EQ 20MG BASE	N203858	003	Dec 21, 2012	Jan CRLD
	+	EQ 60MG BASE	N203858	006	Apr 23, 2015	Jan CRLD

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

IMODIUM

@ J AND J CONSUMER INC 2MG

LOPERAMIDE HYDROCHLORIDE

AB	+	MYLAN	2MG	A072741	001	Sep 18, 1991	Feb CRLD
----	---	-------	-----	---------	-----	--------------	----------

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

BX	HETERO LABS LTD V	25MG	A203835	001	Aug 12, 2015	Apr CTEC
BX		50MG	A203835	002	Aug 12, 2015	Apr CTEC
BX		100MG	A203835	003	Aug 12, 2015	Apr CTEC
BX	LUPIN LTD	25MG	A078232	001	Oct 06, 2010	Apr CTEC
BX		50MG	A078232	002	Oct 06, 2010	Apr CTEC
BX		100MG	A078232	003	Oct 06, 2010	Apr CTEC

LOVASTATIN

TABLET; ORAL

LOVASTATIN

AB	SUN PHARM INDS	10MG	A077520	001	Apr 14, 2006	Mar CAHN
AB		20MG	A077520	002	Apr 14, 2006	Mar CAHN
AB		40MG	A077520	003	Apr 14, 2006	Mar CAHN

LOXAPINE

POWDER; INHALATION

ADASUVE

	+	ALEXZA PHARMS	10MG	N022549	001	Dec 21, 2012	Feb CAHN
--	---	---------------	------	---------	-----	--------------	----------

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	FRESENIUS KABI USA	1GM/100ML	A206486	001	Mar 07, 2016	Feb NEWA	
AP	+	HOSPIRA	1GM/100ML	N020488	001	Jul 11, 1995	Feb CFTG
AP	HQ SPCLT PHARMA	1GM/100ML	A207349	001	Mar 02, 2016	Feb NEWA	
MAGNESIUM SULFATE IN PLASTIC CONTAINER							
AP	FRESENIUS KABI USA	4GM/100ML (40MG/ML)	A206485	001	Mar 15, 2016	Feb NEWA	

INJECTABLE;INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER

AP		4GM/50ML (80MG/ML)	A206485	002	Mar 15, 2016	Feb NEWA
AP		2GM/50ML (40MG/ML)	A206485	003	Mar 15, 2016	Mar NEWA
AP		20GM/500ML (40MG/ML)	A206485	004	Mar 15, 2016	Mar NEWA
AP		40GM/1000ML (40MG/ML)	A206485	005	Mar 15, 2016	Mar NEWA
AP	HOSPIRA	2GM/50ML (40MG/ML)	N020309	003	Jan 26, 2007	Mar CFTG
AP	+	4GM/100ML (40MG/ML)	N020309	001	Jun 24, 1994	Feb CFTG
AP	+	4GM/50ML (80MG/ML)	N020309	002	Jun 24, 1994	Feb CFTG
AP		20GM/500ML (40MG/ML)	N020309	004	Jan 18, 1995	Mar CFTG
AP		40GM/1000ML (40MG/ML)	N020309	005	Jan 18, 1995	Mar CFTG
SOLUTION;INTRAMUSCULAR, INTRAVENOUS						
MAGNESIUM SULFATE						
+	FRESENIUS KABI USA	10GM/20ML (500MG/ML)	N019316	003	Jan 29, 2016	Jan NEWA
+		25GM/50ML (500MG/ML)	N019316	004	Jan 29, 2016	Jan NEWA

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

@	RISEING PHARMS INC	12.5MG	A040179	001	Jan 30, 1997	Jan CAHN
@		25MG	A040179	002	Jan 30, 1997	Jan CAHN

MEFLOQUINE HYDROCHLORIDE

TABLET;ORAL

MEFLOQUINE HYDROCHLORIDE

>A>	@	HIKMA INTL PHARMS	250MG	A077699	001	Apr 21, 2010	May CAHN
>D>	@	HIKMA PHARMS LLC	250MG	A077699	001	Apr 21, 2010	May CAHN

MEGESTROL ACETATE

SUSPENSION;ORAL

MEGACE ES

AB	+	ENDO PHARMS INC	125MG/ML	N021778	001	Jul 05, 2005	Feb CAHN
----	---	-----------------	----------	---------	-----	--------------	----------

MELOXICAM

TABLET;ORAL

MELOXICAM

@	SUN PHARM INDS	7.5MG	A077935	001	Jul 19, 2006	Jan CAHN
@		15MG	A077935	002	Jul 19, 2006	Jan CAHN

MELPHALAN

TABLET;ORAL

ALKERAN

+	APOTEX INC	2MG	N014691	002		Jan CAHN
---	------------	-----	---------	-----	--	----------

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION

ALKERAN

AP	+	APOTEX INC	EQ 50MG BASE/VIAL	N020207	001	Nov 18, 1992	Jan CAHN
		POWDER;IV (INFUSION)					
		EVOMELA					
		SPECTRUM PHARMS	EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016	Mar NEWA

MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEMEROL

@	US PHARM HOLDINGS	25MG/ML	N005010	007		Jan CAHN
@		50MG/ML	N005010	002		Jan CAHN
@		75MG/ML	N005010	009		Jan CAHN
@		100MG/ML	N005010	003		Jan CAHN

SYRUP;ORAL

DEMEROL

@	US PHARM HOLDINGS	50MG/5ML	N005010	005		Jan CAHN
---	-------------------	----------	---------	-----	--	----------

TABLET;ORAL

DEMEROL

AA	+	US PHARM HOLDINGS	50MG	N005010	001	Jan	CAHN
AA	+		100MG	N005010	004	Jan	CAHN
MEPERIDINE HYDROCHLORIDE							
	@	SUN PHARM INDS	50MG	A080448	001	Mar	CAHN
	@		100MG	A080448	002	Mar	CAHN

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

@ AUROLIFE PHARMA LLC	400MG	A080655	001		Feb CAHN
@ SUN PHARM INDS	200MG	A080699	001		Mar CAHN
@	400MG	A080699	002		Mar CAHN

MERCAPTOPURINE

TABLET; ORAL

MERCAPTOPURINE

AB	DR REDDYS LABS INTL	50MG	A040461	001	Feb 11, 2004	Apr CAHN
	PURINETHOL					
	@ STASON PHARMS	50MG	N009053	002		Jan CAHN

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

AP	AMNEAL PHARMS	500MG/VIAL	A205883	001	Apr 12, 2016	Mar NEWA
AP		1GM/VIAL	A205883	002	Apr 12, 2016	Mar NEWA
>A> AP	GLAND PHARMA LTD	500MG/VIAL	A206141	001	Jun 08, 2016	May NEWA
>A> AP		1GM/VIAL	A206141	002	Jun 08, 2016	May NEWA
>A> AP	PAR STERILE PRODUCTS	500MG/VIAL	A204139	001	Jun 09, 2016	May NEWA
>A> AP		1GM/VIAL	A204139	002	Jun 09, 2016	May NEWA
AP	SAVIOR LIFETEC CORP	500MG/VIAL	A206086	001	Apr 19, 2016	Apr NEWA
AP		1GM/VIAL	A206086	002	Apr 19, 2016	Apr NEWA

MESALAMINE

CAPSULE, DELAYED RELEASE; ORAL

DELZICOL

+	APIL	400MG	N204412	001	Feb 01, 2013	Jan CAHN
	TABLET, DELAYED RELEASE; ORAL					
	ASACOL					
	@ APIL	400MG	N019651	001	Jan 31, 1992	Jan CAHN
	ASACOL HD					
+	APIL	800MG	N021830	001	May 29, 2008	Jan CAHN

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB	SUN PHARM INDS	500MG	A076038	001	Feb 21, 2002	Mar CAHN
AB		850MG	A076038	002	Feb 21, 2002	Mar CAHN
AB		1GM	A076038	003	Feb 21, 2002	Mar CAHN
	TABLET, EXTENDED RELEASE; ORAL					
	GLUMETZA					
AB3	SANTARUS INC	500MG	N021748	001	Jun 03, 2005	Jan CTEC
AB3	+	1GM	N021748	002	Jun 03, 2005	Jan CTEC
	METFORMIN HYDROCHLORIDE					
	@ IMPAX LABS	500MG	A076249	001	Jul 30, 2004	Mar DISC
	@	750MG	A076985	001	Sep 13, 2005	Mar DISC
AB1	MARKSANS PHARMA	500MG	A090295	001	Apr 29, 2016	Apr NEWA
AB		750MG	A090295	002	Apr 29, 2016	Apr NEWA
	@ SUN PHARM INDS	500MG	A077124	001	Dec 21, 2005	Mar CAHN

METHENAMINE HIPPURATE

TABLET; ORAL

HIPREX

AB	+	US PHARM HOLDINGS	1GM	N017681	001	Jan CAHN
----	---	-------------------	-----	---------	-----	----------

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB	RISING PHARMS INC	5MG	A202068	001	Mar 07, 2012	Jan CAHN
AB		10MG	A202068	002	Mar 07, 2012	Jan CAHN

METHOCARBAMOL

SOLUTION; IM-IV

METHOCARBAMOL

>A> AP	AUROBINDO PHARMA LTD	1GM/10ML (100MG/ML)	A206128	001	May 27, 2016	May NEWA
--------	----------------------	---------------------	---------	-----	--------------	----------

TABLET; ORAL

METHOCARBAMOL

	@ SANDOZ	500MG	A084616	001		Feb	DISC
	@	750MG	A084615	001		Feb	DISC
	@ SUN PHARM INDS	500MG	A084488	001		Mar	CAHN
	@	750MG	A084486	001		Mar	CAHN
	ROBAXIN						
AA	+ AUXILIUM PHARMS INC	500MG	N011011	004		Mar	CAHN
	ROBAXIN-750						
AA	+ AUXILIUM PHARMS INC	750MG	N011011	006		Mar	CAHN

METHOTREXATE

SOLUTION; SUBCUTANEOUS

OTREXUP

>A>	ANTARES PHARMA INC	12.5MG/0.4ML (12.5MG/0.4ML)	N204824	006	Mar 24, 2016	May	NEWA
>A>		17.5MG/0.4ML (17.5MG/0.4ML)	N204824	007	Mar 24, 2016	May	NEWA
>A>		22.5MG/0.4ML (22.5MG/0.4ML)	N204824	008	Mar 24, 2016	May	NEWA

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

AP	SANDOZ INC	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A090039	001	Mar 31, 2009	Jan	CAHN
AP		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A090039	002	Mar 31, 2009	Jan	CAHN
AP		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A090029	001	Mar 31, 2009	Jan	CAHN

METHOXSALEN

INJECTABLE; INJECTION

UVADEX

	+ MALLINCKRODT HOSP	0.02MG/ML	N020969	001	Feb 25, 1999	Apr	CAHN
--	---------------------	-----------	---------	-----	--------------	-----	------

METHYLDOPA

TABLET; ORAL

METHYLDOPA

	@ SUN PHARM INDS	125MG	A070073	001	Oct 09, 1986	Mar	CAHN
	@	250MG	A070060	001	Oct 09, 1986	Mar	CAHN
	@	500MG	A070074	001	Oct 09, 1986	Mar	CAHN

METHYLENE BLUE

SOLUTION; INTRAVENOUS

PROVAYBLUE

	+ PROVEPHARM SAS	50MG/10ML (5MG/ML)	N204630	001	Apr 08, 2016	Apr	NEWA
--	------------------	--------------------	---------	-----	--------------	-----	------

METHYLERGONOVINE MALEATE

TABLET; ORAL

METHERGINE

	@ EDISON THERAPS LLC	0.2MG	N006035	003		Jan	DISC
	METHYLERGONOVINE MALEATE						
	+ NOVEL LABS INC	0.2MG	A091577	001	May 02, 2011	Jan	CRLD

METHYLPHENIDATE HYDROCHLORIDE

SOLUTION; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA	NOSTRUM LABS INC	5MG/5ML	A201466	001	Nov 12, 2013	Feb	CAHN
AA		10MG/5ML	A201466	002	Nov 12, 2013	Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	TEDOR PHARMA INC	10MG	A204772	001	Feb 29, 2016	Feb	NEWA
AB		20MG	A204772	002	Feb 29, 2016	Feb	NEWA

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

AP	HIKMA FARMACEUTICA	EQ 500MG BASE/VIAL	A202691	001	Feb 16, 2016	Feb	NEWA
AP		EQ 1GM BASE/VIAL	A202691	002	Feb 16, 2016	Feb	NEWA
AP	SAGENT PHARMS	EQ 40MG BASE/VIAL	A040888	001	Jul 18, 2011	Jan	CAHN
AP		EQ 125MG BASE/VIAL	A040888	002	Jul 18, 2011	Jan	CAHN
AP		EQ 500MG BASE/VIAL	A040888	003	Jul 18, 2011	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A040888	004	Jul 18, 2011	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A040888	005	Jul 18, 2011	Jan	CAHN

METHYLTESTOSTERONE

TABLET; ORAL

ANDROID 10

@ VALEANT PHARM INTL

10MG

A086450 001

Apr DISC

METHYLTESTOSTERONE

@ IMPAX LABS

25MG

A084310 001

Mar DISC

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AB SUN PHARM INDS

EQ 5MG BASE

A071536 002

Jan 16, 1997

Mar CAHN

@

EQ 10MG BASE

A071536 001

Apr 28, 1993

Mar CAHN

METOPROLOL TARTRATE

INJECTABLE; INJECTION

METOPROLOL TARTRATE

AP EUROHLTH INTL SARL

1MG/ML

A076495 001

Jul 07, 2003

Apr CAHN

TABLET; ORAL

METOPROLOL TARTRATE

>D> AB

SANDOZ

50MG

A073288 001

Mar 25, 1994

May DISC

>A>

@

50MG

A073288 001

Mar 25, 1994

May DISC

>D> AB

100MG

A073289 001

Mar 25, 1994

May DISC

>A>

@

100MG

A073289 001

Mar 25, 1994

May DISC

AB SUN PHARM INDS

25MG

A073654 002

Jul 15, 2009

Mar CAHN

AB

100MG

A073654 001

Dec 21, 1993

Mar CAHN

METRONIDAZOLE

GEL; VAGINAL

NUVESSA

+ ALLERGAN SALES LLC

1.3%

N205223 001

Mar 24, 2014

Apr CAHN

TABLET; ORAL

METRONIDAZOLE

>A> AB

FLAMINGO PHARMS

250MG

A207309 001

May 16, 2016

May NEWA

>A> AB

500MG

A207309 002

May 16, 2016

May NEWA

AB NOSTRUM LABS INC

250MG

A070772 001

Jul 16, 1986

Jan CAHN

AB

500MG

A070773 001

Jul 16, 1986

Jan CAHN

>A> AB

STRIDES PHARMA

250MG

A208162 001

May 25, 2016

May NEWA

>A> AB

500MG

A208162 002

May 25, 2016

May NEWA

>D>

@ VIVIMED LABS

250MG

A070040 001

Jan 29, 1985

May CMFD

>A> AB

250MG

A070040 001

Jan 29, 1985

May CMFD

>D>

@

500MG

A070039 001

Jan 29, 1985

May CMFD

>A> AB

500MG

A070039 001

Jan 29, 1985

May CMFD

MICONAZOLE

TABLET; BUCCAL

ORAVIG

+ MIDATECH PHARMA US

50MG

N022404 001

Apr 16, 2010

Jan CAHN

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

>D> AP

BEDFORD

EQ 1MG BASE/ML

A075247 002

Jun 23, 2000

May CAHN

>D> AP

EQ 5MG BASE/ML

A075247 001

Jun 23, 2000

May CAHN

>A> AP

EUROHLTH INTL SARL

EQ 1MG BASE/ML

A075247 002

Jun 23, 2000

May CAHN

AP

EQ 1MG BASE/ML

A075421 002

Jun 20, 2000

Apr CAHN

>A> AP

EQ 5MG BASE/ML

A075247 001

Jun 23, 2000

May CAHN

AP

EQ 5MG BASE/ML

A075421 001

Jun 20, 2000

Apr CAHN

MIGLITOL

TABLET; ORAL

GLYSET

AB + PHARMACIA AND UPJOHN

25MG

N020682 001

Dec 18, 1996

Feb CRLD

AB

100MG

N020682 003

Dec 18, 1996

Feb CRLD

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

MILNACIPRAN HYDROCHLORIDE

AB AMNEAL PHARMS

12.5MG

A205081 001

Apr 22, 2016

Apr NEWA

AB

25MG

A205081 002

Apr 22, 2016

Apr NEWA

AB

50MG

A205081 003

Apr 22, 2016

Apr NEWA

AB

100MG

A205081 004

Apr 22, 2016

Apr NEWA

TABLET;ORAL

MILNACIPRAN HYDROCHLORIDE

	@ LIBERTY PHARMA INC	12.5MG	A205071	001	Jan 27, 2016	Jan DISC
		12.5MG	A205071	001	Jan 27, 2016	Jan NEWA
	@	25MG	A205071	002	Jan 27, 2016	Jan DISC
		25MG	A205071	002	Jan 27, 2016	Jan NEWA
	@	50MG	A205071	003	Jan 27, 2016	Jan DISC
		50MG	A205071	003	Jan 27, 2016	Jan NEWA
	@	100MG	A205071	004	Jan 27, 2016	Jan DISC
		100MG	A205071	004	Jan 27, 2016	Jan NEWA
	SAVELLA					
AB	CYPRESS BIOSCIENCE	12.5MG	N022256	001	Jan 14, 2009	Apr CFTG
AB		25MG	N022256	002	Jan 14, 2009	Apr CFTG
AB	+	50MG	N022256	003	Jan 14, 2009	Apr CFTG
AB		100MG	N022256	004	Jan 14, 2009	Apr CFTG

MILRINONE LACTATE

INJECTABLE;INJECTION

MILRINONE LACTATE

AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075660	001	May 28, 2002	Apr CAHN
	MILRINONE LACTATE IN DEXTROSE 5%					
AP	CLARIS	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A077151	002	Jul 20, 2005	Mar CAHN
	MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
	@ CLARIS	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005	Mar CAHN

MINOCYCLINE HYDROCHLORIDE

TABLET;ORAL

MINOCYCLINE HYDROCHLORIDE

AB	SUN PHARM INDS	EQ 50MG BASE	A090217	001	Jan 29, 2016	Jan NEWA
AB		EQ 75MG BASE	A090217	002	Jan 29, 2016	Jan NEWA
AB		EQ 100MG BASE	A090217	003	Jan 29, 2016	Jan NEWA

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

>A> AB	AUROBINDO PHARMA LTD	EQ 80MG BASE	A202261	006	Jun 13, 2016	May NEWA
>A> AB		EQ 105MG BASE	A202261	007	Jun 13, 2016	May NEWA
	@ IMPAX LABS INC	EQ 45MG BASE	A090024	001	Feb 03, 2009	Mar DISC
	@	EQ 90MG BASE	A090024	002	Feb 03, 2009	Mar DISC
	@	EQ 135MG BASE	A090024	003	Feb 03, 2009	Mar DISC

MINOXIDIL

TABLET;ORAL

MINOXIDIL

AB	SUN PHARM INDS	10MG	A072709	001	Dec 14, 1995	Mar CAHN
----	----------------	------	---------	-----	--------------	----------

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINE

@	ACTAVIS LABS FL INC	15MG	A076336	001	Jun 20, 2003	Jan DISC
@		30MG	A076336	002	Jun 20, 2003	Jan DISC
@		45MG	A076336	003	Jun 20, 2003	Jan DISC

MITOMYCIN

INJECTABLE;INJECTION

MITOMYCIN

AP	EUROHLTH INTL SARL	5MG/VIAL	A064117	001	Apr 19, 1995	Apr CAHN
AP		5MG/VIAL	A064180	001	Dec 23, 1999	Jan CAHN
AP		20MG/VIAL	A064117	002	Apr 19, 1995	Apr CAHN
AP		20MG/VIAL	A064180	002	Dec 23, 1999	Jan CAHN

MODAFINIL

TABLET;ORAL

MODAFINIL

AB	WATSON LABS INC	100MG	A076715	001	Nov 01, 2012	Jan CAHN
AB		200MG	A076715	002	Nov 01, 2012	Jan CAHN

MOMETASONE FUROATE

SPRAY, METERED;NASAL
MOMETASONE FUROATE

AB	APOTEX INC	EQ 0.05MG BASE/SPRAY	A091161	001	Mar 22, 2016	Mar NEWA
	NASONEX					
AB	+ MERCK SHARP DOHME	EQ 0.05MG BASE/SPRAY	N020762	001	Oct 01, 1997	Mar CFTG

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL
KADIAN

AB	+ ACTAVIS LABS UT INC	10MG	N020616	008	Apr 20, 2007	Feb CTEC
AB		20MG	N020616	001	Jul 03, 1996	Feb CTEC
AB		30MG	N020616	004	Mar 09, 2001	Feb CTEC
AB		40MG	N020616	009	Jul 09, 2012	Feb CTEC
AB		50MG	N020616	002	Jul 03, 1996	Feb CTEC
AB		60MG	N020616	005	Mar 09, 2001	Feb CTEC
AB		70MG	N020616	010	Jul 09, 2012	Feb CTEC
AB		80MG	N020616	006	Oct 27, 2006	Feb CTEC
AB	+	100MG	N020616	003	Jul 03, 1996	Feb CTEC
AB	+	200MG	N020616	007	Feb 27, 2007	Feb CTEC
AB	+ ALLERGAN SALES LLC	10MG	N020616	008	Apr 20, 2007	Apr CAHN
AB		20MG	N020616	001	Jul 03, 1996	Apr CAHN
AB		30MG	N020616	004	Mar 09, 2001	Apr CAHN
AB		40MG	N020616	009	Jul 09, 2012	Apr CAHN
AB		50MG	N020616	002	Jul 03, 1996	Apr CAHN
AB		60MG	N020616	005	Mar 09, 2001	Apr CAHN
AB		70MG	N020616	010	Jul 09, 2012	Apr CAHN
AB		80MG	N020616	006	Oct 27, 2006	Apr CAHN
AB	+	100MG	N020616	003	Jul 03, 1996	Apr CAHN
		130MG	N020616	011	Jul 09, 2012	Apr CAHN
		150MG	N020616	012	Jul 09, 2012	Apr CAHN
	+	200MG	N020616	007	Feb 27, 2007	Apr CAHN

MORPHINE SULFATE

AB	IMPAX LABS INC	20MG	A200411	001	Apr 12, 2016	Mar NEWA
AB		30MG	A200411	002	Apr 12, 2016	Mar NEWA
AB		50MG	A200411	003	Apr 12, 2016	Mar NEWA
AB		60MG	A200411	004	Apr 12, 2016	Mar NEWA
AB		80MG	A200411	005	Apr 12, 2016	Mar NEWA
AB		100MG	A200411	006	Apr 12, 2016	Mar NEWA
AB	PAR PHARM INC	20MG	A200812	001	Nov 10, 2011	Feb CTEC
AB		30MG	A200812	002	Nov 10, 2011	Feb CTEC
AB		50MG	A200812	003	Nov 10, 2011	Feb CTEC
AB		60MG	A200812	004	Nov 10, 2011	Feb CTEC
AB		80MG	A200812	005	Nov 10, 2011	Feb CTEC
AB		100MG	A200812	006	Nov 10, 2011	Feb CTEC
AB	TEVA PHARMS USA	20MG	A202718	001	Dec 29, 2014	Feb CTEC
AB		30MG	A202718	002	Dec 29, 2014	Feb CTEC
AB		40MG	A202718	007	Jun 03, 2015	Feb CTEC
AB		50MG	A202718	003	Dec 29, 2014	Feb CTEC
AB		60MG	A202718	004	Dec 29, 2014	Feb CTEC
AB		70MG	A202718	008	Jun 03, 2015	Feb CTEC
AB		80MG	A202718	005	Dec 29, 2014	Feb CTEC
AB		100MG	A202718	006	Dec 29, 2014	Feb CTEC
AB	UPSHER SMITH	10MG	A202104	001	Jun 03, 2013	Feb CTEC
AB		20MG	A202104	002	Jun 03, 2013	Feb CTEC
AB		30MG	A202104	003	Jun 03, 2013	Feb CTEC
AB		50MG	A202104	004	Jun 03, 2013	Feb CTEC
AB		60MG	A202104	005	Jun 03, 2013	Feb CTEC
AB		80MG	A202104	006	Jun 03, 2013	Feb CTEC
AB		100MG	A202104	007	Jun 03, 2013	Feb CTEC

SOLUTION;ORAL

MORPHINE SULFATE

AA	NOSTRUM LABS INC	10MG/5ML	A201011	001	Feb 05, 2014	Mar CAHN
AA		20MG/5ML	A201011	002	Feb 05, 2014	Mar CAHN
>A> AA	TRIS PHARMA INC	20MG/5ML	A203519	001	May 18, 2016	May NEWA

MOXIFLOXACIN HYDROCHLORIDE

TABLET;ORAL

MOXIFLOXACIN HYDROCHLORIDE

AB	CROSSMEDIKA SA	EQ 400MG BASE	A205348	001	Jan 14, 2016	Jan NEWA
----	----------------	---------------	---------	-----	--------------	----------

NALIDIXIC ACID

TABLET; ORAL

NALIDIXIC ACID

@ SUN PHARM INDS

250MG

A 070270 001 Jun 29, 1988 Mar CAHN

@

1GM

A 070272 001 Jun 29, 1988 Mar CAHN

NAPROXEN

TABLET; ORAL

NAPROSYN

AB ATNAHS PHARMA US

250MG

N 017581 002 Feb CAHN

AB

375MG

N 017581 003 Feb CAHN

AB +

500MG

N 017581 004 Apr 15, 1982 Feb CAHN

NAPROXEN

@ SANDOZ

250MG

A 074140 001 Dec 21, 1993 Feb DISC

@

375MG

A 074140 002 Dec 21, 1993 Feb DISC

@

500MG

A 074140 003 Dec 21, 1993 Feb DISC

TABLET, DELAYED RELEASE; ORAL

EC-NAPROSYN

AB + ATNAHS PHARMA US

375MG

N 020067 002 Oct 14, 1994 Feb CAHN

AB +

500MG

N 020067 003 Oct 14, 1994 Feb CAHN

NAPROXEN

@ SANDOZ

375MG

A 075061 001 Feb 18, 1998 Feb DISC

@

500MG

A 075061 002 Feb 18, 1998 Feb DISC

NAPROXEN SODIUM

TABLET; ORAL

ANAPROX

AB ATNAHS PHARMA US

EQ 250MG BASE

N 018164 001 Feb CAHN

ANAPROX DS

AB + ATNAHS PHARMA US

EQ 500MG BASE

N 018164 003 Sep 30, 1987 Feb CAHN

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

@ SUN PHARM INDS LTD

50MG

A 076409 001 Sep 16, 2003 Feb DISC

@

100MG

A 076409 002 Sep 16, 2003 Feb DISC

@

150MG

A 076409 003 Sep 16, 2003 Feb DISC

@

200MG

A 076409 004 Sep 16, 2003 Feb DISC

@

250MG

A 076409 005 Sep 16, 2003 Feb DISC

NEOMYCIN SULFATE

TABLET; ORAL

NEOMYCIN SULFATE

>A> AA LANNETT HOLDINGS INC 500MG

A 204435 001 Jun 10, 2016 May NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

CARDENE

>D>

>D> AB CHIESI USA INC

20MG

N 019488 001 Dec 21, 1988 May DISC

>A> @

20MG

N 019488 001 Dec 21, 1988 May DISC

>D> AB +

30MG

N 019488 002 Dec 21, 1988 May DISC

>A> @

30MG

N 019488 002 Dec 21, 1988 May DISC

NICARDIPINE HYDROCHLORIDE

>D> AB MYLAN

30MG

A 074642 002 Jul 18, 1996 May CRLD

>A> AB +

30MG

A 074642 002 Jul 18, 1996 May CRLD

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINE

@ VALIDUS PHARMS

10MG

A 073250 001 Oct 08, 1991 Mar CAHN

@

20MG

A 074045 001 Apr 30, 1992 Mar CAHN

TABLET, EXTENDED RELEASE; ORAL

ADALAT CC

AB1 ALVOGEN

30MG

N 020198 001 Apr 21, 1993 Feb CAHN

AB1 +

60MG

N 020198 002 Apr 21, 1993 Feb CAHN

AB1 +

90MG

N 020198 003 Apr 21, 1993 Feb CAHN

NIFEDIPINE

AB1 VALEANT PHARMS NORTH

30MG

A 075269 001 Dec 04, 2000 Jan CAHN

AB1

60MG

A 075269 002 Dec 04, 2000 Jan CAHN

AB1

90MG

A 076070 001 Aug 16, 2002 Jan CAHN

NIMODIPINECAPSULE;ORAL
NIMODIPINE

AB	+	BIONPHARMA INC	30MG	A076740	001	Jan 17, 2008	Jan CAHN
----	---	----------------	------	---------	-----	--------------	----------

NITISINONESUSPENSION;ORAL
ORFADIN

	+	SOBI	4MG/ML	N206356	001	Apr 22, 2016	Apr NEWA
--	---	------	--------	---------	-----	--------------	----------

NITRIC OXIDEGAS;INHALATION
INOMAX

	+	MALLINCKRODT HOSP	800PPM	N020845	003	Dec 23, 1999	Jan CAHN
--	---	-------------------	--------	---------	-----	--------------	----------

NITROFURANTOINSUSPENSION;ORAL
NITROFURANTOIN

AB		ACTAVIS MID ATLANTIC	25MG/5ML	A205180	001	May 03, 2016	Apr NEWA
AB		NOSTRUM LABS INC	25MG/5ML	A201355	001	Aug 14, 2013	Feb CAHN

NITROFURANTOIN, MACROCRYSTALLINECAPSULE;ORAL
NITROFURANTOIN

AB		SUN PHARM INDS	25MG	A201722	001	Feb 16, 2016	Feb NEWA
AB			50MG	A201722	002	Feb 16, 2016	Feb NEWA
AB			100MG	A201722	003	Feb 16, 2016	Feb NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINECAPSULE;ORAL
MACROBID

AB	+	ALVOGEN MALTA	75MG;25MG	N020064	001	Dec 24, 1991	Jan CAHN
----	---	---------------	-----------	---------	-----	--------------	----------

NITROGLYCERINFILM, EXTENDED RELEASE;TRANSDERMAL
MINITRAN

>D>	AB1	MEDICIS	0.2MG/HR	A089772	001	Aug 30, 1996	May CAHN
>A>	AB1	VALEANT PHARMS NORTH	0.2MG/HR	A089772	001	Aug 30, 1996	May CAHN

NIZATIDINESOLUTION;ORAL
AXID

	@	BRAINTREE	15MG/ML	N021494	001	May 25, 2004	Feb DISC
--	---	-----------	---------	---------	-----	--------------	----------

NIZATIDINE

	+	AMNEAL PHARMS	15MG/ML	A090576	001	Nov 18, 2009	Feb CRLD
--	---	---------------	---------	---------	-----	--------------	----------

NOREPINEPHRINE BITARTRATEINJECTABLE;INJECTION
NOREPINEPHRINE BITARTRATE

AP		CLARIS	EQ 1MG BASE/ML	A040859	001	Mar 27, 2012	Jan CAHN
AP		EUROHLTH INTL SARL	EQ 1MG BASE/ML	A040462	001	Oct 31, 2003	Apr CAHN

NORETHINDRONETABLET;ORAL-28
NOR-QD

AB1	+	APIL	0.35MG	N017060	001		Jan CAHN
-----	---	------	--------	---------	-----	--	----------

NORTRIPTYLINE HYDROCHLORIDECAPSULE;ORAL
NORTRIPTYLINE HYDROCHLORIDE

	@	AUROLIFE PHARMA LLC	EQ 10MG BASE	A074835	001	Jun 30, 1997	Feb CAHN
	@		EQ 25MG BASE	A074835	002	Jun 30, 1997	Feb CAHN
	@		EQ 50MG BASE	A074835	003	Jun 30, 1997	Feb CAHN
	@		EQ 75MG BASE	A074835	004	Jun 30, 1997	Feb CAHN
>A>	@	IDT AUSTRALIA LTD	EQ 10MG BASE	A074054	001	Dec 31, 1992	May CAHN
>A>	@		EQ 25MG BASE	A074054	002	Dec 31, 1992	May CAHN
>A>	@		EQ 50MG BASE	A074054	003	Dec 31, 1992	May CAHN
>A>	@		EQ 75MG BASE	A074054	004	Dec 31, 1992	May CAHN
>D>	@	SANDOZ	EQ 10MG BASE	A074054	001	Dec 31, 1992	May CAHN
>D>	@		EQ 25MG BASE	A074054	002	Dec 31, 1992	May CAHN
>D>	@		EQ 50MG BASE	A074054	003	Dec 31, 1992	May CAHN

		CAPSULE;ORAL							
		NORTRIPTYLINE HYDROCHLORIDE							
>D>	@	EQ 75MG BASE	A074054	004	Dec 31, 1992	May	CAHN		
		<u>NYSTATIN</u>							
		TABLET;ORAL							
		NYSTATIN							
AA	SUN PHARM INDS	500,000 UNITS	A062838	001	Dec 22, 1988	Mar	CAHN		
		<u>NYSTATIN; TRIAMCINOLONE ACETONIDE</u>							
		CREAM;TOPICAL							
		NYSTATIN TRIAMCINOLONE ACETONIDE							
	@ PHARMADERM	100,000 UNITS/GM;0.1%	A062596	001	Oct 08, 1985	Mar	CMS1		
		OINTMENT;TOPICAL							
		MYKACET							
>D> AT	G AND W LABS INC	100,000 UNITS/GM;0.1%	A062733	001	Mar 09, 1987	May	CMS1		
>A> AT		100,000 UNITS/GM;0.1%	A062733	001	Mar 06, 1987	May	CMS1		
>A>		<u>OBETICHOLIC ACID</u>							
>A>		TABLET;ORAL							
>A>		OICALIVA							
>A>	INTERCEPT PHARMS INC	5MG	N207999	001	May 27, 2016	May	NEWA		
>A>	+	10MG	N207999	002	May 27, 2016	May	NEWA		
		<u>OCTREOTIDE ACETATE</u>							
		INJECTABLE;INJECTION							
		OCTREOTIDE ACETATE							
	@ WOCKHARDT USA	EQ 0.2MG BASE/ML	A090986	001	May 11, 2011	Jan	DISC		
	@	EQ 1MG BASE/ML	A090986	002	May 11, 2011	Jan	DISC		
		OCTREOTIDE ACETATE (PRESERVATIVE FREE)							
	@ WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985	001	May 11, 2011	Jan	DISC		
	@	EQ 0.1MG BASE/ML	A090985	002	May 11, 2011	Jan	DISC		
	@	EQ 0.5MG BASE/ML	A090985	003	May 11, 2011	Jan	DISC		
		OCTREOTIDE ACETATE PRESERVATIVE FREE							
	@ WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985	001	May 11, 2011	Feb	CMS1		
	@	EQ 0.1MG BASE/ML	A090985	002	May 11, 2011	Feb	CMS1		
	@	EQ 0.5MG BASE/ML	A090985	003	May 11, 2011	Feb	CMS1		
		<u>OFLOXACIN</u>							
		SOLUTION/DROPS;OPHTHALMIC							
		OFLOXACIN							
AT	ALVOGEN	0.3%	A076830	001	Aug 31, 2004	Mar	CAHN		
		SOLUTION/DROPS;OTIC							
		FLOXIN OTIC							
	@ DAIICHI	0.3%	N020799	001	Dec 16, 1997	Feb	DISC		
		OFLOXACIN							
AT	ALVOGEN	0.3%	A090395	001	Aug 11, 2009	Mar	CAHN		
AT	+	BAUSCH AND LOMB	A076128	001	Mar 17, 2008	Feb	CRLD		
		<u>OLANZAPINE</u>							
		TABLET;ORAL							
		OLANZAPINE							
AB	INVAGEN PHARMS	2.5MG	A203333	001	Mar 15, 2016	Feb	NEWA		
AB		5MG	A203333	002	Mar 15, 2016	Feb	NEWA		
AB		7.5MG	A203333	003	Mar 15, 2016	Feb	NEWA		
AB		10MG	A203333	004	Mar 15, 2016	Feb	NEWA		
AB		15MG	A203333	005	Mar 15, 2016	Feb	NEWA		
AB		20MG	A203333	006	Mar 15, 2016	Feb	NEWA		
AB	QILU PHARM CO LTD	2.5MG	A204319	001	Jan 27, 2016	Jan	NEWA		
AB		5MG	A204319	002	Jan 27, 2016	Jan	NEWA		
AB		7.5MG	A204319	003	Jan 27, 2016	Jan	NEWA		
AB		10MG	A204319	004	Jan 27, 2016	Jan	NEWA		
AB		15MG	A204319	005	Jan 27, 2016	Jan	NEWA		
AB		20MG	A204319	006	Jan 27, 2016	Jan	NEWA		
		TABLET, ORALLY DISINTEGRATING;ORAL							
		OLANZAPINE							
AB	INVAGEN PHARMS	5MG	A203456	001	Mar 16, 2016	Feb	NEWA		
AB		10MG	A203456	002	Mar 16, 2016	Feb	NEWA		
AB		15MG	A203456	003	Mar 16, 2016	Feb	NEWA		
AB		20MG	A203456	004	Mar 16, 2016	Feb	NEWA		

OLOPATADINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

AT	SOMERSET THERAPS LLC	EQ 0.1% BASE	A206306	001	Dec 07, 2015	Mar CAHN
----	----------------------	--------------	---------	-----	--------------	----------

OMEGA-3-ACID ETHYL ESTERSCAPSULE;ORAL
OMEGA-3-ACID ETHYL ESTERS

AB	AMNEAL PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A204940	001	Nov 27, 2015	Jan CMS1
----	---------------	--	---------	-----	--------------	----------

OMEGA-3-ACID ETHYL ESTERS TYPE ACAPSULE;ORAL
OMTRYG

+	TRYGG	1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977	001	Apr 23, 2014	Mar CAIN
---	-------	--	---------	-----	--------------	----------

OMEPRAZOLECAPSULE, DELAYED REL PELLETS;ORAL
OMEPRAZOLE

AB	+	SANDOZ	20MG	A075757	002	Jan 28, 2003	Mar CRLD
AB	+		40MG	A076515	001	Jan 21, 2009	Mar CRLD

ONDANSETRON HYDROCHLORIDEINJECTABLE;INJECTION
ONDANSETRON HYDROCHLORIDE

AP	EUROHLTH INTL SARL	EQ 2MG BASE/ML	A076967	001	Dec 26, 2006	Apr CAHN
----	--------------------	----------------	---------	-----	--------------	----------

AP	ACCORD HLTHCARE	EQ 2MG BASE/ML	A206845	001	Mar 10, 2016	Feb NEWA
----	-----------------	----------------	---------	-----	--------------	----------

AP	EUROHLTH INTL SARL	EQ 2MG BASE/ML	A077011	001	Dec 26, 2006	Apr CAHN
----	--------------------	----------------	---------	-----	--------------	----------

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

>A>	@	HIKMA INTL PHARMS	EQ 4MG BASE	A077545	001	Sep 06, 2007	May CAHN
>A>	@		EQ 8MG BASE	A077545	002	Sep 06, 2007	May CAHN
>A>	@		EQ 24MG BASE	A077545	003	Sep 06, 2007	May CAHN
>D>	@	HIKMA PHARMS LLC	EQ 4MG BASE	A077545	001	Sep 06, 2007	May CAHN
>D>	@		EQ 8MG BASE	A077545	002	Sep 06, 2007	May CAHN
>D>	@		EQ 24MG BASE	A077545	003	Sep 06, 2007	May CAHN

OXALIPLATININJECTABLE;IV (INFUSION)
ELOXATIN

>D>	+	SANOFI AVENTIS US	200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006	May CFTG
>A>	AP	+	200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006	May CFTG

OXALIPLATIN

>A>	AP	QILU PHARM CO LTD	50MG/10ML (5MG/ML)	A204368	001	Jun 07, 2016	May NEWA
	AP		50MG/VIAL	A204616	001	May 11, 2016	Apr NEWA
>A>	AP		100MG/20ML (5MG/ML)	A204368	002	Jun 07, 2016	May NEWA
	AP		100MG/VIAL	A204616	002	May 11, 2016	Apr NEWA
>A>	AP		200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	May NEWA
	AP	SANDOZ INC	50MG/10ML (5MG/ML)	A078812	001	Aug 07, 2009	Jan CAHN
	AP		100MG/20ML (5MG/ML)	A078812	002	Aug 07, 2009	Jan CAHN

OXAZEPAMCAPSULE;ORAL
OXAZEPAM

@	SUN PHARM INDS	10MG	A071026	002	Aug 10, 1987	Mar CAHN
@		15MG	A071026	003	Aug 10, 1987	Mar CAHN
@		30MG	A071026	001	Aug 10, 1987	Mar CAHN

OXICONAZOLE NITRATECREAM;TOPICAL
OXICONAZOLE NITRATE

AB	TARO	EQ 1% BASE	A205076	001	Mar 07, 2016	Feb NEWA
----	------	------------	---------	-----	--------------	----------

AB	+	FOUGERA PHARMS	EQ 1% BASE	N019828	001	Dec 30, 1988	Feb CFTG
----	---	----------------	------------	---------	-----	--------------	----------

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL
OXYTROL

AB	+	ALLERGAN SALES LLC	3.9MG/24HR	N021351	002	Feb 26, 2003	Apr CAHN
		GEL, METERED;TRANSDERMAL					
		GELNIQUE 3%					
	+	ALLERGAN SALES LLC	3%	N202513	001	Dec 07, 2011	Apr CAHN

OXYBUTYNIN CHLORIDE

GEL;TRANSDERMAL
GELNIQUE

+ ALLERGAN SALES LLC 10% (100MG/PACKET)
TABLET, EXTENDED RELEASE;ORAL
OXYBUTYNIN CHLORIDE

N022204 001 Jan 27, 2009 Apr CAHN

AB	ACCORD HLTHCARE	5MG	A207138	001	Feb 29, 2016	Feb NEWA
AB		10MG	A207138	002	Feb 29, 2016	Feb NEWA
AB		15MG	A207138	003	Feb 29, 2016	Feb NEWA
>A> AB	UNIQUE PHARM LABS	5MG	A206121	001	May 27, 2016	May NEWA
>A> AB		10MG	A206121	002	May 27, 2016	May NEWA
>A> AB		15MG	A206121	003	May 27, 2016	May NEWA

OXYCODONE

CAPSULE, EXTENDED RELEASE;ORAL
XTAMPZA ER

>A>	COLLEGIUM PHARM INC	9MG	N208090	001	Apr 26, 2016	May CAIN
>A>		13.5MG	N208090	002	Apr 26, 2016	May CAIN
>A>		18MG	N208090	003	Apr 26, 2016	May CAIN
>A>		27MG	N208090	004	Apr 26, 2016	May CAIN
>A>	+	36MG	N208090	005	Apr 26, 2016	May CAIN

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL
OXYCODONE HYDROCHLORIDE

AB	ANI PHARMS INC	5MG	A205177	001	Mar 31, 2016	Mar NEWA
>D>	CAPSULE, EXTENDED RELEASE;ORAL					
>D>	XTAMPZA ER					
>D>	COLLEGIUM PHARM INC	EQ 9MG BASE	N208090	001	Apr 26, 2016	May CAIN
		EQ 9MG BASE	N208090	001	Apr 26, 2016	Apr NEWA
>D>		EQ 13.5MG BASE	N208090	002	Apr 26, 2016	May CAIN
		EQ 13.5MG BASE	N208090	002	Apr 26, 2016	Apr NEWA
>D>		EQ 18MG BASE	N208090	003	Apr 26, 2016	May CAIN
		EQ 18MG BASE	N208090	003	Apr 26, 2016	Apr NEWA
>D>		EQ 27MG BASE	N208090	004	Apr 26, 2016	May CAIN
		EQ 27MG BASE	N208090	004	Apr 26, 2016	Apr NEWA
>D>		EQ 36MG BASE	N208090	005	Apr 26, 2016	May CRLD
>A>	+	EQ 36MG BASE	N208090	005	Apr 26, 2016	May CRLD
		EQ 36MG BASE	N208090	005	Apr 26, 2016	Apr NEWA

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

AB	ALVOGEN MALTA	5MG	A202116	001	Dec 30, 2011	Jan CAHN
AB		15MG	A202116	002	Dec 30, 2011	Jan CAHN
AB		30MG	A202116	003	Dec 30, 2011	Jan CAHN
AB	COASTAL PHARMS	10MG	A091313	004	Apr 29, 2016	Apr NEWA
AB		20MG	A091313	005	Apr 29, 2016	Apr NEWA
AB	KEN LIFESCIENCE	5MG	A207119	001	Apr 12, 2016	Mar NEWA
AB		10MG	A207119	002	Apr 12, 2016	Mar NEWA
AB		15MG	A207119	003	Apr 12, 2016	Mar NEWA
AB		20MG	A207119	004	Apr 12, 2016	Mar NEWA
AB		30MG	A207119	005	Apr 12, 2016	Mar NEWA

OXYMORPHONE HYDROCHLORIDE

TABLET;ORAL

OXYMORPHONE HYDROCHLORIDE

AB	AUROLIFE PHARMA LLC	5MG	A204459	001	Apr 26, 2016	Apr NEWA
AB		10MG	A204459	002	Apr 26, 2016	Apr NEWA

PACLITAXEL

INJECTABLE;INJECTION
PACLITAXEL

AP	SANDOZ INC	6MG/ML	A078167	001	Dec 26, 2007	Jan CAHN
----	------------	--------	---------	-----	--------------	----------

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
INVEGA SUSTENNA

	JANSSEN PHARMS	117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Mar CRLD
+		156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	Mar CRLD

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS
PALONOSETRON HYDROCHLORIDE

AP	DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A201533	001	Apr 21, 2016	Apr NEWA
----	--------------------	---	---------	-----	--------------	----------

AP		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A201533	002	Apr 21, 2016	Apr NEWA
----	--	--	---------	-----	--------------	----------

SOLUTION;INTRAVENOUS
PALONOSETRON HYDROCHLORIDE

	DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016	Mar NEWA
--	--------------------	---	---------	-----	--------------	----------

		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016	Mar NEWA
--	--	--	---------	-----	--------------	----------

PAMIDRONATE DISODIUM

INJECTABLE;INJECTION
PAMIDRONATE DISODIUM

AP	SAGENT PHARMS	30MG/10ML (3MG/ML)	A078373	001	Dec 23, 2008	Jan CAHN
----	---------------	--------------------	---------	-----	--------------	----------

AP		90MG/10ML (9MG/ML)	A078373	002	Dec 23, 2008	Jan CAHN
----	--	--------------------	---------	-----	--------------	----------

PANTOPRAZOLE SODIUM

INJECTABLE;IV (INFUSION)
PANTOPRAZOLE SODIUM

AP	AUROBINDO PHARMA LTD	EQ 40MG BASE/VIAL	A205675	001	Mar 30, 2016	Mar NEWA
----	----------------------	-------------------	---------	-----	--------------	----------

TABLET, DELAYED RELEASE;ORAL
PANTOPRAZOLE SODIUM

AB	AMNEAL PHARMS	EQ 20MG BASE	A205119	001	Jan 26, 2016	Jan NEWA
----	---------------	--------------	---------	-----	--------------	----------

AB		EQ 40MG BASE	A205119	002	Jan 26, 2016	Jan NEWA
----	--	--------------	---------	-----	--------------	----------

PARICALCITOL

CAPSULE;ORAL
PARICALCITOL

AB	BIONPHARMA INC	1MCG	A202539	001	Mar 27, 2014	Jan CAHN
----	----------------	------	---------	-----	--------------	----------

AB		2MCG	A202539	002	Mar 27, 2014	Jan CAHN
----	--	------	---------	-----	--------------	----------

AB		4MCG	A202539	003	Mar 27, 2014	Jan CAHN
----	--	------	---------	-----	--------------	----------

AB	LOTUS PHARM CO LTD	1MCG	A206710	001	Feb 24, 2016	Feb NEWA
----	--------------------	------	---------	-----	--------------	----------

AB		2MCG	A206710	002	Feb 24, 2016	Feb NEWA
----	--	------	---------	-----	--------------	----------

AB		4MCG	A206710	003	Feb 24, 2016	Feb NEWA
----	--	------	---------	-----	--------------	----------

SOLUTION;INTRAVENOUS
PARICALCITOL

AP	ACCORD HLTHCARE	0.002MG/ML (0.002MG/ML)	N207174	001	Feb 04, 2016	Feb NEWA
----	-----------------	-------------------------	---------	-----	--------------	----------

AP		0.005MG/ML (0.005MG/ML)	N207174	002	Feb 04, 2016	Feb NEWA
----	--	-------------------------	---------	-----	--------------	----------

AP		0.01MG/2ML (0.005MG/ML)	N207174	003	Feb 04, 2016	Feb NEWA
----	--	-------------------------	---------	-----	--------------	----------

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
PAROXETINE HYDROCHLORIDE

>A>	AB	KREMERS URBAN PHARMS	EQ 12.5MG BASE	A204744	001	Jun 10, 2016	May NEWA
-----	----	----------------------	----------------	---------	-----	--------------	----------

>A>	AB		EQ 25MG BASE	A204744	002	Jun 10, 2016	May NEWA
-----	----	--	--------------	---------	-----	--------------	----------

>A>	AB		EQ 37.5MG BASE	A204744	003	Jun 10, 2016	May NEWA
-----	----	--	----------------	---------	-----	--------------	----------

PENBUTOLOL SULFATE

TABLET;ORAL
LEVATOL

@	AUXILIUM PHARMS INC	10MG	N018976	001	Dec 30, 1987	Mar CAHN
---	---------------------	------	---------	-----	--------------	----------

@		20MG	N018976	004	Jan 05, 1989	Mar CAHN
---	--	------	---------	-----	--------------	----------

PENCICLOVIRCREAM;TOPICAL
DENA VIR

+ DENCO ASSET 1% N020629 001 Sep 24, 1996 Apr CAIN

PENTETATE CALCIUM TRISODIUMSOLUTION;INHALATION, INTRAVENOUS
PENTETATE CALCIUM TRISODIUM+ HAMELN PHARMA PLUS EQ 1GM BASE/5ML (EQ 200MG BASE/ML) N021749 001 Aug 11, 2004 Apr CMFD
@ EQ 1GM BASE/5ML (EQ 200MG BASE/ML) N021749 001 Aug 11, 2004 Feb CAHNPENTETATE ZINC TRISODIUMSOLUTION;INHALATION, INTRAVENOUS
PENTETATE ZINC TRISODIUM+ HAMELN PHARMA PLUS EQ 1GM BASE/5ML (EQ 200MG BASE/ML) N021751 001 Aug 11, 2004 Apr CMFD
@ EQ 1GM BASE/5ML (EQ 200MG BASE/ML) N021751 001 Aug 11, 2004 Feb CAHNPENTOBARBITAL SODIUMINJECTABLE;INJECTION
NEMBUTAL SODIUM>D> + OAK PHARMS 50MG/ML A083246 001 May CTEC
>A> AP + 50MG/ML A083246 001 May CTEC
>A> PENTOBARBITAL SODIUM
>A> AP MYLAN INSTITUTIONAL 50MG/ML A206404 001 May 23, 2016 May NEWAPENTOXIFYLLINETABLET, EXTENDED RELEASE;ORAL
PENTOXIFYLLINEAB + APOTEX 400MG A075191 001 Jun 09, 1999 Mar CRLD
@ IMPAX LABS 400MG A075093 001 Aug 10, 1999 Mar DISC
@ PLIVA 400MG A074874 001 May 25, 1999 Mar DISC
TRENTAL
@ US PHARM HOLDINGS 400MG N018631 001 Aug 30, 1984 Jan CAHNPERAMPANELSUSPENSION;ORAL
FYCOMPA

+ EISAI INC 0.5MG/ML N208277 001 Apr 29, 2016 Apr NEWA

PERPHENAZINETABLET;ORAL
PERPHENAZINEAB WILSHIRE PHARMS INC 2MG A205973 001 Dec 17, 2015 Jan CAHN
AB 4MG A205973 002 Dec 17, 2015 Jan CAHN
AB 8MG A205973 003 Dec 17, 2015 Jan CAHN
AB 16MG A205973 004 Dec 17, 2015 Jan CAHNPHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIMTABLET;ORAL
SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HYDROCHLORIDE

@ ABLE 200MG,N/A,N/A;N/A,800MG,160MG N021105 001 Jun 26, 2001 Jan CMS1

PHENTERMINE HYDROCHLORIDECAPSULE;ORAL
PHENTERMINE HYDROCHLORIDEAA SUN PHARM INDS 30MG A040525 001 Oct 23, 2003 Mar CAHN
@ 37.5MG A040527 001 Oct 23, 2003 Mar CAHNTABLET;ORAL
PHENTERMINE HYDROCHLORIDEAA INGENUS PHARMS NJ 37.5MG A091451 001 Sep 21, 2012 Jan CAHN
AA SUN PHARM INDS 37.5MG A040526 001 Oct 23, 2003 Mar CAHNPHENYL BUTAZONECAPSULE;ORAL
PHENYL BUTAZONE

@ SUN PHARM INDS 100MG A088994 001 Dec 04, 1985 Mar CAHN

TABLET;ORAL
PHENYL BUTAZONE

@ SUN PHARM INDS 100MG A088863 001 Dec 04, 1985 Mar CAHN

PHYTONADIONEINJECTABLE; INJECTION
AQUAMEPHYTON@ TELIGENT PHARMA INC 1MG/0.5ML
@ 10MG/MLN012223 002
N012223 001Jan CAHN
Jan CAHNPIMAVANSERIN TARTRATETABLET; ORAL
NUPLAZID

+ ACADIA PHARMS INC EQ 17MG BASE

N207318 001 Apr 29, 2016 Apr NEWA

PINDOLOLTABLET; ORAL
PINDOLOL

>A> @ IDT AUSTRALIA LTD 5MG

A073608 001 Mar 29, 1993 May CAHN

>A> @ 10MG

A073609 001 Mar 29, 1993 May CAHN

>D> @ SANDOZ 5MG

A073608 001 Mar 29, 1993 May CAHN

>D> @ 10MG

A073609 001 Mar 29, 1993 May CAHN

AB SUN PHARM INDS 5MG

A074063 001 Jan 27, 1994 Mar CAHN

AB 10MG

A074063 002 Jan 27, 1994 Mar CAHN

PIROXICAMCAPSULE; ORAL
PIROXICAM

AB MYLAN PHARMS INC 20MG

A074118 001 Jun 15, 1993 Jan CAHN

@ SUN PHARM INDS 20MG

A073536 001 Mar 12, 1993 Mar CAHN

PODOFILOXGEL; TOPICAL
CONDYLOX

+ ALLERGAN SALES LLC 0.5%

N020529 001 Mar 13, 1997 Mar CAHN

SOLUTION; TOPICAL
CONDYLOX

AT + ALLERGAN SALES LLC 0.5%

N019795 001 Dec 13, 1990 Mar CAHN

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

>D> COLYTE

>D> MEDA PHARMS 227.1GM/BOT; 2.82GM/BOT; 6.36GM/BOT; 5.53GM/BOT; 21.5GM/BOT

N018983 010 Jan 31, 1989 May DISC

>A> @ 227.1GM/BOT; 2.82GM/BOT; 6.36GM/BOT; 5.53GM/BOT; 21.5GM/BOT

N018983 010 Jan 31, 1989 May DISC

POLYMYXIN B SULFATEINJECTABLE; INJECTION
POLYMYXIN B SULFATE

AP AUROBINDO PHARMA LTD EQ 500,000 UNITS BASE/VIAL

A206589 001 Apr 04, 2016 Mar NEWA

AP GLAND PHARMA LTD EQ 500,000 UNITS BASE/VIAL

A207322 001 Apr 14, 2016 Apr NEWA

POTASSIUM CHLORIDECAPSULE, EXTENDED RELEASE; ORAL
POTASSIUM CHLORIDE

AB GLENMARK PHARMS LTD 10MEQ

A202868 001 Jan 19, 2016 Jan NEWA

AB KREMERS URBAN PHARMS 8MEQ

A204210 001 Mar 28, 2016 Mar NEWA

AB 10MEQ

A204210 002 Mar 28, 2016 Mar NEWA

AB TRIS PHARMA INC 8MEQ

A201944 001 Mar 04, 2016 Feb NEWA

AB 10MEQ

A201944 002 Mar 04, 2016 Feb NEWA

TABLET, EXTENDED RELEASE; ORAL
POTASSIUM CHLORIDE

AB1 NOVEL LABS INC 10MEQ

A206347 001 Jan 21, 2016 Jan NEWA

AB1 20MEQ

A206347 002 Jan 21, 2016 Jan NEWA

PRAMIPEXOLE DIHYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
PRAMIPEXOLE DIHYDROCHLORIDE

AB ACTAVIS ELIZABETH 0.375MG

A201963 001 Apr 21, 2016 Apr NEWA

AB 0.75MG

A201963 002 Apr 21, 2016 Apr NEWA

AB 1.5MG

A201963 003 Apr 21, 2016 Apr NEWA

AB 3MG

A201963 004 Apr 21, 2016 Apr NEWA

AB 4.5MG

A201963 005 Apr 21, 2016 Apr NEWA

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

AB	CIPLA LTD	80MG	A077904	004	Mar 22, 2016	Mar NEWA
	@ MYLAN	10MG	A077013	001	Oct 23, 2006	Mar DISC
	@	20MG	A077013	002	Oct 23, 2006	Mar DISC
	@	40MG	A077013	003	Oct 23, 2006	Mar DISC
	@	80MG	A077013	004	Dec 28, 2007	Mar DISC

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HYDROCHLORIDE

>A>	@ IDT AUSTRALIA LTD	EQ 1MG BASE	A072576	001	May 16, 1989	May CAHN
>A>	@	EQ 2MG BASE	A072577	001	May 16, 1989	May CAHN
>A>	@	EQ 5MG BASE	A072578	001	May 16, 1989	May CAHN
>D>	@ SANDOZ	EQ 1MG BASE	A072576	001	May 16, 1989	May CAHN
>D>	@	EQ 2MG BASE	A072577	001	May 16, 1989	May CAHN
>D>	@	EQ 5MG BASE	A072578	001	May 16, 1989	May CAHN

PREDNISOLONE

TABLET; ORAL

PREDNISOLONE

	@ AUROLIFE PHARMA LLC	5MG	A084773	001		Feb CAHN
--	-----------------------	-----	---------	-----	--	----------

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

ORAPRED

	@ CONCORDIA PHARMS INC	EQ 15MG BASE/5ML	A075117	001	Dec 14, 2000	Mar DISC
AA	+ WOCKHARDT	EQ 15MG BASE/5ML	A076895	001	Oct 04, 2004	Mar CRLD

PREDNISONE

TABLET; ORAL

PREDNISONE

	@ AUROLIFE PHARMA LLC	5MG	A084774	001		Mar CAHN
	@	10MG	A089983	001	Jan 12, 1989	Mar CAHN
	@	20MG	A085813	001		Mar CAHN
	@	50MG	A089984	001	Jan 12, 1989	Mar CAHN
AB	DELCOR ASSET CORP	5MG	A080292	001		Mar CAHN
AB		10MG	A088832	001	Dec 04, 1985	Mar CAHN
AB		20MG	A083677	001		Mar CAHN
AB	SUN PHARM INDS	20MG	A089247	001	Dec 04, 1985	Mar CAHN

PRIMIDONE

TABLET; ORAL

PRIMIDONE

	@ IMPAX LABS	50MG	A040717	001	Feb 12, 2008	Mar DISC
	@	250MG	A040717	002	Feb 12, 2008	Mar DISC
AB	SUN PHARM INDS	50MG	A040626	001	Sep 29, 2005	Mar CAHN
AB		250MG	A040626	002	Sep 29, 2005	Mar CAHN

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL

PROCAINAMIDE HYDROCHLORIDE

>A>	@ IDT AUSTRALIA LTD	375MG	A089220	001	Jul 01, 1986	May CAHN
>D>	@ SANDOZ	375MG	A089220	001	Jul 01, 1986	May CAHN

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

AP	EUROHLTH INTL SARL	EQ 5MG BASE/ML	A040540	001	May 28, 2004	Apr CAHN
----	--------------------	----------------	---------	-----	--------------	----------

PROGESTERONE

CAPSULE; ORAL

PROGESTERONE

AB	BIONPHARMA INC	100MG	A200900	001	Aug 16, 2013	Jan CAHN
AB		200MG	A200900	002	Aug 16, 2013	Jan CAHN

GEL; VAGINAL

CRINONE

+	ALLERGAN SALES LLC	4%	N020701	001	Jul 31, 1997	Apr CAHN
+		8%	N020701	002	Jul 31, 1997	Apr CAHN

INJECTABLE; INJECTION
PROGESTERONE

AO + ALLERGAN SALES LLC 50MG/ML N017362 002 Apr CAHN

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

AA NOSTRUM LABS INC 6.25MG/5ML A040891 001 Mar 13, 2009 Feb CAHN

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

@ IMPAX LABS	12.5MG	A040724	001	Feb 12, 2008	Mar	DISC
@	25MG	A040724	002	Feb 12, 2008	Mar	DISC
@	50MG	A040791	001	May 20, 2008	Mar	DISC
@ SUN PHARM INDS	12.5MG	A084555	001		Mar	CAHN
@	25MG	A084554	001		Mar	CAHN
@	50MG	A084557	001		Jan	CAHN

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPAFENONE HYDROCHLORIDE

AB MYLAN PHARMS INC	225MG	A203803	001	Apr 29, 2016	Apr	NEWA
AB	325MG	A203803	002	Apr 29, 2016	Apr	NEWA
AB	425MG	A203803	003	Apr 29, 2016	Apr	NEWA

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

AB ORION CORP ORION	150MG	A202445	001	May 11, 2016	Apr	NEWA
AB	225MG	A202445	002	May 11, 2016	Apr	NEWA
AB	300MG	A202445	003	May 11, 2016	Apr	NEWA
AB SUN PHARM INDS	150MG	A075998	001	Nov 29, 2001	Mar	CAHN
AB	225MG	A075998	002	Nov 29, 2001	Mar	CAHN
AB	300MG	A075998	003	Nov 29, 2001	Mar	CAHN

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERAL LA

AB ANI PHARMS INC	60MG	N018553	004	Mar 18, 1987	Apr	CAHN
AB	80MG	N018553	002	Apr 19, 1983	Apr	CAHN
AB	120MG	N018553	003	Apr 19, 1983	Apr	CAHN
AB +	160MG	N018553	001	Apr 19, 1983	Apr	CAHN

PROPRANOLOL HYDROCHLORIDE

>D> BX UPSHER SMITH	60MG	A078311	001	Mar 06, 2009	May	DISC
>A> @	60MG	A078311	001	Mar 06, 2009	May	DISC
BX	60MG	A078311	001	Mar 06, 2009	Mar	CTEC
>D> BX	80MG	A078311	002	Mar 06, 2009	May	DISC
>A> @	80MG	A078311	002	Mar 06, 2009	May	DISC
BX	80MG	A078311	002	Mar 06, 2009	Mar	CTEC
>D> BX	120MG	A078311	003	Mar 06, 2009	May	DISC
>A> @	120MG	A078311	003	Mar 06, 2009	May	DISC
BX	120MG	A078311	003	Mar 06, 2009	Mar	CTEC
>D> BX	160MG	A078311	004	Mar 06, 2009	May	DISC
>A> @	160MG	A078311	004	Mar 06, 2009	May	DISC
BX	160MG	A078311	004	Mar 06, 2009	Mar	CTEC

INJECTABLE; INJECTION

PROPRANOLOL HYDROCHLORIDE

AP EUROHLTH INTL SARL	1MG/ML	A075792	001	Aug 29, 2000	Apr	CAHN
@ SANDOZ	1MG/ML	A076400	001	Feb 26, 2003	Mar	DISC

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

@ SUN PHARM INDS	10MG	A070319	001	Oct 22, 1985	Mar	CAHN
@	20MG	A070320	001	Oct 22, 1985	Mar	CAHN
@	40MG	A070103	001	Oct 22, 1985	Mar	CAHN
@	80MG	A070322	001	Aug 04, 1986	Mar	CAHN

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

@ SUN PHARM INDS	50MG	A083982	001		Mar	CAHN
------------------	------	---------	-----	--	-----	------

PYRIDOSTIGMINE BROMIDE

TABLET, EXTENDED RELEASE;ORAL
PYRIDOSTIGMINE BROMIDE

AB	ALVOGEN MALTA	180MG	A204737	001	Jun 26, 2015	Jan CAHN
----	---------------	-------	---------	-----	--------------	----------

QUAZEPAM

TABLET;ORAL
DORAL

@	CUTIS HEALTH LLC	7.5MG
+		15MG
@		15MG

N018708	003	Feb 26, 1987	Mar CAHN
N018708	001	Dec 27, 1985	Apr CMFD
N018708	001	Dec 27, 1985	Mar CAHN

QUETIAPINE FUMARATE

TABLET;ORAL
QUETIAPINE FUMARATE

@	ACTAVIS GRP PTC	EQ 25MG BASE
@		EQ 50MG BASE
@		EQ 100MG BASE
@		EQ 150MG BASE
@		EQ 200MG BASE
@		EQ 300MG BASE
@		EQ 400MG BASE

A201762	001	Feb 27, 2013	Apr DISC
A201762	002	Feb 27, 2013	Apr DISC
A201762	003	Feb 27, 2013	Apr DISC
A201762	004	Feb 27, 2013	Apr DISC
A201762	005	Feb 27, 2013	Apr DISC
A201762	006	Feb 27, 2013	Apr DISC
A201762	007	Feb 27, 2013	Apr DISC

>A>	AB	MACLEODS PHARMS LTD	EQ 25MG BASE	A203359	001	May 17, 2016	May NEWA
>A>	AB		EQ 50MG BASE	A203359	002	May 17, 2016	May NEWA
>A>	AB		EQ 100MG BASE	A203359	003	May 17, 2016	May NEWA
>A>	AB		EQ 200MG BASE	A203359	004	May 17, 2016	May NEWA
>A>	AB		EQ 300MG BASE	A203359	005	May 17, 2016	May NEWA
>A>	AB		EQ 400MG BASE	A203359	006	May 17, 2016	May NEWA
	AB	UNICHEM LABS LTD	EQ 25MG BASE	A202674	001	Mar 08, 2016	Feb NEWA
	AB		EQ 50MG BASE	A202674	002	Mar 08, 2016	Feb NEWA
	AB		EQ 100MG BASE	A202674	003	Mar 08, 2016	Feb NEWA
	AB		EQ 200MG BASE	A202674	004	Mar 08, 2016	Feb NEWA
	AB		EQ 300MG BASE	A202674	005	Mar 08, 2016	Feb NEWA
	AB		EQ 400MG BASE	A202674	006	Mar 08, 2016	Feb NEWA

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL
QUINAPRIL HYDROCHLORIDE

@	ACTAVIS LABS FL INC	EQ 5MG BASE
@		EQ 10MG BASE
@		EQ 20MG BASE
@		EQ 40MG BASE

A076049	001	Jan 14, 2005	Jan DISC
A076049	002	Jan 14, 2005	Jan DISC
A076049	003	Jan 14, 2005	Jan DISC
A076049	004	Jan 14, 2005	Jan DISC

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL
QUINIDINE GLUCONATE

	@	AUROLIFE PHARMA LLC	324MG
BX	+	SUN PHARM INDS	324MG

A089894	001	Dec 15, 1988	Mar CAHN
A089338	001	Feb 11, 1987	Mar CAHN

QUINIDINE SULFATE

TABLET;ORAL
QUINIDINE SULFATE

AB	SUN PHARM INDS	200MG
AB		300MG

A081030	001	Apr 14, 1989	Mar CAHN
A081031	001	Apr 14, 1989	Mar CAHN

RALOXIFENE HYDROCHLORIDE

TABLET;ORAL
RALOXIFENE HYDROCHLORIDE

AB	AMNEAL PHARMS	60MG
AB	GLENMARK PHARMS LTD	60MG

A208206	001	Apr 08, 2016	Mar NEWA
A204491	001	Mar 22, 2016	Mar NEWA

RANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION
RANITIDINE HYDROCHLORIDE

>A>	AP	MYLAN LABS LTD	EQ 25MG BASE/ML
>D>	AP	ZYDUS PHARMS USA INC	25MG/ML
>A>	AP		EQ 25MG BASE/ML
		ZANTAC	
AP	+	IGI LABS INC	EQ 25MG BASE/ML
		ZANTAC IN PLASTIC CONTAINER	
		@ IGI LABS INC	EQ 1MG BASE/ML

A079076	001	Jun 09, 2016	May NEWA
A091534	001	Feb 22, 2013	May CPOT
A091534	001	Feb 22, 2013	May CPOT
N019090	001	Oct 19, 1984	Jan CAHN
N019593	002	Sep 27, 1991	Jan CAHN

INJECTABLE;INJECTION							
ZANTAC IN PLASTIC CONTAINER							
	@	EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986	Jan	CAHN
SYRUP;ORAL							
RANITIDINE HYDROCHLORIDE							
AA	NOSTRUM LABS INC	EQ 15MG BASE/ML	A091091	001	Sep 20, 2011	Mar	CAHN
	@ WOCKHARDT	EQ 15MG BASE/ML	A079211	001	May 26, 2009	Apr	DISC
	@	EQ 15MG BASE/ML	A079212	001	Feb 23, 2009	Apr	DISC
<u>RASAGILINE MESYLATE</u>							
TABLET;ORAL							
RASAGILINE MESYLATE							
AB	ORCHID HLTHCARE	EQ 0.5MG BASE	A201970	001	Mar 15, 2016	Feb	NEWA
AB		EQ 1MG BASE	A201970	002	Mar 15, 2016	Feb	NEWA
<u>RESERPINE</u>							
TABLET;ORAL							
RESERPINE							
	@ HIKMA INTL PHARMS	0.1MG	A080975	001		Feb	CAHN
	@	0.25MG	A080975	002		Feb	CAHN
	@	1MG	A080975	003		Feb	CAHN
<u>RETAPAMULIN</u>							
OINTMENT;TOPICAL							
ALTABAX							
+	AQUA PHARMS LLC	1%	N022055	001	Apr 12, 2007	Jan	CAHN
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM</u>							
SOLUTION/DROPS;OPHTHALMIC							
PHOTREXA							
+	AVEDRO INC	0.146%	N203324	001	Apr 15, 2016	Apr	NEWA
	PHOTREXA VISCOUS IN DEXTROSE 20%						
+	AVEDRO INC	0.146%	N203324	002	Apr 15, 2016	Apr	NEWA
<u>RIFAMPIN</u>							
INJECTABLE;INJECTION							
RIFAMPIN							
AP	EUROHLTH INTL SARL	600MG/VIAL	A064217	001	Oct 29, 1999	Apr	CAHN
AP	HIKMA PHARMS	600MG/VIAL	A205039	001	Mar 03, 2016	Feb	NEWA
AP	WATSON PHARMS INC	600MG/VIAL	A206736	001	Jan 19, 2016	Jan	NEWA
<u>RILUZOLE</u>							
TABLET;ORAL							
RILUZOLE							
AB	ALKEM LABS LTD	50MG	A204048	001	Mar 30, 2016	Mar	NEWA
<u>RISEDRONATE SODIUM</u>							
TABLET;ORAL							
ACTONEL							
AB	APIL	5MG	N020835	002	Apr 14, 2000	Jan	CAHN
AB		30MG	N020835	001	Mar 27, 1998	Jan	CAHN
AB	+	35MG	N020835	003	May 25, 2002	Jan	CAHN
	@	75MG	N020835	004	Apr 16, 2007	Jan	CAHN
AB	+	150MG	N020835	005	Apr 22, 2008	Jan	CAHN
TABLET, DELAYED RELEASE;ORAL							
ATELVIA							
AB	+	APIL 35MG	N022560	001	Oct 08, 2010	Jan	CAHN
<u>RISPERIDONE</u>							
SOLUTION;ORAL							
RISPERIDONE							
	@ WOCKHARDT	1MG/ML	A078744	001	Oct 08, 2009	Apr	DISC
<u>RIVASTIGMINE</u>							
FILM, EXTENDED RELEASE;TRANSDERMAL							
RIVASTIGMINE							
AB	ALVOGEN MALTA	4.6MG/24HR	A204403	001	Sep 03, 2015	Jan	CAHN
AB		9.5MG/24HR	A204403	002	Sep 03, 2015	Jan	CAHN
AB		13.3MG/24HR	A204403	003	Aug 31, 2015	Jan	CAHN

RIVASTIGMINE TARTRATECAPSULE; ORAL
EXELON

AB	+	NOVARTIS	EQ 6MG BASE	N020823	006	Apr 21, 2000	Jan CRLD
		RIVASTIGMINE TARTRATE					
AB		AUROBINDO PHARMA LTD	EQ 1.5MG BASE	A204572	001	Mar 25, 2016	Mar NEWA
AB			EQ 3MG BASE	A204572	002	Mar 25, 2016	Mar NEWA
AB			EQ 4.5MG BASE	A204572	003	Mar 25, 2016	Mar NEWA
AB			EQ 6MG BASE	A204572	004	Mar 25, 2016	Mar NEWA

RIZATRIPTAN BENZOATE

TABLET; ORAL

RIZATRIPTAN BENZOATE

AB		ALKEM LABS LTD	EQ 5MG BASE	A203269	001	Feb 18, 2016	Feb NEWA
AB			EQ 10MG BASE	A203269	002	Feb 18, 2016	Feb NEWA
AB		NOSTRUM LABS INC	EQ 5MG BASE	A202047	001	Dec 31, 2012	Jan CAHN
AB			EQ 10MG BASE	A202047	002	Dec 31, 2012	Jan CAHN

ROPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ROPIVACAINE HYDROCHLORIDE

AP		AKORN INC	5MG/ML	A203955	001	Apr 11, 2016	Mar NEWA
		SOLUTION; INJECTION					
		NAROPIN					

>A>		@ FRESenius KABI USA	50MG/10ML (5MG/ML)	N020533	013	May 01, 1998	May DISC
>A>			50MG/10ML (5MG/ML)	N020533	013	May 01, 1998	May NEWA
>D>	AP		20MG/10ML (2MG/ML)	N020533	001	Sep 24, 1996	May CMS1
>A>	AP		20MG/10ML (2MG/ML)	N020533	001	May 01, 1998	May CMS1
	AP		20MG/10ML (2MG/ML)	N020533	001	Sep 24, 1996	Mar CDFR
	AP		40MG/20ML (2MG/ML)	N020533	002	Sep 24, 1996	Mar NEWA
		@	75MG/10ML (7.5MG/ML)	N020533	012	Sep 24, 1996	Apr DISC
			75MG/10ML (7.5MG/ML)	N020533	012	Sep 24, 1996	Apr NEWA
>D>			100MG/20ML (5MG/ML)	N020533	003	Sep 24, 1996	May CMS1
>A>			100MG/20ML (5MG/ML)	N020533	003	May 01, 1998	May CMS1
			100MG/20ML (5MG/ML)	N020533	003	Sep 24, 1996	Mar CDFR
	AP		100MG/10ML (10MG/ML)	N020533	005	Sep 24, 1996	Mar NEWA
	AP		150MG/20ML (7.5MG/ML)	N020533	004	Sep 24, 1996	Mar CDFR
	AP		150MG/30ML (5MG/ML)	N020533	008	Sep 24, 1996	Mar NEWA
			200MG/100ML (2MG/ML)	N020533	006	Sep 24, 1996	Mar NEWA
	AP	+	200MG/20ML (10MG/ML)	N020533	011	Sep 24, 1996	Mar NEWA
			400MG/200ML (2MG/ML)	N020533	007	Sep 24, 1996	Mar NEWA
			500MG/100ML (5MG/ML)	N020533	009	Jan 04, 2011	Apr CMS1
			500MG/100ML (5MG/ML)	N020533	009	Sep 24, 1996	Mar NEWA
			1GM/200ML (5MG/ML)	N020533	010	Jan 04, 2011	Apr CMS1
			1GM/200ML (5MG/ML)	N020533	010	Sep 24, 1996	Mar NEWA

ROPIVACAINE HYDROCHLORIDE

AP		HOSPIRA	20MG/10ML (2MG/ML)	A090194	001	Sep 23, 2014	Mar CDFR
AP			40MG/20ML (2MG/ML)	A090194	005	Sep 23, 2014	Mar NEWA
AP			100MG/10ML (10MG/ML)	A090194	004	Sep 23, 2014	Mar CDFR
AP			150MG/30ML (5MG/ML)	A090194	002	Sep 23, 2014	Mar CDFR
AP			150MG/20ML (7.5MG/ML)	A090194	003	Sep 23, 2014	Mar CDFR
AP			200MG/20ML (10MG/ML)	A090194	006	Sep 23, 2014	Mar NEWA
AP		NAVINTA LLC	150MG/30ML (5MG/ML)	A078601	002	Jul 17, 2014	Mar CDFR
AP			200MG/20ML (10MG/ML)	A078601	003	Jul 17, 2014	Mar CDFR
AP		SAGENT STRIDES	40MG/20ML (2MG/ML)	A090318	001	Sep 23, 2014	Mar CDFR
AP			150MG/30ML (5MG/ML)	A090318	002	Sep 23, 2014	Mar CDFR
AP			150MG/20ML (7.5MG/ML)	A090318	003	Sep 23, 2014	Mar CDFR
AP			200MG/20ML (10MG/ML)	A090318	004	Sep 23, 2014	Mar CDFR

ROSUVASTATIN CALCIUM

TABLET; ORAL

CRESTOR

AB		IPR	5MG	N021366	002	Aug 12, 2003	Apr CFTG
AB			10MG	N021366	003	Aug 12, 2003	Apr CFTG
AB			20MG	N021366	004	Aug 12, 2003	Apr CFTG
AB	+		40MG	N021366	005	Aug 12, 2003	Apr CFTG
		ROSUVASTATIN CALCIUM					
AB		WATSON LABS INC	5MG	A079167	001	Apr 29, 2016	Apr NEWA
AB			10MG	A079167	002	Apr 29, 2016	Apr NEWA
AB			20MG	A079167	003	Apr 29, 2016	Apr NEWA
AB			40MG	A079167	004	Apr 29, 2016	Apr NEWA

RUFINAMIDETABLET; ORAL
BANZEL

>D>	EISAI INC	200MG	N021911	002	Nov 14, 2008	May CFTG
>A> AB		200MG	N021911	002	Nov 14, 2008	May CFTG
>D>	+	400MG	N021911	003	Nov 14, 2008	May CFTG
>A> AB	+	400MG	N021911	003	Nov 14, 2008	May CFTG
>A>	RUFINAMIDE					
>A> AB	GLENMARK PHARMS LTD	200MG	A205075	001	May 16, 2016	May NEWA
>A> AB		400MG	A205075	002	May 16, 2016	May NEWA
>A> AB	MYLAN PHARMS INC	200MG	A205095	001	May 16, 2016	May NEWA
>A> AB		400MG	A205095	002	May 16, 2016	May NEWA
>A> AB	ROXANE	200MG	A204988	001	May 16, 2016	May NEWA
>A> AB		400MG	A204988	002	May 16, 2016	May NEWA

SCOPOLAMINEFILM, EXTENDED RELEASE; TRANSDERMAL
TRANSDERM SCOP

>A> AB	+	GLAXOSMITHKLINE CON	1MG/72HR	N017874	001	May CAHN
>D> AB	+	NOVARTIS	1MG/72HR	N017874	001	May CAHN

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

@ SUN PHARM INDS EQ 25MG BASE
 @ EQ 50MG BASE
 @ EQ 100MG BASE

A077818 001 Feb 06, 2007 Mar CAHN
 A077818 002 Feb 06, 2007 Mar CAHN
 A077818 003 Feb 06, 2007 Mar CAHN

SILDENAFIL CITRATE

TABLET; ORAL

SILDENAFIL CITRATE

@ ACTAVIS GRP PTC EQ 20MG BASE
 @ TEVA EQ 25MG BASE
 EQ 25MG BASE
 @ EQ 50MG BASE
 EQ 50MG BASE
 @ EQ 100MG BASE
 EQ 100MG BASE

A200149 001 Feb 25, 2013 Apr DISC
 A077342 001 Mar 09, 2016 Feb DISC
 A077342 001 Mar 09, 2016 Feb NEWA
 A077342 002 Mar 09, 2016 Feb DISC
 A077342 002 Mar 09, 2016 Feb NEWA
 A077342 003 Mar 09, 2016 Feb DISC
 A077342 003 Mar 09, 2016 Feb NEWA

SILODOSINCAPSULE; ORAL
RAPAFLO

+	ALLERGAN SALES LLC	4MG	N022206	001	Oct 08, 2008	Apr CAHN
		8MG	N022206	002	Oct 08, 2008	Apr CAHN

SIMVASTATINSUSPENSION; ORAL
SIMVASTATIN

	ROSEMONT PHARMS LTD	20MG/5ML	N206679	001	Apr 21, 2016	Apr NEWA
+		40MG/5ML	N206679	002	Apr 21, 2016	Apr NEWA

TABLET; ORAL

SIMVASTATIN

@ SUN PHARM INDS LTD 5MG
 @ 10MG
 @ 20MG
 @ 40MG
 @ 80MG

A076285 001 Dec 20, 2006 Feb DISC
 A076285 002 Dec 20, 2006 Feb DISC
 A076285 003 Dec 20, 2006 Feb DISC
 A076285 004 Dec 20, 2006 Feb DISC
 A076285 005 Jun 23, 2006 Feb DISC

SODIUM BENZOATE; SODIUM PHENYLACETATESOLUTION; IV (INFUSION)
AMMONUL

AP	+	MEDICIS	10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005	Feb CFTG
		SODIUM PHENYLACETATE AND SODIUM BENZOATE					
AP		AILEX PHARMS PVT LTD	10%;10% (5GM/50ML;5GM/50ML)	A207096	001	Feb 24, 2016	Feb NEWA

SODIUM BICARBONATEINJECTABLE; INJECTION
SODIUM BICARBONATE

HOSPIRA INC 0.5MEQ/ML

A202981 001 Mar 04, 2016 Feb NEWA

SODIUM CHLORIDE

INJECTABLE; INJECTION
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 >A> AP JUBILANT HOLLISTRSTR 9MG/ML

A203352 001 May 18, 2016 May NEWA

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS
 SODIUM FLUORIDE F-18

>A> AP KREITCHMAN PET CTR 10-200mCi/ML
 AP ZEVACOR PHARMA INC 10-200mCi/ML

A203936 001 May 19, 2016 May NEWA
 A203592 001 Aug 18, 2015 Feb CAHN

SODIUM IODIDE I-131

CAPSULE; ORAL

SODIUM IODIDE I 131

JUBILANT DRAXIMAGE 0.009-0.1mCi
 @ 2-200mCi

N021305 006 May 19, 2005 Mar CMS1
 N021305 004 Nov 18, 2004 Mar CMS1

SODIUM PHENYLBUTYRATE

POWDER; ORAL

BUPHENYL

AB + HORIZON PHARMA INC 3GM/TEASPOONFUL

N020573 001 Apr 30, 1996 Mar CAHN

TABLET; ORAL

BUPHENYL

AB + HORIZON PHARMA USA 500MG
 SODIUM PHENYLBUTYRATE

N020572 001 May 13, 1996 Mar CAHN

AB PAR PHARM 500MG

A204395 001 Apr 15, 2016 Apr NEWA

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA BELCHER PHARMS LLC 454GM/BOT
 AA INVATECH PHARMA 454GM/BOT

A205727 001 Feb 23, 2016 Feb NEWA
 A206815 001 Feb 18, 2016 Feb NEWA

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HYDROCHLORIDE

@ IMPAX PHARMS 80MG
 @ 120MG
 @ 160MG
 @ 240MG
 @ SUN PHARM INDS 80MG
 @ 80MG
 @ 120MG
 @ 120MG
 @ 160MG
 @ 160MG
 @ 240MG

A075663 001 Nov 07, 2000 Mar DISC
 A075663 002 Nov 07, 2000 Mar DISC
 A075663 003 Nov 07, 2000 Mar DISC
 A075663 004 Nov 07, 2000 Mar DISC
 A075515 001 Oct 15, 2001 Mar CAHN
 A076576 001 Apr 08, 2004 Mar CAHN
 A075515 004 Oct 15, 2001 Mar CAHN
 A076576 002 Apr 08, 2004 Mar CAHN
 A075515 002 Oct 15, 2001 Mar CAHN
 A076576 003 Apr 08, 2004 Mar CAHN
 A075515 003 Oct 15, 2001 Mar CAHN

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

AB SUN PHARM INDS 25MG
 AB 50MG
 AB 100MG

A089424 001 Jul 23, 1986 Mar CAHN
 A089424 002 Aug 11, 1999 Mar CAHN
 A089424 003 Aug 11, 1999 Mar CAHN

SUCRALFATE

TABLET; ORAL

SUCRALFATE

AB MYLAN IRELAND LTD 1GM

A074415 001 Jun 08, 1998 Jan CAHN

SUGAMMADEX SODIUM

SOLUTION; INTRAVENOUS

BRIDION

ORGANON SUB MERCK EQ 200MG BASE/2ML (EQ 100MG
 BASE/ML)

N022225 002 Dec 15, 2015 Jan CPOT

+ EQ 500MG BASE/5ML (EQ 100MG
 BASE/ML)

N022225 001 Dec 15, 2015 Jan CPOT

SULFAMETHOXAZOLE

TABLET; ORAL

SULFAMETHOXAZOLE

@ AUROLIFE PHARMA LLC 500MG

A085844 001

Feb CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

BACTRIM

AB SUN PHARM INDS 400MG; 80MG

N017377 001

Mar CAHN

BACTRIM DS

AB + SUN PHARM INDS 800MG; 160MG

N017377 002

Mar CAHN

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB SUN PHARM INDS 800MG; 160MG

A071017 001 Aug 25, 1986

Mar CAHN

SULFASALAZINE

TABLET; ORAL

SULFASALAZINE

@ SUN PHARM INDS 500MG

A089590 001 Oct 19, 1987

Mar CAHN

SULFISOXAZOLE

TABLET; ORAL

SULFISOXAZOLE

@ AUROLIFE PHARMA LLC 500MG

A085628 001

Feb CAHN

SULINDAC

TABLET; ORAL

SULINDAC

AB SUN PHARM INDS 150MG

A072050 001 Apr 17, 1991

Mar CAHN

AB 200MG

A072051 001 Apr 17, 1991

Mar CAHN

SUMATRIPTAN

SPRAY; NASAL

IMITREX

AB + GLAXOSMITHKLINE 5MG/SPRAY

N020626 001 Aug 26, 1997

Feb CFTG

AB + 20MG/SPRAY

N020626 003 Aug 26, 1997

Feb CFTG

SUMATRIPTAN

AB LANNETT 5MG/SPRAY

A204841 001 Feb 19, 2016

Feb NEWA

AB 20MG/SPRAY

A204841 002 Feb 19, 2016

Feb NEWA

SUMATRIPTAN SUCCINATE

POWDER; INHALATION

ONZETRA XSAIL

+ AVANIR PHARMS EQ 11MG BASE

N206099 001 Jan 27, 2016

Jan NEWA

SOLUTION; SUBCUTANEOUS

ZEMBRACE SYMTOUCH

DR REDDYS LABS LTD EQ 3MG BASE/0.5ML (EQ 3MG
BASE/0.5ML)

N208223 001 Jan 28, 2016

Jan NEWA

TAMOXIFEN CITRATE

SOLUTION; ORAL

SOLTAMOX

MIDATECH PHARMA US EQ 10MG BASE/5ML

N021807 001 Oct 29, 2005

Jan CAHN

TABLET; ORAL

TAMOXIFEN CITRATE

@ ACTAVIS LABS FL INC EQ 10MG BASE

A076179 001 Feb 20, 2003

Jan DISC

@ EQ 20MG BASE

A076179 002 Feb 20, 2003

Jan DISC

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INTRAVENOUS

ULTRA-TECHNEKOW FM

+ MALLINKRODT NUCLEAR 1-19 CI/GENERATOR
@ 0.25-3 CI/GENERATOR

N017243 003 Feb 18, 2014

Jan CAHN

N017243 002

Jan CAHN

TEGASEROD MALEATE

TABLET; ORAL

ZELNORM

@ US WORLDMEDS LLC EQ 2MG BASE

N021200 001 Jul 24, 2002

Jan CAHN

@ EQ 6MG BASE

N021200 002 Jul 24, 2002

Jan CAHN

TELITHROMYCIN

TABLET; ORAL

KETEK

@ SANOFI AVENTIS US

300MG

N021144 002 Feb 09, 2005 Mar DISC

@

400MG

N021144 001 Apr 01, 2004 Mar DISC

TELMISARTAN

TABLET; ORAL

TELMISARTAN

AB HETERO LABS LTD V

20MG

A205901 001 Apr 22, 2016 Apr NEWA

AB

40MG

A205901 002 Apr 22, 2016 Apr NEWA

AB

80MG

A205901 003 Apr 22, 2016 Apr NEWA

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

>A> AB AMNEAL PHARMS

7.5MG

A203482 001 May 23, 2016 May NEWA

>A> AB

15MG

A203482 002 May 23, 2016 May NEWA

>A> AB

22.5MG

A203482 003 May 23, 2016 May NEWA

>A> AB

30MG

A203482 004 May 23, 2016 May NEWA

AB SUN PHARM INDS

7.5MG

A078581 001 Sep 08, 2009 Mar CAHN

@

15MG

A071174 001 Jul 10, 1986 Mar CAHN

AB

22.5MG

A071175 002 Sep 14, 2009 Mar CAHN

@

30MG

A071175 001 Jul 10, 1986 Mar CAHN

TEMOZOLOMIDE

CAPSULE; ORAL

TEMOZOLOMIDE

AB IDT AUSTRALIA LTD

5MG

A206413 001 Apr 12, 2016 Mar NEWA

AB

20MG

A206413 002 Apr 12, 2016 Mar NEWA

AB

100MG

A206413 003 Apr 12, 2016 Mar NEWA

AB

140MG

A206413 004 Apr 12, 2016 Mar NEWA

AB

180MG

A206413 005 Apr 12, 2016 Mar NEWA

AB

250MG

A206413 006 Apr 12, 2016 Mar NEWA

AB KREMERS URBAN PHARMS

5MG

A203898 001 Feb 10, 2016 Jan NEWA

AB

20MG

A203898 002 Feb 10, 2016 Jan NEWA

AB

100MG

A203898 003 Feb 10, 2016 Jan NEWA

AB

140MG

A203898 004 Feb 10, 2016 Jan NEWA

AB

180MG

A203898 005 Feb 10, 2016 Jan NEWA

AB

250MG

A203898 006 Feb 10, 2016 Jan NEWA

AB LOTUS PHARM CO LTD

5MG

A206309 001 Apr 27, 2016 Apr NEWA

AB

20MG

A206309 002 Apr 27, 2016 Apr NEWA

AB

100MG

A206309 003 Apr 27, 2016 Apr NEWA

AB

140MG

A206309 004 Apr 27, 2016 Apr NEWA

AB

180MG

A206309 005 Apr 27, 2016 Apr NEWA

AB

250MG

A206309 006 Apr 27, 2016 Apr NEWA

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

AP + EUROHLTH INTL SARL

1MG/ML

A076770 001 Apr 23, 2004 Apr CAHN

TABLET; ORAL

TERBUTALINE SULFATE

@ IMPAX LABS

2.5MG

A075877 001 Jun 26, 2001 Mar DISC

@

5MG

A075877 002 Jun 26, 2001 Mar DISC

LANNETT

2.5MG

A077152 001 Mar 25, 2005 Mar CTEC

5MG

A077152 002 Mar 25, 2005 Mar CTEC

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL

ANDRODERM

+ ALLERGAN SALES LLC

2MG/24HR

N020489 003 Oct 20, 2011 Mar CAHN

@

2.5MG/24HR

N020489 001 Sep 29, 1995 Mar CAHN

+

4MG/24HR

N020489 004 Oct 20, 2011 Mar CAHN

@

5MG/24HR

N020489 002 May 02, 1997 Mar CAHN

PELLET; IMPLANTATION

TESTOPEL

+ AUXILIUM PHARMS INC

75MG

A080911 001 Mar CAHN

TABLET, EXTENDED RELEASE; BUCCAL

STRIANT

+ AUXILIUM PHARMS INC

30MG

N021543 001 Jun 19, 2003 Mar CAHN

TETRABENAZINE

TABLET; ORAL

TETRABENAZINE

AB	HETERO LABS LTD V	12.5MG	A204574	001	Feb 03, 2016	Jan NEWA
AB		25MG	A204574	002	Feb 03, 2016	Jan NEWA

TETRACAINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC

TETRACAINE HYDROCHLORIDE

+	ALCON RES LTD	0.5%	N208135	001	Feb 29, 2016	Feb NEWA
---	---------------	------	---------	-----	--------------	----------

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

TETRACYCLINE HYDROCHLORIDE

AB	CHARTWELL CIENCA	250MG	A062752	001	Aug 12, 1988	Apr CMFD
AB		500MG	A062752	002	Aug 12, 1988	Apr CMFD
	@ SUN PHARM INDS	250MG	A060736	001		Mar CAHN
	@	500MG	A060736	002		Mar CAHN

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEO-24

AUXILIUM PHARMS INC

200MG

A087943 001 Aug 22, 1983 Mar CAHN

300MG

A087944 001 Aug 22, 1983 Mar CAHN

+ 400MG

A081034 001 Feb 28, 1992 Mar CAHN

SOLUTION, ELIXIR; ORAL

ELIXOPHYLLIN

+ NOSTRUM LABS INC

80MG/15ML

A085186 001

Jan CAHN

TABLET, EXTENDED RELEASE; ORAL

THEOCHRON

AB NOSTRUM LABS INC

100MG

A088320 001 Feb 21, 1985 Jan CAHN

AB

200MG

A088321 001 Feb 21, 1985 Jan CAHN

@

300MG

A087400 002 Jan 11, 1983 Jan CAHN

THEOPHYLLINE

AB MYLAN IRELAND LTD

400MG

A040560 003 Apr 21, 2006 Jan CAHN

AB +

600MG

A040560 002 Apr 21, 2006 Jan CAHN

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

AB SUN PHARM INDS

10MG

A089953 004 Aug 01, 1986 Mar CAHN

@

15MG

A088461 001 Nov 18, 1983 Mar CAHN

AB

25MG

A089953 003 Aug 01, 1986 Mar CAHN

AB

50MG

A089953 002 Aug 01, 1986 Mar CAHN

AB

100MG

A089953 001 Oct 07, 1988 Mar CAHN

@

150MG

A088737 001 Sep 26, 1984 Mar CAHN

@

200MG

A088738 001 Oct 16, 1984 Mar CAHN

THIOTHIXENE

CAPSULE; ORAL

THIOTHIXENE

@ SANDOZ

1MG

A071610 001 Jun 24, 1987 Mar DISC

@

2MG

A071570 001 Jun 24, 1987 Mar DISC

@

5MG

A071529 001 Jun 24, 1987 Mar DISC

@

10MG

A071530 001 Jun 24, 1987 Mar DISC

TINIDAZOLE

TABLET; ORAL

TINIDAZOLE

BX UNIQUE PHARM LABS

250MG

A202489 001 Oct 09, 2013 Apr CTEC

BX

500MG

A202489 002 Oct 09, 2013 Apr CTEC

TOFACITINIB CITRATE

TABLET, EXTENDED RELEASE; ORAL

XELJANZ XR

+ PFIZER INC

EQ 11MG BASE

N208246 001 Feb 23, 2016 Feb NEWA

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

@ SUN PHARM INDS	100MG	A071357	001	Jul 16, 1987	Mar CAHN
@	250MG	A071358	001	Jul 16, 1987	Mar CAHN
@	500MG	A071359	001	Jul 16, 1987	Mar CAHN

TOLMETIN SODIUM

CAPSULE; ORAL

TOLMETIN SODIUM

@ SUN PHARM INDS	EQ 400MG BASE	A073311	001	Nov 27, 1991	Mar CAHN
------------------	---------------	---------	-----	--------------	----------

TABLET; ORAL

TOLMETIN SODIUM

AB	SUN PHARM INDS	EQ 200MG BASE	A073310	001	Nov 27, 1991	Mar CAHN
----	----------------	---------------	---------	-----	--------------	----------

TOPIRAMATE

TABLET; ORAL

TOPIRAMATE

AB	@ ACTAVIS TOTOWA	25MG	A078637	001	Feb 27, 2013	Apr DISC
		25MG	A078637	001	Feb 27, 2013	Jan CAHN
	@	50MG	A078637	002	Feb 27, 2013	Apr DISC
AB		50MG	A078637	002	Feb 27, 2013	Jan CAHN
	@	100MG	A078637	003	Feb 27, 2013	Apr DISC
AB		100MG	A078637	003	Feb 27, 2013	Jan CAHN
	@	200MG	A078637	004	Feb 27, 2013	Apr DISC
AB		200MG	A078637	004	Feb 27, 2013	Jan CAHN

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

AB	ACI HEALTHCARE LTD	50MG	A202075	001	Nov 28, 2011	Mar CAHN
AB	SUN PHARM INDS	50MG	A076100	001	Jun 20, 2002	Mar CAHN

TABLET, EXTENDED RELEASE; ORAL

ULTRAM ER

AB1	+ VALEANT PHARMS	100MG	N021692	001	Sep 08, 2005	Mar CAHN
AB1		200MG	N021692	002	Sep 08, 2005	Mar CAHN
AB1		300MG	N021692	003	Sep 08, 2005	Mar CAHN

TRANEXAMIC ACID

INJECTABLE; INJECTION

TRANEXAMIC ACID

>A>	AP	AKORN	100MG/ML	A206634	001	Jun 09, 2016	May NEWA
	AP	AUROBINDO PHARMA LTD	100MG/ML	A205035	001	Jan 14, 2016	Jan NEWA
	AP	NORTH CREEK PHARMS	100MG/ML	A202755	001	Feb 25, 2016	Feb NEWA

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

	@ AUROLIFE PHARMA LLC	50MG	A072484	001	Apr 30, 1990	Feb CAHN
AB	SUN PHARM INDS	50MG	A073137	002	Mar 24, 1993	Mar CAHN
AB		100MG	A073137	001	Mar 24, 1993	Mar CAHN
AB		150MG	A073137	003	Dec 22, 1995	Mar CAHN

TRETINOIN

CREAM; TOPICAL

TRETINOIN

AB	ELAN PHARMA INTL LTD	0.025%	A075264	001	Dec 24, 1998	Feb CAHN
AB1		0.05%	A075265	001	Dec 24, 1998	Feb CAHN
AB		0.1%	A075213	001	Dec 24, 1998	Feb CAHN

GEL; TOPICAL

TRETINOIN

AB	ELAN PHARMA INTL LTD	0.01%	A075589	001	Jun 11, 2002	Feb CAHN
AB		0.025%	A075529	001	Feb 22, 2000	Feb CAHN

TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

>A>	AT	TELIGENT PHARMA INC	0.1%	A205373	001	May 13, 2016	May NEWA
-----	----	---------------------	------	---------	-----	--------------	----------

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE;ORAL						
TRIMETHOBENZAMIDE HYDROCHLORIDE						
AB	SUN PHARM INDS	300MG	A076570	001	Aug 28, 2003	Mar CAHN

TRIMETHOPRIM

TABLET;ORAL						
TRIMETHOPRIM						
	@ SUN PHARM INDS	200MG	A070495	001	Sep 24, 1986	Mar CAHN

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION;ORAL						
PRIMSOL						
	@ AYU PHARMS	EQ 25MG BASE/5ML	A074374	001	Jun 23, 1995	Jan CAHN
+		EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000	Jan CAHN

TRIMIPRAMINE MALEATE

CAPSULE;ORAL						
TRIMIPRAMINE MALEATE						
AB	CROSSMEDIKA SA	EQ 25MG BASE	A208127	001	Apr 15, 2016	Apr NEWA
AB		EQ 50MG BASE	A208127	002	Apr 15, 2016	Apr NEWA
AB		EQ 100MG BASE	A208127	003	Apr 15, 2016	Apr NEWA

TRIPTORELIN PAMOATE

INJECTABLE;INTRAMUSCULAR						
TRELSTAR						
+	ALLERGAN SALES LLC	EQ 3.75MG BASE/VIAL	N020715	001	Jun 15, 2000	Apr CAHN
+		EQ 11.25MG BASE/VIAL	N021288	001	Jun 29, 2001	Apr CAHN
+		EQ 22.5MG BASE/VIAL	N022437	001	Mar 10, 2010	Apr CAHN

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL						
TROSPIUM CHLORIDE						
	@ SANDOZ INC	60MG	A091635	001	Apr 29, 2015	Apr DISC

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS;OPHTHALMIC						
RESCULA						
	@ R-TECH UENO LTD	0.15%	N021214	001	Aug 03, 2000	Mar DISC
	@ SUCAMPO PHARMA LLC	0.15%	N021214	001	Aug 03, 2000	Mar CAHN

URSODIOL

CAPSULE;ORAL						
ACTIGALL						
	@ ALLERGAN SALES LLC	150MG	N019594	001	Dec 31, 1987	Mar CAHN
AB	+	300MG	N019594	002	Dec 31, 1987	Mar CAHN

VALGANCICLOVIR HYDROCHLORIDE

TABLET;ORAL						
VALGANCICLOVIR HYDROCHLORIDE						
AB	AUROBINDO PHARMA LTD	EQ 450MG BASE	A204750	001	Mar 31, 2016	Mar NEWA
AB	HETERO LABS LTD V	EQ 450MG BASE	A205166	001	Mar 18, 2016	Mar NEWA

VALPROATE SODIUM

INJECTABLE;INJECTION						
VALPROATE SODIUM						
AP	EUROHLTH INTL SARL	EQ 100MG BASE/ML	A076295	001	Nov 14, 2002	Apr CAHN

VALPROIC ACID

CAPSULE;ORAL						
VALPROIC ACID						
AB	BIONPHARMA INC	250MG	A073484	001	Jun 29, 1993	Jan CAHN
SYRUP;ORAL						
VALPROIC ACID						
AA	NOSTRUM LABS INC	250MG/5ML	A090517	001	May 28, 2010	Mar CAHN

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION
VANCOMYCIN HYDROCHLORIDE

>A>	AP	AMNEAL PHARMS CO	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	May CAHN
>A>	AP		EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	May CAHN
	AP	AUROBINDO PHARMA LTD	EQ 500MG BASE/VIAL	A205780	001	Mar 31, 2016	Mar NEWA
	AP		EQ 1GM BASE/VIAL	A205780	002	Mar 31, 2016	Mar NEWA
	AP		EQ 5GM BASE/VIAL	A205779	001	Mar 29, 2016	Mar NEWA
	AP		EQ 10GM BASE/VIAL	A205779	002	Mar 29, 2016	Mar NEWA
	AP	GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A205694	001	Jan 21, 2016	Jan NEWA
	AP		EQ 1GM BASE/VIAL	A205694	002	Jan 21, 2016	Jan NEWA
>D>	AP	MUSTAFA NEVZAT ILAC	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	May CAHN
>D>	AP		EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	May CAHN

VECURONIUM BROMIDE

INJECTABLE; INJECTION
VECURONIUM BROMIDE

	AP	EUROHLTH INTL SARL	10MG/VIAL	A075549	001	Jun 13, 2000	Apr CAHN
	AP		20MG/VIAL	A075549	002	Jun 13, 2000	Apr CAHN
>A>	AP	GLAND PHARMA LTD	10MG/VIAL	A205390	001	May 26, 2016	May NEWA
>A>	AP		20MG/VIAL	A205390	002	May 26, 2016	May NEWA
	AP	SAGENT PHARMS	10MG/VIAL	A078274	001	Dec 29, 2008	Jan CAHN
	AP		20MG/VIAL	A078274	002	Dec 29, 2008	Jan CAHN

VENETOCLAX

TABLET; ORAL
VENCLEXTA

ABBVIE INC 10MG
50MG
+ 100MG

N208573 001 Apr 11, 2016 Apr NEWA
N208573 002 Apr 11, 2016 Apr NEWA
N208573 003 Apr 11, 2016 Apr NEWA

VERAPAMIL HYDROCHLORIDE

SOLUTION; INTRAVENOUS
VERAPAMIL HYDROCHLORIDE

AP	EXELA PHARMA SCS LLC	5MG/2ML (2.5MG/ML)	N018925	001	Mar 30, 1984	Apr CMFD
	TABLET, EXTENDED RELEASE; ORAL					
	CALAN SR					
	@ PFIZER	180MG	N019152	002	Dec 15, 1989	Feb DISC

VINORELBINE TARTRATE

INJECTABLE; INJECTION
VINORELBINE TARTRATE

AP	EUROHLTH INTL SARL	EQ 10MG BASE/ML	A076461	001	Dec 11, 2003	Apr CAHN
----	--------------------	-----------------	---------	-----	--------------	----------

VORICONAZOLE

FOR SUSPENSION; ORAL
VORICONAZOLE

	AB	AMNEAL PHARMS	200MG/5ML	A205034	001	Apr 13, 2016	Mar NEWA
>A>	AB	NOVEL LABS INC	200MG/5ML	A206799	001	May 31, 2016	May NEWA
		INJECTABLE;IV (INFUSION)					
		VORICONAZOLE					
	AP	ALVOGEN INC	200MG/VIAL	A206398	001	Mar 23, 2016	Mar NEWA
		TABLET;ORAL					
		VORICONAZOLE					
>A>	AB	AJANTA PHARMA LTD	50MG	A206181	001	May 24, 2016	May NEWA
>A>	AB		200MG	A206181	002	May 24, 2016	May NEWA
>A>	AB	APPCO PHARMA LLC	50MG	A206762	001	May 24, 2016	May NEWA
>A>	AB		200MG	A206762	002	May 24, 2016	May NEWA
	AB	AUROBINDO PHARMA LTD	50MG	A206837	001	Jan 22, 2016	Jan NEWA
	AB		200MG	A206837	002	Jan 22, 2016	Jan NEWA
>A>	AB	NOVEL LABS INC	50MG	A207371	001	May 24, 2016	May NEWA
>A>	AB		200MG	A207371	002	May 24, 2016	May NEWA
>A>	AB	ZYDUS PHARMS USA INC	50MG	A206747	001	May 24, 2016	May NEWA
>A>	AB		200MG	A206747	002	May 24, 2016	May NEWA

XENON XE-133

GAS; INHALATION
XENON XE 133

LANTHEUS MEDCL 20mCi/VIAL
MALLINKRODT NUCLEAR 10mCi/VIAL
20mCi/VIAL

N017284 002
N018327 001 Mar 09, 1982 Feb CTFC
N018327 002 Mar 09, 1982 Feb CMFD

ZOLMITRIPTAN

TABLET; ORAL

ZOLMITRIPTAN

>A>	AB	AJANTA PHARMA LTD	2.5MG	A204041	001	May 20, 2016	May NEWA
>A>	AB		5MG	A204041	002	May 20, 2016	May NEWA
	AB	AUROBINDO PHARMA LTD	2.5MG	A207021	001	May 11, 2016	Apr NEWA
	AB		5MG	A207021	002	May 11, 2016	Apr NEWA

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

@	SUN PHARM INDS	5MG	A077288	001	Apr 23, 2007	Mar CAHN
@		10MG	A077288	002	Apr 23, 2007	Mar CAHN

ZONISAMIDE

CAPSULE; ORAL

ZONEGRAN

AB		SUNOVION PHARMS INC	25MG	N020789	003	Aug 22, 2003	Feb CAHN
AB			50MG	N020789	002	Aug 22, 2003	Feb CAHN
AB	+		100MG	N020789	001	Mar 27, 2000	Feb CAHN
		ZONISAMIDE					
AB		BIONPHARMA INC	25MG	A077813	001	Aug 16, 2006	Jan CAHN
AB			50MG	A077813	002	Aug 16, 2006	Jan CAHN
AB			100MG	A077813	003	Aug 16, 2006	Jan CAHN
	@	SUN PHARM INDS	25MG	A077635	001	Dec 22, 2005	Mar CAHN
	@		50MG	A077635	002	Dec 22, 2005	Mar CAHN
	@		100MG	A077635	003	Dec 22, 2005	Mar CAHN

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET; ORAL

EXCEDRIN (MIGRAINE)

+	GLAXOSMITHKLINE CONS	250MG; 250MG; 65MG	N020802	001	Jan 14, 1998	Feb CAHN
---	----------------------	--------------------	---------	-----	--------------	----------

BUDESONIDE

SPRAY, METERED; NASAL

BUDESONIDE

	APOTEX INC	0.032MG/SPRAY	A078949	002	Nov 20, 2015	Apr NEWA
--	------------	---------------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE

CAPSULE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

	BIONPHARMA INC	5MG	N022429	001	Jul 23, 2009	Jan CAHN
--	----------------	-----	---------	-----	--------------	----------

+		10MG	N022429	004	Jul 23, 2009	Jan CAHN
---	--	------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

	BIONPHARMA INC	5MG	N022429	003	Jul 23, 2009	Jan CAHN
--	----------------	-----	---------	-----	--------------	----------

+		10MG	N022429	002	Jul 23, 2009	Jan CAHN
---	--	------	---------	-----	--------------	----------

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

@	CYPRESS PHARM	5MG/5ML	A090300	001	Oct 10, 2008	Apr DISC
---	---------------	---------	---------	-----	--------------	----------

	NOSTRUM LABS INC	5MG/5ML	A091327	001	Oct 17, 2011	Mar CAHN
--	------------------	---------	---------	-----	--------------	----------

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@	CYPRESS PHARM	5MG/5ML	A090300	002	Oct 10, 2008	Apr DISC
---	---------------	---------	---------	-----	--------------	----------

	NOSTRUM LABS INC	5MG/5ML	A091327	002	Oct 17, 2011	Mar CAHN
--	------------------	---------	---------	-----	--------------	----------

TABLET, CHEWABLE; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

	NOVEL LABS INC	5MG	A206793	001	Mar 08, 2016	Feb NEWA
--	----------------	-----	---------	-----	--------------	----------

		10MG	A206793	002	Mar 08, 2016	Feb NEWA
--	--	------	---------	-----	--------------	----------

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

CHLORAPREP ONE-STEP

>A>	+	BECTON DICKINSON CO	2%; 70% (3ML)	N020832	001	Jul 14, 2000	May CAHN
-----	---	---------------------	---------------	---------	-----	--------------	----------

>A>	+		2%; 70% (10.5ML)	N020832	004	Aug 20, 2003	May CAHN
-----	---	--	------------------	---------	-----	--------------	----------

>A>	+		2%; 70% (26ML)	N020832	006	Nov 21, 2006	May CAHN
-----	---	--	----------------	---------	-----	--------------	----------

>D>	+	CAREFUSION	2%; 70% (3ML)	N020832	001	Jul 14, 2000	May CAHN
-----	---	------------	---------------	---------	-----	--------------	----------

>D>	+		2%; 70% (10.5ML)	N020832	004	Aug 20, 2003	May CAHN
-----	---	--	------------------	---------	-----	--------------	----------

>D>	+		2%; 70% (26ML)	N020832	006	Nov 21, 2006	May CAHN
-----	---	--	----------------	---------	-----	--------------	----------

CHLORAPREP ONE-STEP FREPP

>A>	+	BECTON DICKINSON CO	2%; 70% (1.5ML)	N020832	003	Apr 26, 2002	May CAHN
-----	---	---------------------	-----------------	---------	-----	--------------	----------

>D>	+	CAREFUSION	2%; 70% (1.5ML)	N020832	003	Apr 26, 2002	May CAHN
-----	---	------------	-----------------	---------	-----	--------------	----------

CHLORAPREP WITH TINT

>A>	+	BECTON DICKINSON CO	2%; 70% (26ML)	N020832	002	May 03, 2005	May CAHN
-----	---	---------------------	----------------	---------	-----	--------------	----------

>A>	+		2%; 70% (10.5ML)	N020832	005	Apr 03, 2006	May CAHN
-----	---	--	------------------	---------	-----	--------------	----------

>A>	+		2%; 70% (3ML)	N020832	007	Oct 10, 2006	May CAHN
-----	---	--	---------------	---------	-----	--------------	----------

>D>	+	CAREFUSION	2%; 70% (26ML)	N020832	002	May 03, 2005	May CAHN
-----	---	------------	----------------	---------	-----	--------------	----------

>D>	+		2%; 70% (10.5ML)	N020832	005	Apr 03, 2006	May CAHN
-----	---	--	------------------	---------	-----	--------------	----------

>D>	+		2%; 70% (3ML)	N020832	007	Oct 10, 2006	May CAHN
-----	---	--	---------------	---------	-----	--------------	----------

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

>A>	+	BECTON DICKINSON CO	2%; 70% (0.67ML)	N021555	001	Oct 07, 2002	May CAHN
-----	---	---------------------	------------------	---------	-----	--------------	----------

>D>	+	CAREFUSION	2%; 70% (0.67ML)	N021555	001	Oct 07, 2002	May CAHN
-----	---	------------	------------------	---------	-----	--------------	----------

CHLORAPREP SINGLE SWABSTICK

>A>	+	BECTON DICKINSON CO	2%; 70% (1.75ML)	N021555	002	May 10, 2005	May CAHN
-----	---	---------------------	------------------	---------	-----	--------------	----------

>D>	+	CAREFUSION	2%; 70% (1.75ML)	N021555	002	May 10, 2005	May CAHN
-----	---	------------	------------------	---------	-----	--------------	----------

CHLORAPREP TRIPLE SWABSTICK

>A>	+	BECTON DICKINSON CO	2%; 70% (5.25ML)	N021555	003	Jun 10, 2009	May CAHN
-----	---	---------------------	------------------	---------	-----	--------------	----------

>D>	+	CAREFUSION	2%; 70% (5.25ML)	N021555	003	Jun 10, 2009	May CAHN
-----	---	------------	------------------	---------	-----	--------------	----------

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE

@	AUROLIFE PHARMA LLC	12MG	A070797	001	Aug 12, 1988	Feb CAHN
---	---------------------	------	---------	-----	--------------	----------

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

BIONPHARMA INC

25MG;EQ 200MG FREE ACID AND
POTASSIUM SALT

A090397 001 Nov 22, 2010 Jan CAHN

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

AUROBINDO PHARMA LTD

10MG
20MG

A206531 001 Apr 26, 2016 Apr NEWA

A206531 002 Apr 26, 2016 Apr NEWA

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLUTICASONE PROPIONATE

APOTEX TECHNOLOGIES

0.05MG/SPRAY

A208150 001 Feb 29, 2016 Feb NEWA

>A>

ROXANE

0.05MG/SPRAY

A207957 001 May 26, 2016 May NEWA

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

BIONPHARMA INC

EQ 200MG FREE ACID AND POTASSIUM
SALT

A078682 001 Mar 24, 2009 Jan CAHN

MIDOL LIQUID GELS

+ BIONPHARMA INC

200MG

N021472 001 Oct 18, 2002 Jan CAHN

TABLET;ORAL

IBUPROFEN

STRIDES PHARMA

200MG

A079129 001 Mar 28, 2011 May CAHN

>A>

STRIDES PHARMA

200MG

A091355 001 Apr 04, 2011 May CAHN

>A>

@ SUN PHARM INDS

200MG

A070493 001 Dec 24, 1985 Mar CAHN

@

200MG

A070908 001 Sep 26, 1986 Mar CAHN

@

200MG

A071462 001 Oct 02, 1986 Mar CAHN

>D>

SVADS HOLDINGS SA

200MG

A079129 001 Mar 28, 2011 May CAHN

>D>

SVADS HOLDINGS SA

200MG

A091355 001 Apr 04, 2011 May CAHN

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

MYLAN PHARMS INC

15MG

A203187 001 Jun 01, 2016 May NEWA

>A>

LEVONORGESTREL

TABLET;ORAL

HER STYLE

NOVAST LABS LTD

1.5MG

A207976 001 Mar 11, 2016 Feb NEWA

LEVONORGESTREL

GLENMARK PHARMS LTD

1.5MG

A207044 001 Mar 25, 2016 Mar NEWA

+ PERRIGO R AND D

0.75MG

A090740 001 Dec 30, 2010 Apr CRLD

@ WATSON LABS

0.75MG

A078665 001 Aug 28, 2009 Apr DISC

PLAN B

@ TEVA BRANDED PHARM

0.75MG

N021045 002 Aug 24, 2006 Apr DISC

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

BIONPHARMA INC

1MG

N021855 001 Aug 04, 2005 Jan CAHN

+

2MG

N021855 002 Aug 04, 2005 Jan CAHN

MICONAZOLE NITRATE

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

MONISTAT 3 COMBINATION PACK

+ MEDTECH PRODUCTS

2%,200MG

N020670 002 Apr 16, 1996 Mar CMS1

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

+ BIONPHARMA INC

EQ 200MG BASE

N021920 001 Feb 17, 2006 Mar CAHN

TABLET;ORAL

NAPROXEN SODIUM

AUROBINDO PHARMA LTD

EQ 200MG BASE

A205497 001 Mar 18, 2016 Mar NEWA

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

ACTAVIS LABS NY INC EQ 2MG BASE
EQ 4MG BASEA204794 001 May 10, 2016 Apr NEWA
A204833 001 Feb 26, 2016 Feb NEWAOXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL FOR WOMEN

+ ALLERGAN SALES LLC 3.9MG/24HR

N202211 001 Jan 25, 2013 Jan CAHN

POTASSIUM IODIDE

SOLUTION;ORAL

POTASSIUM IODIDE

MISSION PHARMACAL CO 65MG/ML

A206211 001 Mar 24, 2016 Mar NEWA

TABLET;ORAL

THYRO-BLOCK

>A> @ MEDA PHARMS 130MG

N018307 001 May CAHN

>D> @ MEDPOINTE PHARM HLC 130MG

N018307 001 May CAHN

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

>D> SHASUN CHEMS EQ 75MG BASE

A201745 001 Feb 29, 2012 May CAHN

>A> STRIDES PHARMA EQ 75MG BASE

A201745 001 Feb 29, 2012 May CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 05 MAY 2016

NO MAY 2016 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MAY 2016 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEO</u>						
N 205551 001	9242986	Dec 08, 2029	DS DP			
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539 001 >A>	9327028	Jul 21, 2031	U-1839			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 001	8747894	May 08, 2032	DP U-1373			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 002	8747894	May 08, 2032	DP U-1373			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001 >A>	9333195	Jul 07, 2020	DP U-1263			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917 001	8809305	Dec 23, 2022	U-1078			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001 >A>	8426586	Oct 10, 2029	DS		>A> ODE	Apr 15, 2023
	>A> RE43431	Jan 22, 2022	DS			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002 >A>	8426586	Oct 10, 2029	DS		>A> ODE	Apr 15, 2023
	>A> RE43431	Jan 22, 2022	DS			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003 >A>	8426586	Oct 10, 2029	DS		I-730	Apr 15, 2019
	>A> RE43431	Jan 22, 2022	DS		>A> ODE	Apr 15, 2023
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	8978966	Jan 13, 2032	DP		NPP	Apr 28, 2019
	9216260	Jun 28, 2031	DP			
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434 001					ODE	Dec 11, 2022
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002					M-177	Apr 05, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006					M-177	Apr 05, 2019
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u>						
N 208081 001					>A> NP	May 10, 2019
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 001	8709491	Jun 28, 2032	DP			
	8840924	Jun 05, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 002	8709491	Jun 28, 2032	DP			
	8840924	Jun 05, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 003	8709491	Jun 28, 2032	DP			
	8840924	Jun 05, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 004	8709491	Jun 28, 2032	DP			
	8840924	Jun 05, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 005	8709491	Jun 28, 2032	DP			
	8840924	Jun 05, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 006	8709491	Jun 28, 2032	DP			
	8840924	Jun 05, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	>A> 9326945	Feb 24, 2031	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	>A> 9326945	Feb 24, 2031	DP			
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043 001					>A> PC	Nov 28, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043 002					>A> PC	Nov 28, 2016
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043 003					>A> PC	Nov 28, 2016
<u>ASPIRIN - ASPIRIN</u>						
N 203697 001	9216150	Sep 29, 2032	DP			
	9226892	Sep 29, 2032	U-1731			
	9226892	Sep 29, 2032	U-1732			
	9226892	Sep 29, 2032	U-1733			
<u>AVANAFIL - STENDRA</u>						
N 202276 001	6656935	Apr 27, 2025	DS DP U-155			
<u>AVANAFIL - STENDRA</u>						
N 202276 002	6656935	Apr 27, 2025	DS DP U-155			
<u>AVANAFIL - STENDRA</u>						
N 202276 003	6656935	Apr 27, 2025	DS DP U-155			
<u>AXITINIB - INLYTA</u>						
N 202324 001	6534524	Apr 29, 2025	DS DP			
<u>AXITINIB - INLYTA</u>						
N 202324 002	6534524	Apr 29, 2025	DS DP			
<u>AZELAIC ACID - FINACEA</u>						
N 207071 001	9265725	Dec 08, 2027	DP			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	9259428	Jun 13, 2023	U-644			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 001	9169238	Feb 04, 2030	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002	9169238	Feb 04, 2030	DP			
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N 022205 001	9192616	Aug 02, 2026	U-1229			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	9265831	Jan 28, 2031	DP			
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001					NDF	Feb 05, 2019
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	9241918	Mar 16, 2025	DP U-1814			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	9216183	Jan 15, 2023	U-1487			
	9226931	Jan 15, 2023	U-1799			
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021262 001	>A> 9295641	Jul 10, 2021	U-1833			
	>A> 9295641*PED	Jan 10, 2022				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	>A> 9295641	Jul 10, 2021	U-1833			
	>A> 9295641*PED	Jan 10, 2022				
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001	6784197	Feb 21, 2021	DS DP U-1815		>A> NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002	6784197	Feb 21, 2021	DS DP U-1815		>A> NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003	6784197	Feb 21, 2021	DS DP U-1815		>A> NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004	6784197	Feb 21, 2021	DS DP U-1815		>A> NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005	6784197	Feb 21, 2021	DS DP U-1815		>A> NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205837 001	6784197	Feb 21, 2021	DS DP U-1815		>A> NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001	6784197	Feb 21, 2021	DS DP U-1815		>A> NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BROMFENAC SODIUM - BROMSITE</u>						
N 206911 001	8778999	Sep 03, 2029	DP U-1834		NP	Apr 08, 2019
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	9192576	Apr 30, 2032	DP U-976			
<u>BUDESONIDE - ENTOCORT EC</u>						
N 021324 001					M-178 NPP	Apr 29, 2019 Apr 29, 2019
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	9320716	Jun 09, 2020	DP U-1325			
<u>BUPRENORPHINE HYDROCHLORIDE - PROBUPHINE</u>						
N 204442 001					>A> NP	May 26, 2019
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	9259421	Sep 18, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	9259421	Sep 18, 2032	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	9248123	Jan 13, 2032	U-1808			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	>A> 7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	>A> 8497284	Sep 24, 2024		U-1220	NP	Apr 25, 2019
	>A> 8877776	Oct 08, 2030	DS DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	>A> 7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	>A> 8497284	Sep 24, 2024		U-1220	NP	Apr 25, 2019
	>A> 8877776	Oct 08, 2030	DS DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	>A> 7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	>A> 8497284	Sep 24, 2024		U-1220	NP	Apr 25, 2019
	>A> 8877776	Oct 08, 2030	DS DP			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001					>A> I-733	May 20, 2019
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002					>A> I-733	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001					>A> I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002					>A> I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003					>A> I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004					>A> I-735	May 20, 2019
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	9295687	Jul 10, 2035	DP			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001					I-722	Jan 21, 2019
					I-723	Jan 21, 2019
<u>CEFIXIME - SUPRAX</u>						
N 202091 001	9233112	Dec 14, 2028	DP U-1676			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001					>A> NPP	May 27, 2019
					>A> NPP	May 27, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002					>A> NPP	May 27, 2019
					>A> NPP	May 27, 2019
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	>A> 9320740	Mar 14, 2034	DP			
<u>CERITINIB - ZYKADIA</u>						
N 205755 001	9309229	Jan 18, 2032	DS DP			
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 001					>A> NCE	Mar 17, 2020
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 002					>A> NCE	Mar 17, 2020
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986 001	9233068	Dec 11, 2029	DP		NP	Dec 10, 2018
<u>CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE - OTOVEL</u>						
N 208251 001	8932610	Mar 24, 2030	DP U-1578		NC	Apr 29, 2019
<u>CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX</u>						
N 021537 001	>A> 9345714	Sep 13, 2022	DP U-1578			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	7803788	Feb 02, 2022	U-257			
	9296769	Aug 15, 2032	DS DP U-257			
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001					ODE	Nov 10, 2022
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001					ODE	Mar 11, 2023
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002					ODE	Mar 11, 2023
<u>CYCLOSPORINE - RESTASIS</u>						
N 050790 001	9248191	Aug 27, 2024	U-1479			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	9233077	Jun 17, 2034	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	9233077	Jun 17, 2034	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	9233956	May 04, 2029	U-1811		M-170	Nov 20, 2018
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	9233956	May 04, 2029	U-1811		M-170	Nov 20, 2018
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 001					D-161	Feb 05, 2019
					D-162	Feb 05, 2019
					I-726	Feb 05, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843	001				I-727	Feb 05, 2019
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843	002				D-161	Feb 05, 2019
					D-162	Feb 05, 2019
					I-726	Feb 05, 2019
					I-727	Feb 05, 2019
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883	001				D-154	Jan 20, 2019
<u>DAPSONE - ACZONE</u>						
N 207154	001	5863560	Sep 11, 2016	DP	NS	Feb 24, 2019
		6060085	Sep 11, 2016	U-124		
		6620435	Sep 11, 2016	DP		
		9161926	Nov 18, 2033	DP		
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619	001	>A> 8492386	Sep 04, 2032	U-1840	D-163	Apr 22, 2019
		>A> 8685984	Sep 04, 2032	U-1840		
<u>DEFERASIROX - JADENU</u>						
N 206910	001	9283209	Nov 21, 2034	DS DP	ODE	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910	002	9283209	Nov 21, 2034	DS DP	ODE	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910	003	9283209	Nov 21, 2034	DS DP	ODE	Jan 23, 2020
<u>DEFIBROTIDE SODIUM - DEFITELIO</u>						
N 208114	001				NCE	Mar 30, 2021
					ODE	Mar 30, 2023
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315	001	9283178	Oct 20, 2020	U-1205		
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
N 050818	001	8450287	Dec 19, 2027	DP		
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287	001	9233103	Mar 05, 2032	U-1805		
		9238029	Jan 17, 2026	DP		
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287	002	9233103	Mar 05, 2032	U-1805		
		9238029	Jan 17, 2026	DP		
<u>DEXLANSOPRAZOLE - DEXILANT SOLUTAB</u>						
N 208056	001	6238994	May 17, 2019	DP		
		6238994*PED	Nov 17, 2019			
		6462058	Jun 15, 2020	DS DP	U-950	
		6462058	Jun 15, 2020	DS DP	U-951	
		6462058*PED	Dec 15, 2020			
		6664276	Jan 30, 2023	DS DP	U-950	
		6664276	Jan 30, 2023	DS DP	U-951	
		6664276*PED	Jul 30, 2023			
		6939971	Jun 15, 2020		U-950	
		6939971	Jun 15, 2020		U-951	
		6939971*PED	Dec 15, 2020			
		7285668	Jun 15, 2020	DS		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - DEXILANT SOLUTAB</u>						
N 208056 001	7285668*PED	Dec 15, 2020				
	7399485	May 26, 2018	DP			
	7399485*PED	Nov 26, 2018				
	7431942	May 17, 2019	DP			
	7431942*PED	Nov 17, 2019				
	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8784885	Oct 15, 2023	DP			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	8871273*PED	Jul 11, 2028				
	9011926	Feb 24, 2026	DP			
	9145389	Jun 15, 2020	DS DP			
	9238029	Jan 17, 2026	DP			
	9241910	Mar 10, 2029	DP			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	9220784	Oct 17, 2027	U-1488			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 001	9308195	Sep 30, 2033	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 002	9308195	Sep 30, 2033	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 003	9308195	Sep 30, 2033	DP			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 001	9242986	Dec 08, 2029	DS DP			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	8513299	Sep 07, 2030	U-620			
	9107898	May 01, 2028	U-620			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	8513299	Sep 07, 2030	U-620			
	9107898	May 01, 2028	U-620			
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	9241946	Apr 05, 2022	U-1063			
<u>DOXYCYCLINE HYCLATE - DOXYCYCLINE HYCLATE</u>						
A 090431 003					>A> PC	Nov 19, 2016
<u>DOXYCYCLINE HYCLATE - DOXYCYCLINE HYCLATE</u>						
A 090431 005					>A> PC	Nov 15, 2016
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	9302009	Oct 24, 2030	DP			
<u>ELBASVIR; GRAZOPREXVIR - ZEPATIER</u>						
N 208261 001	7973040	Jul 24, 2029	DS DP U-1813		NCE	Jan 28, 2021
	8871759	May 04, 2031	DS DP U-1813			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	8551957	Oct 19, 2029	DP U-1651		M-174	Mar 18, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	8551957	Oct 19, 2029	DP U-1651		M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	7407955	May 02, 2025	DS DP			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	7407955	May 02, 2025	DS DP			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351 001	5814639	Sep 29, 2015	DS DP		NCE	Nov 05, 2020
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-257			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	6838464	Feb 26, 2021	DS DP			
	7067522	Dec 20, 2019	DS DP			
	7125879	Aug 09, 2022	DS DP U-257			
	7390791	May 07, 2022	DS DP			
	7803788	Feb 02, 2022	U-257			
	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
	8754065	Aug 15, 2032	DS DP U-257			
	9296769	Aug 15, 2032	DS DP U-257			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001	5814639	Sep 29, 2015	DS DP	Y	NCE	Nov 05, 2020
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-257			
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	7390791	May 07, 2022	DS DP			
	7803788	Feb 02, 2022	U-257			
	8754065	Aug 15, 2032	DS DP U-257			
	9296769	Aug 15, 2032	DS DP U-257			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 002	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 002	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-1259			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-1259			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 004	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 004	5977089	Jul 25, 2017	DS DP U-1259			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-1259			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	9238108	Jan 22, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	9238108	Jan 22, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204200 001	9119876	Mar 13, 2035	DP			
	9295657	Mar 13, 2035	U-1829			
	9295657	Mar 13, 2035	U-1830			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204640 001	9295657	Mar 13, 2035	U-1829			
<u>EPINEPHRINE HYDROCHLORIDE - EPINEPHRINE</u>						
N 205029 001	9283197	Aug 15, 2034	DP U-1828			
	9283197	Aug 15, 2034	DP U-1829			
	9283197	Aug 15, 2034	DP U-1830			
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	6469182	Jun 16, 2019	U-1096		I-721	Jan 28, 2019
	6469182	Jun 16, 2019	U-1812		ODE	Jan 28, 2023
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001					>A> D-164	May 20, 2019
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002					>A> D-164	May 20, 2019
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003					>A> D-164	May 20, 2019
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	>A> 5753646	Jun 27, 2017	DS DP U-1451			
	>A> 5753646	Jun 27, 2017	DS DP U-1746			
	>A> 5753646	Jun 27, 2017	DS DP U-1842			
	>A> 9206135	Apr 21, 2026	DS			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	>A> 5753646	Jun 27, 2017	DS DP U-1451			
	>A> 5753646	Jun 27, 2017	DS DP U-1746			
	>A> 5753646	Jun 27, 2017	DS DP U-1842			
	>A> 9206135	Apr 21, 2026	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	>A> 5753646	Jun 27, 2017	DS DP U-1451			
	>A> 5753646	Jun 27, 2017	DS DP U-1746			
	>A> 5753646	Jun 27, 2017	DS DP U-1842			
	>A> 9206135	Apr 21, 2026	DS			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	>A> 5753646	Jun 27, 2017	DS DP U-1451			
	>A> 5753646	Jun 27, 2017	DS DP U-1746			
	>A> 5753646	Jun 27, 2017	DS DP U-1842			
	>A> 9206135	Apr 21, 2026	DS			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	>A> 5753646	Jun 27, 2017	DS DP U-1451			
	>A> 5753646	Jun 27, 2017	DS DP U-1746			
	>A> 5753646	Jun 27, 2017	DS DP U-1842			
	>A> 9206135	Apr 21, 2026	DS			
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER</u>						
N 205703 001	>A> 8829054	Mar 15, 2033	DP			
	>A> 8835505	Mar 15, 2033	DP			
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER</u>						
N 205703 002	>A> 8829054	Mar 15, 2033	DP			
	>A> 8835505	Mar 15, 2033	DP			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	9220698	Mar 10, 2031	U-1781			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	9238076	Apr 15, 2024	DP U-412			
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	5424286	Dec 01, 2016	U-1108			
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6858576	Jan 06, 2017	U-656			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	6872700	Jan 14, 2020	U-654			
	6956026	Jan 07, 2018	U-687			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018	U-1224			
	8216180	Jan 12, 2028	DP	Y		
	8329648	Aug 18, 2026	U-1313			
	8431685	Apr 13, 2025	DP U-412			
	8439864	Mar 25, 2028	DP	Y		
	8461105	Apr 13, 2025	DP U-412			
	8906851	Aug 18, 2026	U-1313			
	9238076	Apr 15, 2024	DP U-412			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695 005	9314447	May 31, 2033	DP U-1447			
	9314447	May 31, 2033	DP U-1448			
<u>FENTANYL - SUBSYS</u>						
N 202788 001	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	9241935	Jan 25, 2027	DP			
<u>FIDAXOMICIN - DIFICID</u>						
N 201699 001	>A> 8586551	Jul 15, 2023	DS DP			
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001					>A> NCE	May 27, 2021
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N 022051 001	>A> 9320862	Nov 06, 2024	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 001	>A> 9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 002	>A> 9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	>A> 9333310	Oct 02, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	>A> 9333310	Oct 02, 2027	DP			
<u>FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE</u>						
N 208294 001	>A> 8324266	May 28, 2030	U-1841		NP	Apr 25, 2019
	>A> 8703806	May 28, 2030	U-1841			
	>A> 8808713	May 28, 2030	DP U-1841			
	>A> 8815258	Mar 17, 2031	U-1841			
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 002					D-155	Feb 01, 2019
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	8329680	Jan 09, 2021	U-596		I-725	Feb 19, 2019
	8329680	Jan 09, 2021	U-1826			
	8329680*PED	Jul 09, 2021				
<u>GADOBUTROL - GADAVIST</u>						
N 201277 002					I-731	Apr 27, 2019
<u>GADOBUTROL - GADAVIST</u>						
N 201277 006	5980864	Nov 09, 2021	DS DP U-1119			
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 001					PC	Jul 27, 2016
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 002					PC	Apr 25, 2016
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 003					PC	Apr 25, 2016
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	5968979	Jul 28, 2018	DS DP U-1378			
	9254278	Mar 09, 2032	U-1816			
	>A> 9326966	Mar 09, 2032	U-1816			
<u>GLYCOPYRROLATE - SEEBRI</u>						
N 207923 001	6582678	Apr 24, 2018	DP			
<u>GLYCOPYRROLATE ; INDACATEROL MALEATE - UTIBRON</u>						
N 207930 001	6582678	Apr 24, 2018	DP			
	6878721	Feb 25, 2025	DS DP U-1773			
<u>GRANISETRON - SANCUSO</u>						
N 022198 001	7608282	Jan 22, 2025	DP U-1011			
<u>HALOBETASOL PROPIONATE - ULTRAVATE</u>						
N 208183 001					NP	Nov 06, 2018
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	>A> 9333201	Jul 25, 2033	U-1810			
	>A> 9339499	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	>A> 9333201	Jul 25, 2033	U-1810			
	>A> 9339499	Jul 25, 2033	U-1810			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	>A> 9333201	Jul 25, 2033	U-1810			
	>A> 9339499	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	>A> 9333201	Jul 25, 2033	U-1810			
	>A> 9339499	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	>A> 9333201	Jul 25, 2033	U-1810			
	>A> 9339499	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	>A> 9333201	Jul 25, 2033	U-1810			
	>A> 9339499	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	>A> 9333201	Jul 25, 2033	U-1810			
	>A> 9339499	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9289391	Oct 30, 2021	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	9296753	Oct 30, 2033	DS DP		>A> D-165 I-729 >A> I-736 >A> I-737 ODE >A> ODE	May 06, 2019 Mar 04, 2019 May 06, 2019 May 06, 2019 Mar 04, 2023 May 06, 2023
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	>A> 9295639	Sep 30, 2029	U-1756			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057	001				>A> NCE	Jul 26, 2017
<u>ILOPERIDONE - FANAPT</u>						
N 022192	001				>A> M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192	002				>A> M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192	003				>A> M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192	004				>A> M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192	005				>A> M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192	006				>A> M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192	007				>A> M-180	May 26, 2019
<u>IMATINIB MESYLATE - IMATINIB MESYLATE</u>						
A 078340	001				PC	Jul 30, 2016
<u>IMATINIB MESYLATE - IMATINIB MESYLATE</u>						
A 078340	002				PC	Jul 30, 2016
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335	001	RE43932	Jul 16, 2018	DS DP		
		RE43932*PED	Jan 16, 2019			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335	002	RE43932	Jul 16, 2018	DS DP		
		RE43932*PED	Jan 16, 2019			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588	001	7544799	Jul 16, 2018	DS DP	Y	
		7544799*PED	Jan 16, 2019			
		RE43932	Jul 16, 2018	DS DP		
		RE43932*PED	Jan 16, 2019			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588	002	7544799	Jul 16, 2018	DS DP	Y	
		7544799*PED	Jan 16, 2019			
		RE43932	Jul 16, 2018	DS DP		
		RE43932*PED	Jan 16, 2019			
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383	001	6878721	Feb 25, 2025	DS DP U-1168		
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833	001	7410656	Oct 10, 2020	U-1222		
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833	002	7410656	Oct 10, 2020	U-1222		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N 021172 004	9265893	Sep 23, 2032	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N 020986 003	9265893	Sep 23, 2032	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXPEN</u>						
N 021536 002	9265893	Sep 23, 2032	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			
<u>INSULIN HUMAN - HUMULIN R</u>						
N 018780 004	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	>A> 9339615	Oct 20, 2029	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	>A> 9339615	Oct 20, 2029	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	>A> 9339615	Oct 20, 2029	DP			
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	>A> 9339497	Jun 12, 2033	U-1848		ODE	Oct 22, 2022
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	9216969	Nov 08, 2026	DS DP			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	9233117	Mar 13, 2034	U-1631			
	9233118	Mar 13, 2034	U-1631			
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 001	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 002	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 003	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	9216167	May 28, 2024	U-1800			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - Omidria</u>						
N 205388 001	9278101	Jul 30, 2023	U-1518			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	9284342	Sep 13, 2030	DS DP U-1470		D-158 D-159 D-160	Feb 12, 2019 Feb 12, 2019 Feb 12, 2019
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001					>A> I-734	May 13, 2019
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002					>A> I-734	May 13, 2019
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	8003681	Aug 25, 2025	DS			
	8084483	Aug 17, 2029		U-1801		
	8283369	Nov 26, 2028		U-1802		
	8283369	Nov 26, 2028		U-1804		
	8357713	Nov 26, 2028	DP	U-1801		
	8357713	Nov 26, 2028	DP	U-1802		
	8357713	Nov 26, 2028	DP	U-1803		
	8546436	Feb 29, 2032	DS DP			
	8546437	Apr 29, 2029		U-1803		
	9216179	Aug 02, 2030		U-1806		
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021379 001	9283282	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021488 001	9283282	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731 001	9283282	Oct 28, 2018	DS DP			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	7407955	May 02, 2025	DS DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	7407955	May 02, 2025	DS DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	7407955	May 02, 2025	DS DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	7407955	May 02, 2025	DS DP			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	9265893	Sep 23, 2032	DP		M-176	Apr 22, 2019
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2020	DS DP	U-1317		
	9265758	Mar 07, 2025		U-1316		
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2020	DS DP	U-1317		
	9265758	Mar 07, 2025		U-1316		
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2020	DS DP	U-1317		
	9265758	Mar 07, 2025		U-1316		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001 >A>	5900488	Jul 05, 2017	DS DP U-540			
	9199977	Sep 06, 2033	DS DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9259423	May 23, 2031	U-1822			
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	9265762	May 29, 2027	DP U-1820			
<u>MEGESTROL ACETATE - MEGESTROL ACETATE</u>						
A 203139 001					PC	Jan 24, 2016
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	8410077	Mar 13, 2029	DP		ODE	Mar 10, 2023
	9200088	Mar 13, 2029	DP			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 001	9233184	Aug 01, 2027	DP			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 002	9233184	Aug 01, 2027	DP			
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A 091664 001					PC	Jul 30, 2016
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A 091664 002					PC	Jul 30, 2016
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 001 >A>	9320714	Feb 03, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 002	>A> 9320714	Feb 03, 2029	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001	>A> 9339472	Oct 14, 2025	DP		M-175	Apr 05, 2019
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	RE44186	Jul 31, 2023	DS DP U-1097		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	RE44186	Jul 31, 2023	DS DP U-1097		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001	7326708	Nov 24, 2026	DS DP U-802			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002	7326708	Nov 24, 2026	DS DP U-802			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001	7326708	Nov 24, 2026	DS DP U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002	7326708	Nov 24, 2026	DS DP U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 003	7326708	Nov 24, 2026	DS DP U-1227			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 006	>A> 6746429	Apr 12, 2020	DP			
	>A> 8021335	Oct 04, 2026	DP			
	>A> 8480631	Mar 19, 2030	DP			
	>A> 8562564	Jan 24, 2026	DP			
	>A> 8579865	Mar 19, 2030	DP			
	>A> 8945063	Mar 19, 2030	DP			
	>A> RE44846	Aug 10, 2019	DP			
	>A> RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 007	>A> 6746429	Apr 12, 2020	DP			
	>A> 8021335	Oct 04, 2026	DP			
	>A> 8480631	Mar 19, 2030	DP			
	>A> 8562564	Jan 24, 2026	DP			
	>A> 8579865	Mar 19, 2030	DP			
	>A> 8945063	Mar 19, 2030	DP			
	>A> RE44846	Aug 10, 2019	DP			
	>A> RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 008	>A> 6746429	Apr 12, 2020	DP			
	>A> 8021335	Oct 04, 2026	DP			
	>A> 8480631	Mar 19, 2030	DP			
	>A> 8562564	Jan 24, 2026	DP			
	>A> 8579865	Mar 19, 2030	DP			
	>A> 8945063	Mar 19, 2030	DP			
	>A> RE44846	Aug 10, 2019	DP			
	>A> RE44847	Aug 10, 2019	DP U-1442			
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 001				>A> ODE		Apr 08, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	8999386	Aug 14, 2033	DP		NP	Dec 04, 2018
	9295642	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	8999386	Aug 14, 2033	DP		NP	Dec 04, 2018
	9295642	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	8999386	Aug 14, 2033	DP		NP	Dec 04, 2018
	9295642	Aug 14, 2033	DP U-1827			
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444 001	9278105	May 12, 2031	U-282			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	6346532	Mar 27, 2022	DS DP			
	RE44872	Nov 04, 2023	U-1527			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	6346532	Mar 27, 2022	DS DP			
	RE44872	Nov 04, 2023	U-1527			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 001	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 002	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 003	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 004	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 005	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 001	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 002	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 003	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 004	7955619	Aug 12, 2028	DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	9238108	Jan 22, 2027	DP			
	9278182	Feb 01, 2026	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	9205082	Dec 22, 2018	DP U-1556			
	9283216	May 10, 2022	DP U-1819			
>A>	9345701	May 10, 2022	DP U-1819			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	9205082	Dec 22, 2018	DP U-1556			
	9283216	May 10, 2022	DP U-1819			
>A>	9345701	May 10, 2022	DP U-1819			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 003	9205082	Dec 22, 2018	DP U-1556			
	9283216	May 10, 2022	DP U-1819			
>A>	9345701	May 10, 2022	DP U-1819			
<u>NITISINONE - ORFADIN</u>						
N 206356 001	9301932	Feb 02, 2033	DP U-1836			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	9265911	Jan 06, 2031	DP U-1824			
	9265911*PED	Jul 06, 2031				
	9279794	Feb 19, 2034	DP U-1823			
	9279794*PED	Aug 19, 2034				
	9295802	Jan 06, 2031	DP U-1226			
	9295802*PED	Jul 06, 2031				
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001					M-173	Mar 18, 2019
<u>OMEGA-3-ACID ETHYL ESTERS TYPE A - OMTRYG</u>						
N 204977 001					>A> NCE	Apr 23, 2019
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2017	DP		>A> NCE	May 05, 2019
	5948818	May 13, 2017	DP			
<u>OMEPRazole MAGNESIUM - PRILOSEC</u>						
N 022056 001	5900424	May 04, 2016	DS U-864			
	5900424	May 04, 2016	DS U-1817			
	6428810	Nov 03, 2019	DP U-864			
	6428810	Nov 03, 2019	DP U-1817			
<u>OMEPRazole MAGNESIUM - PRILOSEC</u>						
N 022056 002	5900424	May 04, 2016	DS U-864			
	5900424	May 04, 2016	DS U-1817			
	6428810	Nov 03, 2019	DP U-864			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 001	5840737	Jul 15, 2016	U-588			
	6489346	Jul 15, 2016	DP U-588		Y	
	6645988	Jul 15, 2016	DP		Y	
	6699885	Jul 15, 2016	U-588		Y	
	6780882	Jul 15, 2016	DS DP			
	7399772	Jul 15, 2016	U-588			
	RE45198	Jul 15, 2016	U-588			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 002	5840737	Jul 15, 2016	U-623			
	5840737	Jul 15, 2016	U-624			
	6489346	Jul 15, 2016	DP U-623		Y	
	6489346	Jul 15, 2016	DP U-624		Y	
	6645988	Jul 15, 2016	DP		Y	
	6699885	Jul 15, 2016	U-623		Y	
	6699885	Jul 15, 2016	U-624		Y	
	6780882	Jul 15, 2016	DS DP			
	7399772	Jul 15, 2016	U-623			
	7399772	Jul 15, 2016	U-624			
	RE45198	Jul 15, 2016	U-623			
	RE45198	Jul 15, 2016	U-624			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 002	5840737	Jul 15, 2016	U-623			
	5840737	Jul 15, 2016	U-624			
	6489346	Jul 15, 2016	DP U-623	Y		
	6489346	Jul 15, 2016	DP U-624	Y		
	6645988	Jul 15, 2016	DP	Y		
	6699885	Jul 15, 2016	U-623	Y		
	6699885	Jul 15, 2016	U-624	Y		
	6780882	Jul 15, 2016	DS DP			
	7399772	Jul 15, 2016	U-623			
	7399772	Jul 15, 2016	U-624			
	RE45198	Jul 15, 2016	U-623			
	RE45198	Jul 15, 2016	U-624			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021849 001	7399772	Jul 15, 2016	U-588			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021849 002	7399772	Jul 15, 2016	U-623			
	7399772	Jul 15, 2016	U-624			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001					ODE	Nov 13, 2022
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002					ODE	Nov 13, 2022
<u>OSPENIFENE - OSPHENA</u>						
N 203505 001	9241915	Feb 13, 2024	U-1369			
	9241915	Feb 13, 2024	U-1370			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	>A> 9351975	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	>A> 9351975	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	>A> 9351975	Apr 13, 2027	DP			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	9259388	Nov 06, 2029	U-1644			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001					NP	Apr 26, 2019
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002					NP	Apr 26, 2019
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003					NP	Apr 26, 2019
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004					NP	Apr 26, 2019
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005					NP	Apr 26, 2019
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	9066980	Jan 30, 2024	DP U-528			
	9066980*PED	Jul 30, 2024				
	9125905	Jan 30, 2024	DP			
	9125905*PED	Jul 30, 2024				
	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 001	>A> 7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 002	>A> 7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 003	>A> 7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 004	>A> 7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	7598271	May 04, 2025	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	>A> 6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
	>A> 8772497	May 16, 2026	DS			
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
N 022159 001					NPP	Mar 18, 2019
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	>A> 6756393	Mar 06, 2021	DS DP		NCE	Apr 29, 2021
	>A> 6815458	Mar 06, 2021	DS DP U-1843			
	>A> 7115634	Oct 06, 2021	DS DP			
	>A> 7601740	Jun 17, 2027	DS DP			
	>A> 7659285	Aug 24, 2026	U-1844			
	>A> 7732615	Jun 03, 2028	DS DP			
	>A> 7858789	Dec 13, 2020	DS DP			
	>A> 7923564	Sep 26, 2025	DS DP			
	>A> 8110574	Dec 13, 2020	DS DP			
	>A> 8618130	Jan 15, 2024	U-1845			
	>A> 8921393	Jan 15, 2024	U-1846			
	>A> 9296694	Mar 06, 2021	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A 202206	004				PC	May 18, 2016
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307	001	>A> 5288726	Apr 14, 2017	DS DP U-991		
		>A> 5288726*PED	Oct 14, 2017			
		>A> 8404703	Jan 02, 2023	U-1381		
		>A> 8404703*PED	Jul 02, 2023			
		>A> 8569325	Jan 02, 2023	U-1381		
		>A> 8569325*PED	Jul 02, 2023			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307	002	>A> 5288726	Apr 14, 2017	DS DP U-991		
		>A> 5288726*PED	Oct 14, 2017			
		>A> 8404703	Jan 02, 2023	U-1381		
		>A> 8404703*PED	Jul 02, 2023			
		>A> 8569325	Jan 02, 2023	U-1381		
		>A> 8569325*PED	Jul 02, 2023			
<u>PROPOFOL - PROPOFOL</u>						
A 205307	001				PC	Feb 24, 2016
<u>REGADENOSON - LEXISCAN</u>						
N 022161	001	9289446	Jun 22, 2019	DP U-116		
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA</u>						
N 203324	001				>A> ODE	Apr 15, 2023
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA VISCOUS IN DEXTROSE 20%</u>						
N 203324	002				>A> ODE	Apr 15, 2023
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361	001	>A> 9271968	Feb 27, 2026	DP		
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554	001	>A> 9271968	Feb 27, 2026	DP		
<u>RIVAROXABAN - XARELTO</u>						
N 022406	001	7157456	Aug 28, 2024	DS DP U-1301		
		7157456	Aug 28, 2024	DS DP U-1302		
<u>RIVAROXABAN - XARELTO</u>						
N 022406	002	7157456	Aug 28, 2024	DS DP U-1301		
		7157456	Aug 28, 2024	DS DP U-1302		
<u>RIVAROXABAN - XARELTO</u>						
N 022406	003	7157456	Aug 28, 2024	DS DP U-1301		
		7157456	Aug 28, 2024	DS DP U-1302		
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533	006	>A> 7828787	Oct 18, 2025	DP		
		>A> 7857802	Nov 28, 2026	DP		
		>A> 8118802	May 18, 2023	DP		
		>A> 8162915	May 23, 2024	DP		
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533	007	>A> 7828787	Oct 18, 2025	DP		
		>A> 7857802	Nov 28, 2026	DP		
		>A> 8118802	May 18, 2023	DP		
		>A> 8162915	May 23, 2024	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 002	6858618	Dec 17, 2021	U-618		>A> ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1032			
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 003	6858618	Dec 17, 2021	U-618		>A> ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1032			
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 004	6858618	Dec 17, 2021	U-618		>A> I-732 >A> ODE	May 27, 2019 May 27, 2023
	6858618	Dec 17, 2021	U-1032			
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 005					>A> ODE	May 27, 2023
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 001	9216178	Nov 01, 2032	DP			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 002	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				
	9216178	Nov 01, 2032	DP			
	RE43797	Nov 17, 2024	U-1590			
	RE43797*PED	May 17, 2025				
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001	RE44186	Jul 31, 2023	DS DP U-995		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1837			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002	RE44186	Jul 31, 2023	DS DP U-995		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1837			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 001	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 002	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 003	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 004	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 005	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 006	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 007	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 008	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 001	9095509	Dec 06, 2030	DP			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 002	9095509	Dec 06, 2030	DP			
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001					M-171	Feb 26, 2019
					>A> M-179	May 20, 2019
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001	7326708	Nov 24, 2026	DS DP U-802			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	7326708	Nov 24, 2026	DS DP U-802			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003	7326708	Nov 24, 2026	DS DP U-802			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	9284342	Sep 13, 2030	DS DP U-1470			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001	7265099	Aug 07, 2020	U-1795		NCE	Dec 15, 2020
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002	7265099	Aug 07, 2020	U-1795		NCE	Dec 15, 2020
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684 001					I-728	Mar 31, 2019
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 202278 001	9272137	Sep 07, 2027	DP			
	>A> 9327114	Oct 08, 2032	DP U-1328			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	6715485	Mar 03, 2020	DP			
	7975690	Aug 18, 2025	DP U-1809			
	8047202	Jul 02, 2023	DP			
	8327844	Oct 03, 2023	U-1809			
	8550073	Oct 22, 2029	DP			
	8555877	Mar 03, 2020	DP			
	8590530	Sep 15, 2025	DP U-1809			
	8875704	Apr 07, 2028	DP U-1809			
	8899229	Aug 18, 2030	DP			
	8978647	Dec 06, 2030	DP			
	9108015	Sep 15, 2025	DP			
	9119932	Apr 23, 2024	DP			
<u>TAFLUPROST - ZIOPTAN</u>						
N 202514 001	5886035	Dec 18, 2022	DS DP U-778			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2020	DS DP U-1320			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 001	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 002	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 003	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	9289586	Feb 26, 2027	U-1390			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 002	9295675	Feb 11, 2034	DP U-1531			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 003	9295675	Feb 11, 2034	DP U-1531			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	9254328	Mar 13, 2026	DP			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912 001	6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 001	6770660	Jun 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 002	6770660	Jun 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 003	6770660	Jun 01, 2023	U-1444			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	6956027	Mar 25, 2023	DS		NCE	Nov 06, 2017
	6956041	Dec 08, 2020	DP			
	7091208	Dec 08, 2020	U-247			
	7265221	Dec 08, 2020	DS			
	7301023	May 23, 2022	DS			
	RE41783	Dec 08, 2020	DS			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	9271941	Jan 28, 2032	DP		M-170	Nov 20, 2018
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	9271941	Jan 28, 2032	DP		M-170	Nov 20, 2018
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	>A> 9339507	Mar 10, 2028	DP			
	>A> 9358240	May 05, 2028	U-1849			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	9278901	May 24, 2024	U-1475		D-156 D-157	Jan 28, 2019 Jan 28, 2019
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	9278901	May 24, 2024	U-1475		D-156 D-157	Jan 28, 2019 Jan 28, 2019
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	9278901	May 24, 2024	U-1475		D-156 D-157	Jan 28, 2019 Jan 28, 2019
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	9278901	May 24, 2024	U-1475		D-156 D-157	Jan 28, 2019 Jan 28, 2019
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	9283233	Apr 13, 2030	U-1821			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001 >A>	9333310	Oct 02, 2027	DP		M-172	Feb 24, 2019
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001 >A>	9333310	Oct 02, 2027	DP			
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159 001					ODE	Dec 11, 2022
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	8546399	Jun 27, 2031	DS DP		NCE	Apr 11, 2021
	9174982	May 26, 2030	U-1835		ODE	Apr 11, 2023
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	8546399	Jun 27, 2031	DS DP		NCE	Apr 11, 2021
	9174982	May 26, 2030	U-1835		ODE	Apr 11, 2023
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	8546399	Jun 27, 2031	DS DP		NCE	Apr 11, 2021
	9174982	May 26, 2030	U-1835		ODE	Apr 11, 2023
<u>VISMODEGIB - ERIVEDGE</u>						
N 203388 001	9278961	Dec 15, 2028	U-1825			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001	9227946	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002	9227946	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003	9227946	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004	9227946	Jun 15, 2027	U-1668			
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A 204299 001					PC	Sep 18, 2016
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A 204299 002					PC	Sep 18, 2016
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 001	9265720	May 13, 2030	U-674			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 002	9265720	May 13, 2030	U-674			
<u>ZOLPIDEM TARTRATE - ZOLPIMIST</u>						
N 022196 001 >A>	8236285	Aug 07, 2032	DS DP U-70			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 36th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>